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ABSTRACT 
Resistance to antimalarial drugs is increasing nearly everywhere in the tropical world, 
confounding global attempts to "Roll Back Malaria". Antimalarial treatment with 
artemisinin, artesunate, or artemether has proved rapidly effective in the treatment of non 
complicated and complicated malaria and remarkably nontoxic. However there is a 
number of important questions that still need urgent attention: Should artemisinin be 
deployed alone or in combination with other antimalarial drugs such mefloquine or other 
compound (s); which is the best regimen (s); can artemisinin and its derivatives 
(artesunate or artemether) reduce the mortality in severe malaria and which is the best 
drug(s); are there important neurotoxic side effects in patients treated with this group of 
antimalarial drugs. 
In order to answer those questions a series of studies were conducted in Vietnam and 
these form the basis of this thesis. The conclusion is 
11 Dihydroartemisinin-piperaquine is an inexpensive, safe, highly efficacious fixed-
dose antimalarial combination treatment that could make an important contribution 
to the control of multidrug-resistant fa1ciparum malaria for Vietnan1 and other 
countries. 
21 Artemether is a satisfactory alternative to quinine for the treatment of severe 
malaria in adults. The rectal administration of artemisinin would obviollsly 
constitute a useful therapeutic advance, in comparing \\"ith parenteral drugs such as 
artemether and artesunate, particularly in areas where parenteral administration is 
difficult. 
3/ The artemisinin derivatives have an acceptable safety profile. 
4/ Viet Nam has shown that it is possible to "Roll Back Malaria" assuming one has 
access to good drugs and a willingness to implement change. 
Those studies have helped to confirm that the qinghaosu (artemisinin) group of drugs is 
the most important new class of antimalarials developed in the last fifty years. 
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Criteria for a new antimalarial drug: 
............ To salivary glands they want 
And start again; there is no end 
The moral of this age-old story 
Is that we can't aspire to glory 
Until our principal objective 
Will make control much more effective 
And faced with chloroquine resistance 
We must depend on more assistance 
And find a new medicament 
To solve our great predicament 
A compound that in all event 
Is active, cheap, polyvalent"""""""""""""""" 
Ballad of the Plasmodium. Leonard Bruce-Chwatt (1907-1989) 
And how to build up a new antimalarial drug policy for a country: 
As long as 1937 L.H. Hackett remarked: 
"Clearly governments can trust no formulas devised in Geneva or elsewhere, but must 
create the simple machinery necessary to define and resolve their own problems, localizv 
by locality" (Malaria in Europe. Oxford University Press, p. 274, 1937) 
His remark is still pertinent today, although the complexity of the disease will not allow 
simple mechanism for the resolution of the problems. 
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Chapter 1: INTRODUCTION 
CHAPTER! 
INTRODUCTION 
Malaria is one of humanity's worst diseases and is becoming now a global crisis. One-
fifth of the world's population is still at risk of malaria. Nearly five times as many cases 
of malaria were reported in 2000 as tuberculosis, AIDS, measles and leprosy cases 
combined. In the time it takes to say the word "malaria" ten children will contract the 
disease and begin fighting for their lives (WHO, 2000a). Malaria kills over a million 
people each year. Malaria has an insidious and far-reaching effect on economic and social 
development. In addition to the direct costs of treatment and prevention, malaria is 
responsible for significant losses in productivity and it undermines educational 
achievement. It discourages savings and investment by households, constrains optimal 
land use and deters foreign investment and tourism. A recent study in Viet Nam has 
shown that living in malaria-endemic regions places an economic burden on households 
even if they do not actually suffer an episode of malaria. Households living in endemic 
malarial regions are less likely to have access to economic opportunities and may have to 
modify agricultural practices and other household behaviour to adapt to their disease 
environment. Data from Vietnam demonstrate that reductions in malaria incidence 
through government-financed malaria control programmes can contribute to higher 
17 
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household income for all households in endemic areas (R Laxminarayan, 2004). In effect, 
malaria cripples the economies of malaria endemic countries, and has been shown to be 
responsible for losses of up to 1.3% of economic growth per year in sub-Saharan Africa. 
This negative effect has widened disparity in the economic status between malarious and 
non-malarious regions of the world. In the 1950s the World Health Organization (WHO) 
optimistically targeted malaria for eradication; since then many countries in the Western 
world had wiped out the diseases and other countries in Latin America were making 
progress. Unfortunately, over the past 20 years, efforts to control malaria have met with 
less and less success. The hope of eradication has disappeared and even control now 
seems a distant dream. In such a changing world malaria is also exacerbated by altered 
geographic, ecologic, social factors such as global warming, poverty, political upheavals. 
1.1. Malaria 
1.1.1 History of malaria 
The mere mention of the word malaria suffices to evoke the devastating effects of this 
still unconquered disease. Fa1ciparum malaria is a disease largely prevalent in tropical and 
subtropical regions, but Plasmodium vivax, which can survive at lower temperatures in its 
anopheline mosquito vectors, may also occur in temperate areas. 
Until Laveran's identification of the malaria parasite, malaria was synonymous with ague, 
a debilitating febrile illness associated with intermittent chills or rigors. As early as the 
5th century BC Hippocrates was able to diagnose malaria in Asia Minor and to 
distinguish between different stages of fever. This knowledge became the property of his 
successors. When malaria occurred in Attica, it was reported by Plato (427- 347 BC) and 
Aristotle (384-322 BC). Even in the secondary century AD Aretaeus' treatise on the 
treatment of acute and chronic diseases was based on the findings of Hippocrates, and the 
18 
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polymath medical author Galen (130-200 AD) also relied upon these writings. The 
Roman historian Livy (59 BC-17 AD) reported malaria-like diseases in Rome. After the 
2nd Punic War whole localities were abandoned by their inhabitants because of the danger 
of malaria. The Roman scholar Marcus Terentius Varro (116- 27 BC) stated in the his 
work Res rusticate that in humid places there were minute insects which could cause 
grievous diseases in the bodies of human beings, although these were barely perceptible 
to the human eye (W Schreiber & FK Mathys, 1987). 
Because of its widespread distribution and tremendous infectious potential, malaria was 
often a more decisive factor than arms in military defeats. The Goth and Norman invaders 
had to pay a heavy toll of lives. In the Napoleonic wars the English troops landing on the 
continent in 1809 failed because a large proportion of the soldiers landing on the 
Netherland's island of Walcher en fell victim to malaria. In 1916 and 1917 the Allied 
military campaigns in Macedonia were completely paralysed by the disease: among the 
French alone more than 100,000 out of 150,000 came down with malaria and among the 
English the figure was 70,000. This occurred in spite of a burgeoning increase in 
knowledge about the infection. In 1880, the Frenchman Charles Louis Laveran (1845-
1922) had succeeded in Constantine, North Africa, in detecting the malaria parasite of 
Plasmodium in the blood of malaria patients. His findings were confirmed by other 
workers. In 1897, Ronald Ross (1857-1932) working in Secunderabad, India, had reached 
the conclusion that mosquitoes inoculated human beings with the disease. Italian 
scientists soon confirmed the complete cycle of infection in man.(W Schreiber & FK 
Mathys, 1987) (HM Gilles & DA Warrell, 1993) Doctors waged the war against the 
disease with the most diverse agents: roots, herbs, and mole's claws, snake heart 
practices, which were maintained until well into the 19th century. 
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Extracts of the plant qinghao (Artemisia annua), known as qinghaosu, have been used in 
traditional medical practice in China for over two millennia. In AD340 Ge Hong 
described use of qinghao infusions for the treatment of fever in the famous Handbook of 
Emergency Treatments. Thereafter qinghao is mentioned frequently in the Chinese 
materia medica as a treatment for agues. The antimalarial properties of qinghaosu were 
rediscovered in 1971 when low temperature ethylether extracts of the plant were shown to 
have activity against experimental rodent malaria. 
On the other side of the world another medicinal plant came to medical attention during 
the reign of the Count of Cinch on as Viceroy of Peru between 1628 and 1629. Legend has 
it that the Viceroy's wife, the Countess, was afflicted by ague in Lima. She was a well-
known and popular figure and news of her illness spread inland. It eventually reached 
Loja where a Spaniard was in governorship. He knew of a local remedy obtained from the 
bark of a tree and sent it to the ailing Countess. The therapeutic result was excellent; she 
improved rapidly, and was so impressed that she ordered the bark in quantity and 
dispensed it to the poor of Lima who commonly suffered from the dangerous tertian 
fevers. The pulverised bark became known as "los polvos de la Condeca" or the 
Countess's powder, and Linnaeus subsequently named the tree from which the bark was 
obtained 'Cinchona' in honour of the Countess (IA McGregor, 1996) Sadly the detective 
work of one A. W. Haggis, reported in 1941, has shown that 'the fabulous story of the 
Countess of Cinchon' is almost certainly a romantic fable. Nevertheless it is likely that 
the bark was introduced to Europe by the Fathers of the Society of Jesus around the time 
of the story, or even earlier (c.1630) and was widely promoted in Europe by the Jesuit 
Cardinal Juan de Hugo. For these reasons it became known as Jesuit's bark. Not everyone 
was convinced by the new remedy, and when in 1653 Archduke Leopold of Austria 
relapsed one month after being cured of double quartan fever, his personal physician 
20 
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Jean-Jacques Chifflet began a bitter polemic on the merits of the bark which was to last 
for 200 years. Much of the dispute stemmed from the fact that many considered all fevers 
had the same cause, and clearly not all responded to Jesuit's bark. It was probably Torti 
in 1712 who first stated that the bark was "specific solely for the ague". 
Another source of debate, and one that is still active today was dosage. Sir Robert Talbor 
(Talbot) was one of the few physicians who was not afraid to give the bark in large and 
repeated doses, and when he cured the Dauphin (the son of Louis XIV) with his "remede 
anglais" his fame spread far and wide. He subsequently treated Charles II of England 
successfully with the same medicament. Others were less enthusiastic. Many Protestants 
believed the bark to be a poison disseminated by the Jesuits. Lind, who demonstrated 
clearly that in order to get best results the bark should be given in full doses as soon as the 
disease was diagnosed, clarified the dose-response question in 1768 (advice that has stood 
the test of time). In 1820 the French chemists Pierre Pelletier and Joseph Caventou 
isolated the alkaloid quinine from cinchona bark. Purification of the various cinchona 
alkaloids allowed standardization of dosage. Adequate doses could now be given in 
relatively small amounts of pure drug, but by the middle of the nineteenth century 
enormous doses (up to 100-150 grains over two days) were being prescribed. Toxicity 
was common and the popularity of the medicine fell. Gradually, however, the diagnosis 
of agues and the prescription of Cinchona alkaloids became more rational and logical. 
The new colonial powers recognized the importance of Cinchona, and improved methods 
of horticulture resulted in better yields of the alkaloids from the cultivated trees. Ledger's 
identification of high yielding Cinchona ledgeriana, and the subsequent rejection by the 
British authorities of his offer of seeds gave the The Dutch an opportunity, which they 
gladly accepted. They then took the lead and established vast plantations of high yielding 
Cinchona ledgeriana in the East Indies (principally in Java). 
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Laveran, having identified haematozoa as the cause of paludism, later concluded that 
quinine cured the disease by killing the newly discovered parasites. This theory 
encountered considerable resistance in the years immediately following its publication. In 
1880 Bacelli described the intravenous method of administering quinine (although there is 
evidence that this route had been used for 50 years before that). Laveran considered 
intravenous injection to be dangerous, giving rise to both local and general complications, 
and was only justified in 'the most grave and pernicious disease'. He also confirmed the 
earlier observations of Thomas Willis (1659) that cinchona cured the acute attacks of 
ague, but did not prevent relapses, and also appeared to have no effect on crescents 
(gametocytes of P. Jalciparum). The eminent Italian malariologists subsequently showed 
that quinine prevented asexual blood-stage development but could not stop sporulation of 
formed segmenters (meronts). 
In 1856 William Henry Perkin discovered analine purple (mauve) whilst attempting to 
synthesize quinine from coal tar products. Thus began the synthetic dye industry. Later 
in Germany, the antimicrobial properties of those newly discovered aniline dyes were 
investigated. In 1890, Ehrlich showed that methylene blue had antimalarial activity 
against P. cathemerium in canaries, but the dye proved disappointing in clinical practice, 
and structural modifications did not lead to compounds with improved activity. 
During the Great War (1914-1918) whole armies were immobilized in the Balkans 
because of malaria, and there were heavy losses in Mesopotamia, East Africa and the 
Jordan Valley. The British and French armies used quinine extensively, and despite 
frequent objections to the bitter medicament many lives were saved. The military and 
strategic importance of antimalarial drugs stimulated much research immediately after the 
war. In the early 1920s the resurgent German chemical industry again focused its 
attention on new antimicrobial compounds. The first synthetic antimalarial was 
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discovered in 1926. This was an aminoquinoline compound, pamaquine, also known as 
plasmoquine or plasmochin, a precursor of the 8-aminoquinoline primaquine. Pamaquine 
was followed by the acridine compound mepacrine (quinacrine) in 1932, and the 
structurally related 4-aminoquinoline, chloroquine, in 1934. Initially chloroquine was 
rejected as being too toxic for human use, and the research team at Bayer was asked to 
produce a safer compound. They then produced 3-methy1chloroquine (Sontoquine) but, 
despite clinical studies, these compounds were generally unavailable at the outbreak of 
the Second World War. 
Malaria research has often been tied to warfare. Annies fighting in tropical theatres of 
war usually lose more men to malaria than bullets. At the outset of the Second World 
War, the Allies knew their position was precarious in the tropics as most of the world's 
Cinchona was grown in Java, and this was vulnerable to Japanese invasion. They 
embarked upon a tremendous combined research effort into the development and 
evaluation of new antimalarials. In the event Java did fall to the Japanese, but widespread 
use of mepacrine ( quinacrine) prophylaxis by the Allied soldiers proved highly effective 
(albeit somewhat toxic) and probably saved the day. Information on chloroquine was, in 
fact, available to the Allied Powers through pre-war reciprocal arrangements between the 
pharmaceutical companies, Bayer and Winthrop, but lay buried in documents until the 
defection of two French soldiers in North Africa in 1943. They brought with them a 
German antimalarial, later identified as Sontoquine. However, chloroquine was not fully 
evaluated until the end of the war. An entirely separate line of research in the UK led to 
the discovery in 1945 of the antimalarial biguanides, proguanil and subsequently 
chlorproguanil. These compounds were later shown to inhibit the plasmodial enzyme 
dihydrofolate reductase (DHFR). Researchers at the Wellcome Research Laboratories 
synthesizing purine analogues developed the antimitotic compound 6-mercaptopurine 
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(and later azathioprine) and in 1952 discovered the antiprotozoal DHFR inhibitor 
pyrimethamine. This same line of Nobel Prize winning research later developed 
trimethoprim, which has considerably greater affinity for bacterial DHFR (but also 
inhibits the plasmodial enzyme), and also allopurinol, acyclovir and zidovudine (AZT). 
By the early 1950s the 4-aminoquinolines, chloroquine, and to a much lesser extent 
amodiaquine, had become the treatment of choice for all malaria throughout the world. 
Pyrimethamine was used in treatment, and chloroquine, pyrimethamine and proguanil 
were used for prophylaxis. Primaquine was given to prevent relapses of P. vivax and P. 
ovale. The Cinchona alkaloids were little used outside francophone Africa, and with the 
discontinuation of quinine, blackwater fever became a rarity. This was the heyday of the 
malaria eradication era, and with the tremendous successes in Europe and many urban 
areas of the tropics, interest in the development of new antimalarial drugs waned rapidly. 
But eradication in the tropics failed, and in the 1960s antimalarial drug resistance 
emerged as a major threat (NJ White, 2003). 
Although the cause of the disease, the role of the female Anopheles mosquito in spreading 
it, and the use of quinine are well known, malaria still defies all efforts to control it in the 
20th century as it did in the nineteenth. As late as 1951 the World Health Organisation 
estimated that 64% of the World's population was living in malaria-infested territories. 
The major outbreaks in our century were in USSR in 1923, with 5 million patients and 
60,000 fatalities; in Ceylon in 1934/1935 with 3 million patients and more than 80,000 
fatal cases, and in Ethiopia (1958) with 3 million patients and 150,000 deaths (R 
Fontaine, et aI., 1961). It is estimated that today there are still 500-700 million people 
affected by this disease and that 1-2 million of them die every year. 
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1.1.2 History of malaria in Vietnam 
If you go to Phu Qui can you come back? 
This is the green tomb where the wife is mourning/or her husband 
Malaria in Vietnam has been associated with water and forest. An early expression for 
fever-associated malaria was "nga nuoc" translated literally as "water falling" disease and 
"sot ret rung": "cold forest fever". The early concepts of health in Vietnam inform us 
about associations of knowledge relating to the forest and particular types of water: the 
term "rung thieng, nuoc doc" (spiritual forest, poisoned water). Inhabitants of the plains 
expressed in these terms their conviction that the hinterland was unwholesome place. 
Physicians accompanying the French navy during 1875 occupation of the Red River Delta 
quickly established that soldiers in the uplands were highly susceptible to fever. At the 
end of the colonial period the "forest spirits" and "poisoned water" was more adequately 
explained by Pierre Gourou in 1940: "the only propagating agent of malaria is the 
mosquito; nor the forest spirits nor the poisoned water feared by Vietnamese have the 
least responsibility. The sunlit terraced rice fields with running water of hill regions are 
veritable breeding sites for the larvae of dangerous anopheles, in contrast with the 
stagnant paddies of the plains". The geographical spread of the disease is evident in 
Simond's map of malaria, which was published in 1907. 
Malaria control for civilians was first applied in the context of major projects of public 
works; but it should be emphasized that the policies were based on economic and not 
humanitarian calculations. This means they were based on the costs of malaria in terms of 
the lives and health and loss of productivity of certain categories of people. This is 
reflected clearly in the railroad project in the Northern provinces and the rubber plantation 
in the southern provinces. The most ambitious one was the French programme to build a 
railroad from Hai Phong (Viet Nam) to Yunnan (China). As the work progressed in 190-+, 
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a French medical officer observed that the workers were suffering excessive morbidity 
with a very high mortality. The difficulty of finding labourers for this project which relied 
on forced recruitment, led to the recommendation of measures for their protection. In 
addition to the distribution of quinine, other measures of basic hygiene, such as sanitary 
house construction and the availability of warm drinks were implemented, but they had 
little effect on the epidemic. In the early days of the "rubber rush" after its introduction to 
Indochina in 1910, malaria took a heavy toll among plantation labourers. By the 1920's 
the high cost of a plantation worker's recruitment, transportation, and maintenance made 
action against the disease economically essential (A Hardy, 2000). Malaria became 
immediately and intimately associated with war; the geography of malaria played a 
crucial role in the conduct of the war of independence. Central to the success of the 
resistance forces was their ability to survive in an environment of high malaria 
endemicity. 
After 1954 both North and South Vietnam adopted scientific strategies of malaria 
eradication. In the North, imported insecticides and expertise acquired during the war and 
from the Soviet Union formed the basis of an extensive and rather impressive programme. 
In the South, campaigns funded by the USA and the WHO met with less success. 
Wars have many times led to the development of new technology but also of new 
medicaments. The antimalarial drugs are typical examples. Chloroquine resulted from the 
Second World War. Mefloquine resulted from the Vietnam War at the side of the 
Americans. Artemisnin also results from the Vietnamese war. When this war was raging 
in the sixties many Vietnamese soldiers died from malaria, caused by parasites resistant to 
the currently used medicaments. Ho Chi Minh, the Vietnamese leader, asked for help 
from his Chinese neighbour. Mao Tse Tung offered very generously his help and. 
"Project 523 - a secret military outfit that was set up in 1967 to help Vietnamese to deal 
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with malaria". The biggest enemy for both the Americans and the Vietnameses was 
malaria. Project 523 was set up to help the Vietnamese military defeat malaria," said 
Professor Li, who joined 523 at its inception. He spent the next seven years trying to find 
a cure. Then, on a trip to the mountainous Yunnan province in 1974, he came across a 
plant called qinghao - which was first mentioned as a cure for malaria in Chinese 
medicine books dating from 340 BC. The plant extract is called artemisinin, and Professor 
Li was astonished to see that it could even cure patients with advanced cases of 
complicated malaria, such as the cerebral version, which are usually fatal. The 
Vietnamese used the compound for their troops in the final stages of the Vietnam War 
(Anonymity, 2004) (Li GQ personal communication). 
Peace returned in 1975, but - for malaria control - peace did not herald an end to 
difficulties. Malaria became an important factor of the country's post-war development. It 
was only during the 1990's that economic growth and support from international agencies 
ensured a greater availability of resources for malaria control. In addition, the use of 
artemisinin and its derivatives, which also grows in northern regions of Vietnam, has 
dramatically reduced the mortality and the morbidity rates of malaria. 
1.1.3 Current malaria situation on the world 
There are 300 to 500 million clinical cases of malaria every year and between one to two 
million deaths, mostly of children, are attributable to malaria on the world. Although the 
last century witnessed many successful programmes at country level to eliminate malaria, 
the world is now facing a rapidly increasing disease burden. This has been attributed to 
several causes, including population movements into malarious region, changing 
agricultural practices such as irrigation projects, building damps, weakening of public 
health systems and speculatively, long-terms climate changes as global warming and El 
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Nino phenomenon. But of greater importance has been the development of resistance to 
drugs and insecticides with a rapidly growing population in areas with high malaria 
transmission, it has been estimated that in the absence of effective measures the number 
of malaria cases will double over the next 20 years. 
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Figure 1.1: Malaria situation in the world (Source: WHO 2002) 
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1.1.4 Current malaria situation in Vietnam 
1.1.4.1. Parasites 
P Jalciparum is currently the predominant cause of malaria in Vietnam (72%) but P. vivax 
is dominant in Red River and Mekong River deltas. Whereas the level of chloroquine 
resistance of P. Jalciparum is variable in the North the parasite is highly resistant to 
chloroquine, and pyrimethamine in southern and central Vietnam. Decreased sensitivity 
of quinine has been reported and mefloquine resistance has also been detected in the 
south part of the country (see later chapters in this thesis) 
1.1.4.2. Vectors 
There are 3 important malaria vectors in Vietnam: 
A. minimus: found only in mountainous and hilly areas; their density is relatively 
independent of rainfall. They are partly zoophilic, partly exophilic and exophagic 
A. dirus: a highly effective vector, by Asian standards, is associated with the forest; their 
density is related to rainfall. They are highly anthropophilic, exophilic and exophagic. A. 
dirus is jointly responsible for the intense transmission in forested areas, particularly in 
central and southern Vietnam. 
A.sundaicus: a brackish water breeder, found in Vietnam, largely confined to stagnant 
water collections in the Mekong delta and on the south coast, south of Phan Thiet. They 
are mainly endophilic. 
There are about 7 secondary vectors: A. jeyporiensis in some rubber plantations; A. 
subpictus and A. vagus have been considered as vectors in plains areas. The other ones are 
A. macculatus, A. aconitus, A. hyrcanus var. sinensis, A.indefinitus (Source: unpublishes 
data from Institute of Malariology Entomology and Parasitology [IMPE] of Ho Chi Minh 
City Vietnam.) 
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1.1.4.3. Epidemiological patterns:(Source: NMCP of Vietnam) 
Transmission is geographically and temporally variable. In the South and the Central 
malaria transmission tends to be more perennial than in the North and rainfall influences 
its intensity. On basis of the entomological, ecological and social characteristics it is 
possible to classify the malaria patterns region by region 
+ Hills and mountains of northern provinces: 
In lower hill areas A. minimus is the main vector where transmission is of low intensity. 
Malaria risk may be associated with sleeping in huts. 
In higher mountains inhabited by different ethnic groups: malaria is stable with 
significant immunity developing. Migrants have been affected with outbreaks. A.dirus is 
the main vector in these areas 
+ Red River and other plains 
Malaria is rarely transmitted in this area. Occasionally, A.minimus causes mmor 
outbreaks. Above lIoN A.subpictus and A.aconitus breed in brackish water being 
associated with minor P. vivax outbreaks. 
+ The Central and southern highlands: 
That is a region with remaining dense, primary forest inhabited by ethnic minority groups 
who are perennially exposed to intense malaria transmission. 
Transmission by A.minimus and A. dirus is more intense and perennial with peaks 
occurring at the beginning and at the end of the rainy season. 
+ The Mekong delta: 
Malaria occurs in foci along the river banks and estuaries with P. vivax predominating; 
and transmitted by A. vagus 
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1.1.4.4. Morbidity & mortality 
A malaria eradication programme was implemented in 1958 in North Viet Nam. The 
smear positive rate in samples of 10% of the population was 5.6%. This had been 
reduced to 0.28 % in 1964. During the war (1965-1975) the malaria situation fluctuated 
because of difficulties in the programme but was still maintained below 1 %. 
In the South after the reunification of the country in 1975 the malaria eradication 
programme became nationwide. Several surveys which were conducted by the National 
Programme for Malaria Eradication in different sites by taking blood smears from one 
million people (about 10% of inhabitants in the malaria region) from the end of 1975 to 
1996 revealed a positive rate of 11.7% in 1976 and 2.9% in 1980. But since 1981 malaria 
was undergoing resurgence. The main contributing factors were the movement of 
population, serious lack of resources, degradation of the health service network, 
emergence of drug-resistant strains of P Jalciparum and the nadir was in 1991 with 4646 
fatal cases reported, the highest figure ever recorded. 
Malaria situation in Vietnam is presented in Table 1.1.1 and Figure 1.2 compared with the 
situation in Mekong Sub Region (Figure 1.3) 
32 
Table l.l.l: Malaria situation in Vietnam 1981-2000 (Source IMPE ofRo Chi Minh City) 
Year 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 
Cases x 106 654 527 830 875 958 1,417 1,265 1,300 952 873 
P falciparum(%) 67.8 68.6 65.2 6l.2 60.0 47.2 49.1 59.3 74.0 73.1 
Severe cases 2,882 3,950 4,306 4,199 5,381 7,056 8,811 10,470 13,709 11,613 
Deaths 1,152 1,360 1,659 1,256 1,413 1,838 2,133 2,465 3,434 2,911 
Year 91 92 93 94 95 96 97 98 99 2000 
Cases x 106 1,059 1,270 1,066 861 666 541 455 383 341 268 
P Jalciparum (%) 76.9 76.3 7l.3 7l.1 71.8 72.8 73.9 76.2 77.6 77.5 
Severe cases 31,741 26,553 14,308 8,076 4222 2146 1530 1447 1516 1075 
Deaths 4,646 2,658 1,054 604 348 198 152 183 190 139 
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Figure l.2: Malaria situation in Vietnam 1958- 1999 (Source: NMCP of Vietnam) 
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Figure 1.3: Malaria confinned cases in the Mekong Sub-region 2000 
" \\+1-: 
Source: Mekong Malaria Forum 2000 
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1.1.4.5. Anti-malarial drug use 
Viet Nam is a microcosm of the global situation. Resistance rates in vitro to chloroquine, 
quinine, and mefloquine are 92% (61/66), 18% (11/61) and 6% (4/62) respectively and a 
recent clinical trial showed that failure rates with mefloquine (15 mglkg single dose) 
monotherapy or artemisinin (20 mglkg x 5 days) monotherapy of up to 60% (TT Hien, et 
ai., 1997). 
1.1.4.6. National malaria control programme 
A National Committee chaired by a Vice Minister of Health directs the National Malaria 
Control Programme (NMCP). The Institute of Malariology-Parasitology-Entomology 
(Th1PE) which includes a headquarter in Hanoi and two regional Th1PEs - one in the 
central area (Quy Nhon) and another in the south area (Ho Chi Minh City) is responsible 
for the day-to-day management of the programme. The Th1PE is responsible for technical 
advice, research, training and data analysis, and assists the peripheral level staff in 
operations when necessary. In provinces where malaria is not a major concern, the 
malaria control stations are integrated with the Preventive Medicine Centres; but III 
provinces where the disease is a major health threat, malaria stations are split as 
independent institutions under the provincial health servIce. At the district level, the 
malarial control programme is conducted by specialised teams integrated into the district 
medical centre, which provides other medical services such as treatment (district hospital) 
hygiene, epidemiology. 
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1.2 Malaria parasite 
There are four species of parasites causing malaria in humans: 
Plasmodium malariae (Laveran 1881) 
Plasmodium vivax (Grassi and Feletti, 1890) 
Plasmodium Jalciparum (Welch, 1897) 
Plasmodium ovale (Stephens, 1922) 
P. Jalciparum and P. vivax are the main cause of morbidity and mortality of malaria in 
human being. 
The life cycle of all species of human malaria is essentially similar. It includes a sexual 
phase in the human host with transmission and multiplication in Anopheles mosquitoes 
(sporogony), of which about 60 are important malaria vectors in nature, and an asexual 
phase (schizogony) with multiplication in man. The latter phase comprises the phase 
occurs in the liver parenchyma cells (exo-erythrocytic schizogony) and the development 
cycle in the red blood cells (erythrocytic schizogony). 
1.2.1. Parasite life cycle 
1.2.1.1 Exo-erythrocytic schizogony 
Following the inoculation of sporozoites by the female mosquitoes into the subcutaneous 
tissue and less-frequently directly into the bloodstream, many of them are destroyed by 
phagocytes but some travel to the liver. Evidence indicates that sporozoites pass through 
several hepatocytes before invasion (M Mota, et aI., 2001) median of 8 to 10 sporozoites 
successfully invade. The thrombospondin domains on the circum sporozoite protein (CSP) 
and on thrombospondin-related protein (TRAP) are the co-receptors on sporozoites that 
mediate the invasion. These domains bind specifically to heparan sulphate proteoglycan, a 
hepatocyte surface molecule in the region in apposition to sinusoidal endothelium and 
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Kuppfer cells. Each sporozoite develops subsequently into tens of thousands of 
merozoites, which can each invades and red blood cell on release from the hepatocytes (U 
Frevert & A Crisanti, 1998). 
It was discovered in 1980 that the sporozoites of the relapsing species of human malaria 
parasites, P. vivax, P. ovale, differentiate either into tissue schizonts or into hypnozoites in 
varying proportions, depending on the strain. The hypnozoites remains dormant in the 
liver parenchymal cell as uni-nucleated forms, at a predetermined time those hypnozoites 
begin to grow and undergo exo-erythrocytic shizogony forming a wave of merozoites that 
are released and then invade the RBCs (W Krotoski, et aI., 1982). 
1.2.1.2 Erythrocytic schizogony 
All clinical and pathogenic manifestations associated with malaria infection are caused 
by the asexual phase of Plasmodium life cycle. Thousands of merozoites are released 
from mature schizont in the hepatocytes of the liver. These forms of the malaria parasites 
invade the RBCs where they develop into trophozoites and after full development then 
begin to multiply within the cells, forming multi-nucleated blood-stage schizonts. These 
infected RBCs then ruptures, releasing newly formed merozoites into the bloodstream 
that can invade new RBCs. Parasite ligands binding to specific receptors on the RBC 
surface is an integral part of the invasion process. The invasion-related antigens of the 
parasite are located in the apical organelles; namely, rhoptries, micronemes and dense 
granules. These apical organelles play an important role in the entry of the merozoite into 
host cell. 
The description of the sequence of the invasion of parasites comes from 1975 video 
recording of merozoites invading RBCs. The first phase of the invasion involves the 
identification of a potential host cell and the apical attachment: initial attachment of a 
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merozoite to an RBC, which can occur at any part of the parasite surface; reorientation of 
the merozoite so that its apical pole is directed toward the RBC, a process that appears to 
be facilitated by the adhesive fibrils of the surface coat; tight junction formation between 
merozoite and RBC. The second phase of the invasion involves a number of molecular 
events that allow the merozoite to gain physical entry into the RBC and become 
encapsulated inside a vacuole surrounded by a lipid membrane. Events that occur include 
(i) movement of the junctional adhesion zone around the merozoite toward its posterior 
pole, with concomitant entry of the merozoite; (ii) release of the contents of the rhoptries; 
(iii) localised alteration of the RBC membrane architecture; (iv) invagination of the RBC 
membrane with the creation of the parasitophorous membrane and a parasitophorous 
vacuole (PV) and (v) closure and sealing of the RBC and PV membrane. The final phase 
includes simultaneous closure of the RBC membrane and the PV membrane, which now 
envelops the merozoite; complete internalisation of the merozoite followed by the 
extrusion of dense bodies and the parasite's transformation into a young trophozoit 
The interaction observed between the merozoite and the RBC during invasion suggests 
that the contacts are molecularly mediated between specific receptors in the RBC 
membrane and ligands of the merozoite. Receptors that mediate invasion of RBCs by 
merozoites are found in micronemes, on the cell surface, and in rhoptries. The location of 
these receptors within organelles may protect the parasite from antibody-mediated 
neutralization, as release from apical organelles after contact with RBC may limit their 
exposure to antibody OW Barnwell, et al., 1989). 
P jalciparum and P. vivax develop over 48 hours III RBCs, producing about 20 
merozoites per mature parasite with each merozoite able to invade other RBCs. A few 
merozoites, invading the RBCs then differentiate into sexual stage parasites, male and 
female gametocytes. P. vivax develops into gametocytes soon after the release of 
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merozoites from the hepatocytes; Pfalciparum gametocytes develop much later. The 
early treatment of clinical attacks of malaria by anti blood stage drugs for P falciparum 
also kills the developing gametocytes; but P. vivax may transmit before the onset of the 
clinical stage of the disease. When taken up in the blood meal by feeding female 
anopheline mosquitoes, gamete fonnation, fertilisation, and sporozoite development occur 
and the cycle from mosquito to a new host begins again. 
1.2.2. Pathophysiology of malaria 
The disease malaria results from the blood stage of infection with asexual stages of the 
parasite; the hepatic stages and sexual stages (gametocytes) do not cause organ 
dysfunction. Pathophysiological processes in malaria result from the destruction of RBCs, 
the liberation of parasite and erythrocyte material into the bloodstream, and the host 
reaction to these events. Pfalciparum infected RBCs also sequester in the capillaries and 
venules of vital organs, interfering with microcirculation and host tissues metabolism. 
1.2.2.1 Parasite multiplication: 
When the hepatic schizonts rupture, they release approximately 105 to 106 merozoites 
into the circulation. On average, parasites are detectable in the blood by microscopy (20-
50 parasites/ J.lL of blood) on the 11th day after sporozoite inoculation (SF Kitchen, 
1949). At this stage the host may still feel well or may complain of vague symptoms such 
as malaise, headache, myalgia or anorexia. The fever usually begins two days later. At the 
onset of fever, the adult patient has approximately 108 parasites in the body, which 
corresponds to 20-200 parasites in each J.lL of blood. In endemic areas, persons with 
immunity may tolerate parasitaemias up to 10,000/J.lL of blood without feeling ill (N 
White, 2003). The variation of peripheral parasite count resembles a sine wave pattern 
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with considerable amplitude in synchronous Pfalciparum infections. In most cases, the 
parasite multiplication tenninates abruptly to limit the infection at a parasitaemia of 10-+ to 
10
5 
filL. Only P fa lcipa rum has the capacity for untrammeled multiplication, and parasite 
counts may exceed 50% in some cases. Several factors limit the parasite mUltiplication. 
The host mobilizes non-specific then specific immune defenses. The parasites are also 
damaged by high fever, and this could explain the brake on parasite expansion (D 
Kwiatkowski & M Nowak, 1990). The untreated infection increases exponentially then 
the rate of expansion decelerates rapidly, parasitaemia fluctuates, then declines and 
continues for several weeks or months at low levels before finally being eliminated. 
Although natural infections often contain 2 or more genetically different parasite strains, 
development of the parasite population tends to be synchronous from the onset. The 
malaria paroxysm (fever and rigors) is associated with the rupture of blood schizonts. In 
P falciparum infection, there is usually at least one minor brood or subpopulation cycling 
24 hours out of phase with the major brood (GQ Li, et aI., 1982a). 
1.2.2.2 Sequestration 
The essential pathological feature of severe fa1ciparum malaria is sequestration of 
erythrocytes containing mature fonns of the parasite in the deep vascular beds of vital 
organs. Sequestration is not unifonnly distributed among the vital organs; it is usually 
greatest in the brain which may explain why cerebral malaria is such a prominent feature 
of severe fa1ciparum malaria in man, and least in the skin (GG MacPherson, et at., 1985, 
E Pongponratn, et al., 1991). Sequestration is also not unifonnly distributed at a 
microvascular level. Some vessels are completely packed with parasitized RBCs, while 
adjacent vessels are clear (K Silamut, et aI., 1999). This may cause more gradually 
reduction in blood flow perhaps with less hypoxia because of preserved flow in adjacent 
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capillaries. Two principal mechanisms have been proposed to account for such 
obstruction, but in both cases the result is capillaries congested with red cells containing 
parasites. 
Decreased deform ability 
Normal RBCs must undergo considerable deformation in order to traverse the capillary. 
As the parasite grows inside the red cell, it becomes more rigid and the surface becomes 
more irregular and covered in small protrusions (RA Cranston, et aI., 1984). Several 
factors are likely to account for reduced deformability of parasitized erythrocytes, notably 
changes in the cytoskeleton, increased membrane stiffness, increased cytoplasmic 
viscosity resulting from changes in membrane permeability, reduced surface area to 
volume ratio (increased sphericity), and principally the rigidity of the parasite itself. 
Cytoadherence. 
Pathological studies show an intimate apposition of endothelial cell and infected 
erythrocyte membranes. Cytoadherence, the binding of mature RBCs to endothelial cells 
in post- capillary venules, is believed to be a key virulence factor. The precise molecular 
mechanisms underlying this interaction have recently been characterized. Cytoadherence 
is mediated by receptors on endothelial cells, molecules expressed on the surface of 
infected RBCs. Uninfected erythrocytes will also bind to the surface of RBCs containing 
mature forms of the parasite, by a mechanism similar to that of cytoadherence to 
endothelial cells, causing "rosetting". 
Parasites sequester themselves in various organs such as brain, heart, lung, liver, kidney, 
subcutaneous tissue and placenta. The endothelial cells in those organs express different 
and various amounts of host receptors. The adhesion phenotype is not homogenous, 
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different parasites can bind to variable numbers of host receptors. The variability is 
thought to affect the tissue distribution and pathogenesis of parasites. Molecules on the 
surface of endothelial cells which bind P. Jalciparum infected RBCs include 
thrombospondin, CD 36, intercellular adhesive molecule 1 (ICAM 1), vascular adhesive 
molecules 1 (VCAM 1), E selectin, chondroitine sulfate A (CSA), hyaluronic acid (HA). 
Pfalciparum derived molecules on the RBC surface which mediate adherence include Pf 
EMP 1, sequestrin, modified RBC band 3, rosettins, Pf 332 (N White, 2003) 
Cytoadherence results in sequestration of infected RBCs in the deep vasculature of 
organs, and therefore it localizes parasites in sites of low oxygen tension which are ideal 
for their growth It also prevents infected RBCs being destroyed in the spleen and it is 
thought to be the cause of organ dysfunction through microcirculation obstnlction, 
endothelial cell activation and damage, cytokine release. 
Roselling. 
Rosetting is ability of infected RBCs to adhere to uninfected RBCs. This phenomenon 
occurs in RBCs containing mature stage of parasite. Rosetting takes place only on the 
venous side of the microcirculation. The adhesive capacity varies between different 
P falciparum isolates (J Carlson, et aI., 1994). Rosetting is mediated by PfEMP1 and 
rosettins and involves the complement receptor, heparan sulphate, blood group A antigen, 
and probably other red cell surface molecule (A Rowe, et al., 1994, A Rowe, et al., 1995). 
Parasites with broad adhesive capacities might be the ones that are involved in excessive 
binding and blockade of the microcirculation and the induction of severe malaria. 
Rosetting has been associated with severe malaria in some studies but not in others (A 
Rowe, et aI., 1995, PA Zimmerman, et aI., 2003) 
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1.2.2.3 Cytokines 
For many years, it was thought that parasites secreted toxin(s) at schizont rupture and 
cause the malaria symptoms. No toxin has been identified but malaria parasites do induce 
the release of cytokines. Tumor necrosis factor (TNF-a), interleukin (IL)-l and gamma 
interferon (y-IFN) are produced and these induce the release of a cascade of "pro-
inflammatory" cytokines including IL-8, IL-12, IL-18. These are balanced by production 
of the "anti-inflammatory" cytokines IL-6, IL-10 (M Ho, et aI., 1998, P Kern, et aI., 
1989). Plasma concentration of the cytokines are elevated in both vivax and falciparum 
malaria (GE Grau, et aI., 1989, ND Karunaweera, et aI., 1992). Acute malaria is 
associated with high levels of most cytokines, but the balance differs in relation to 
severity. Il-12 and TGF-p 1 (transforming growth factor), which may regulate the balance 
between pro- and anti- inflammatory cytokines, are higher in uncomplicated than in 
severe malaria (DJ Perkins, et aI., 2000) 
Cytokines are responsible for many of the symptoms and signs of malaria particularly 
fever and malaise. There is no direct evidence that systemic release of TNF or other 
cytokines causes coma in human. In a recent study on severe malaria in adults, elevated 
plasma TNF concentrations were associated specifically with acute renal failure and TNF 
levels were actually lower in patients with pure cerebral malaria than those of other 
complications (NP Day, et al., 1999). Cytokine are probably involved in placental 
function, suppression of erythropoiesis and inhibition of gluconeogenesis. Cytokines also 
up-regulate the endothelial expression of vascular ligands for P Jalciparum infected red 
blood cells, notably ICAM-1 and thus promote cytoadherence. 
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1.2.2.4 Cerebral malaria 
Cerebral malaria, a diffuse reversible encephalopathy, is the major lethal complication of 
the infection. The sequestration of RBCs containing mature forms of P Jalciparum in the 
cerebral microvasculature is considered the essential underlying pathological process, 
although how this cause coma and death remains unanswered. Various theories have been 
proposed and tested. 
Sequestration results from the adherence of parasitized RBCs to vascular endothelium. In 
vitro studies suggest that infected RBCs begin to cytoadhere at the late ring or early 
trophoizoite stage of the parasite's cycle. Studies in vivo and histopathological 
observations in fatal P Jalciparum malaria cases suggest that the RBCs containing more 
mature parasites are sequestered in the brain and other organs. Post- mortem studies have 
given conflicting results on the predominant stage of parasite development encountered in 
the brain. Lemercier et al reported almost exclusively schizonts (G Lemercier, et aI., 
1966) whereas MacPherson found that both trophozoites and schizonts predominate (GG 
MacPherson, et aI., 1985). Microvascular sequestration was assessed in the brains of 50 
Vietnamese and Thai patients who died from severe malaria; the results have shown that 
within the same brain different vessels had discrete but different populations of parasites 
indicating that the adhesion characteristics of cerebrovascular endothelium change 
asynchronously during malaria, and that significant re-circulation of parasitized RBCs is 
unlikely. Furthermore there were significantly more ring form parasites in the cerebral 
microcirculation than expected (nine fold)(K Silamut, et aI., 1999). The possible role of 
local mechanical factors causing microvascular obstruction (resulted from parasitized 
RBC sequestration) and resulting in hypoxia and ischemia can only be inferred and not 
proved with neuropathological and immunohistochemical or ultrastructural examination 
(E Pongponratn, et al., 2003). There is no evidence of widespread hypoxic-ischemic 
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patterns of brain damage. The increased cerebral lactate production reflected in increased 
jugular venous and cerebrospinal fluid (CSF) concentrations of lactate indicates 
significant anoxic metabolism, but it is not clear whether these changes in themselves 
provide sufficient explanation for coma (NJ White & MHo, 1992). 
The role of cerebral oedema in the pathogenesis of coma has been debated for decades. 
Although this pathological feature has been seen in some post-mortem investigations, it 
was not common in a MRI study on adults with cerebral malaria in South East Asia. This 
is consistent with the observations in recent studies on the structural integrity of the 
blood-brain- barrier and ultrastructure of the brain in fatal cases of P. Jalciparum malaria 
(H Brown, et aI., 1999, 1M Medana, et aI., 2001, 1M Medana, et aI., 2002a) 
The relative good prognosis of cerebral malaria survivors differs from that following 
coma in encephalitis, trauma, or vascular diseases. This suggests that coma in cerebral 
malaria is a metabolic or anaesthetic encephalopathy. This obviously involves 
neurotransmitter abnormalities and potent inhibitors of neurotransmission could play a 
role. Recent studies of Kenyan children with cerebral malaria have proposed that the 
imbalances of excitatory mediators may be implicated in the initiation and maintenance 
of seizures and neuronal degeneration and might contribute to neurological symptoms in 
cerebral malaria (M Dobbie, et aI., 2000). An imbalance in the production of excitotoxic 
and neuroprotective tryptophan metabolites produced from the kynurenine (KYN) 
pathway has also been observed in a murine model of CM in which these pathological 
processes are prominent. In a retrospective study of 261 Vietnamese adult patients with 
severe malaria three metabolites, the excitotoxin quinolinic acid (QA); the protective 
receptor antagonist kynurenic acid (KA); and the proinflammatory mediator picolinic 
acid (PA) were measured and related to the incidence of neurologic complications, CSF 
lactate level and the disease outcome. The results have indicated that there was no 
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difference in the levels of KA between groups; no association between CSF QA 
concentrations and convulsion or depth of coma, and that the significant elevation of QA, 
P A levels and QA:KA ratio in patients with poor outcome was only a consequence of 
impaired renal function in this group (lM Medana, et aI., 2002b). In another post-mortem 
study on 54 Vietnamese patients who died from severe Pfalciparum malaria the authors 
have found a marker of potentially reversible axonal damage, namely ~-amyloid 
precursor protein (~-APP) normally transported along the axon, and which accumulates 
at the site of axonal injury, that is significantly associated with cerebral malaria in adults 
and that this distinguishes cerebral malaria from non-cerebral malaria. This marker 
highlights the internal capsule and pons as areas of primary involvement in axonal 
injuries. Unlike other pathological correlates such as neuronal stress markers, axonal 
injury does not seem to purely reflect the systemic contribution of severe malaria to the 
specific neurological syndrome of cerebral malaria (lM Medana, et al., 2002a) and axonal 
injury may be an important step in understanding the mechanism of cerebral malaria. 
1.2.2.5 Renal failure 
Renal failure is a common complication of P. Jalciparum infection in adults; 
approximately half of these patients have evidence of renal impairment (TT Trang, et aI., 
1992). But renal failure is rare in children with complicated fa1ciparum malaria in Africa 
and much less common in children than adults in South East Asia. The basic pathology is 
acute tubular necrosis. Renal impairment may be compounded by hypovolemia, severe 
aenemia and haemoglobinuria. The pathological processes that result in acute tubular 
necrosis have not been clarified. Cytoadherence of parasitized red cells in the glomerular 
capillaries is occasionally seen, but is not as pronounced as in other organs such as the 
brain (GG MacPherson, et aI., 1985). Studies of renal cortical blood flo\\' (V Sitprija, el 
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aI., 1977) and radiological studies (angiography and contrast urography) (S Arthachinta, 
et aI., 1974) have shown a reduction in cortical perfusion during the acute stage of disease 
as in other fonns of acute tubular necrosis. The oxygen consumption of the kidneys is 
reduced in acute renal failure and it is not improved by administration of dopamine \vhich 
induces arteriolar vasodilatation and consequently increases the renal blood flow; 
therefore that suggests a fixed injury (NP Day, et aI., 2000) The role of local cytokine 
release and altered regulation of renal microvascular flow is uncertain because vivax 
malaria does not cause acute renal failure despite the massive cytokine release that occurs 
during paroxysms. 
1.2.2.6 Hepatic dysfunction 
Impainnent of hepatic function is common in severe malaria. Jaundice is significantly 
more common in adults with severe malaria than in children. The measurable 
consequences of hepatic dysfunction are coagulation abnonnalities resulting from failure 
to synthesize clotting factors (which may be complicated by the consumption of clotting 
factors), hypo-albuminaemia, and reduced metabolic clearance of many substances 
including alanine and lactate, and antimalarial drugs. Hepatic blood flow, measured by 
indocyanine green clearance, is reduced during acute malaria, and is significantly lower in 
severe malaria than in uncomplicated malaria. Indocyanine green clearance may reflect 
not only liver blood flow but also biliary excretion. Galactose clearance, an alternative 
measure of liver blood flow, and also glycerol clearance have been found to be relatively 
unperturbed by malaria (S Pukrittayakamee, et at., 1992). These data suggest that 
sequestration and consequent microcirculatory obstruction in the portal and hepatic 
circulations, or portal venoconstriction as demonstrated in rhesus monkeys infected with 
P. knowlesi is unlikely to be the sole cause of liver dysfunction. Clearly, some metabolic 
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processes, such as gluconeogenesis, are more perturbed than others. Liver biopsy usually 
reveals Kupffer cell hyperplasia and mononuclear cell infiltration. Other studies have 
shown either no structural changes or slight hepatocyte swelling (S Sherlock, 1975). 
Centrizonal necrosis has been reported (YK Joshi, et al., 1986). More discriminating 
measures of liver function are needed to define the importance of hepatic impairment in 
severe malaria. Recent study investigating the prevalence of hepatitis B virus infection 
among Vietnamese patients with severe falciparum malaria has revealed that the overall 
prevalence of HBsAg was higher than that in general catchment population for the study 
hospital and patients admitted with cerebral malaria had a greater risk of registering 
positive HbsAg to other manifestation of severe malaria (MJ Barcus, et aI., 2002). 
1.2.2.7 Hypoglycaemia 
Hypoglycaemia is increasingly recognized as an important manifestation of falciparum 
malaria. There are several possible causes of hypoglycaemia and different patterns of 
associated biochemical abnormalities. 
Quinine/quinidine-induced hyperinsulinaemia: quinine is a most potent in vitro stimulus 
to islet cell insulin secretion and has been shown to release insulin in vivo in healthy 
subjects and in patients with falciparum malaria, both in pregnant women with severe or 
relatively mild disease, and in adults and children with severe disease (TM Davis, et aI., 
1993b, S Krishna, et al., 1994, S Looareesuwan, et al., 1985b, W Okitolonda, et aI., 1987, 
NJ White, et al., 1983c). Increased glucose consumption: glucose consumption increases 
in fever and infection. Increased glucose turnover in acute falciparum malaria is caused 
by both increased glucose consumption of the host and the parasite (TM Davis. et al.. 
1993a) although the host's requirements are considerably greater. Children with se\"ere 
malaria have considerably increased glucose requirements compared with adults. 
49 
Chapter 1: INTRODUCTION 
Glycogen depletion or impaired gluconeogenesis: hypoglycaemia in African children with 
severe malaria, and in adults who have not received previous quinine treatment, is 
associated with appropriately low plasma concentrations of insulin (TE Taylor, et al., 
1988). Hypoglycaemia is considered to result both from variable depletion in hepatic 
glycogen, an inhibition of hepatic gluconeogenesis, and a 2 - 3 fold increase in glucose 
turnover (TM Davis, et aI., 1993a). 
1.2.2.8 Lactic acidosis. 
Lactic acidosis is a major cause of death from severe fa1ciparum malaria (NJ White, et aI., 
1983c ),(S Krishna, et al., 1994, TE Taylor, et aI., 1988, NJ White, et aI., 1987b). 
Metabolic acidosis is a consistent feature of severe malaria in adults and children (K 
Marsh, et al., 1995) and in children this is mainly a lactic acidosis, whereas in adults renal 
failure and lactic acidosis both contribute. Lactate, measured either in venous or arterial 
blood, or cerebrospinal fluid is an accurate prognostic indicator in severe malaria (NJ 
White, et al., 1985),(D Waller, et aI., 1995). Lactic acidosis results from several 
processes: the tissue anaerobic glycolysis due to microvascular obstruction, the 
production of lactate by parasites and the failure of hepatic and renal lactate clearance (NJ 
White & M Ro, 1992) (MA PfaIler, et aI., 1982, DL Vander J agt, et aI., 1990) 
1.2.2.9 Pulmonary oedema 
The heart function is well preserved in severe malaria despite intense sequestration in the 
myocardial vessels. Pulmonary oedema in severe malaria results from a sudden increase 
in pulmonary capillary permeability but the cause of this phenomenon is not known.(P 
Charoenpan, et al., 1990, MF James, 1985) 
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1.2.3 The clinical aspect of malaria infection 
The clinical outcome of malaria infection depends on many parasite, host, geographic and 
social factors. Those converge in the patient to result in a spectrum, from an 
asymptomatic infection to severe disease and death. 
1.2.3.1 Asymptomatic infection 
Clinical aspects of malaria are markedly different In non-Immune and semI-Immune 
populations. The term immune is not used because natural infection does not produce true 
immunity against either reinfection or disease. In non-immune persons such as expatriate 
travelers, detectable parasistaemias produce significant symptoms, complications or 
death. In contrast, many infected semi-immune have no symptoms at all. 
1.2.3.2 Non- complicated malaria: 
The first symptoms of malaria are not specific: loosing the sense of well-being, headache, 
fatigue, muscle and joint aches, abdominal discomfort, followed by fever, are similar to 
the symptoms of a minor viral infection. In some instances, a prominence of headache, 
chest pain, abdominal pain, arthralgia, myalgia, or diarrhea may suggest another 
diagnosis. Headache may be severe in malaria, but there is no neck stiffness, and neither 
are Kemig's or Brudzinski signs positive as in meningitis. Myalgia may be prominent as 
severe as in dengue fever, or as in leptospirosis. Nausea and vomiting are common. The 
classic malarial paroxysms, in which fever spikes, chills, and rigors occur at regular 
intervals, only develop after days or weeks of untreated infection. The fever is irregular at 
the onset of illness. The temperature of non-immune individuals and children often rises 
above 40°C in conjunction with tachycardia and sometimes delirium. Although childhood 
febrile convulsions may occur with any of the malarias, generalized seizures are 
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specifically associated with falciparum malaria and may herald the development of 
cerebral disease. Many clinical abnormalities have been described in acute malaria, but 
most patients with uncomplicated infections have few abnormal physical findings other 
than fever, mild anaemia, and a palpable spleen. Anaemia is quite common among young 
children living in high transmission. Mild jaundice and slight enlargement of the liver is 
also commonly seen in adults. Malaria is not usually associated with rash like those seen 
in patients with measles, viral exanthems or drug reactions; neither are there skin 
hemorrhages (petechia) as in meningococcal septicemia, or viral hemorrhagic fevers. 
Uncomplicated falciparum malaria carries a mortality rate of about 0.1 %. However, once 
vital organ dysfunction occurs, mortality rises steeply (NJ White, 2003). 
1.2.3.3 Cerebral Malaria: 
Cerebral malaria is the most common clinical presentation and cause of death in adult 
with severe malaria. It manifests as a diffuse symmetric encephalopathy; focal neurologic 
signs are unusual. Coma is a characteristic and ominous feature of falciparum malaria 
and, despite treatment, is associated with death rates above 20% (TT Hien, et al., 1996, 
DA Warrell, 1992). The onset may be gradual or sudden following a convulsion. Lesser 
degrees of obtundation, delirium, and abnormal behavior may also occur. The eyes may 
be divergent and a pout reflex is common, but other primitive reflexes are usually absent. 
The tendon reflexes are variable, and the plantar reflexes may be flexor or extensor. 
Decortication (flexor) or decerebration (extensor) posturing is also documented. Muscle 
tone may be either increased or decreased. The corneal reflexes are preserved except in 
deep coma (NJ White). Approximately 15 - 22% of patients have retinal hemorrhages (S 
Looareesuwan, et al., 1983, JF Schemann, et al., 2002); with pupillary dilatation and 
indirect ophthalmoscopy, this figure increases to 30 to 40%. Other abnormalities include 
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discrete spots of retinal opacification (30 to 60%), papillooedema (8% of children, rare in 
adults), cotton wool spots «5%), and decolourization of a retinal vessel or segment of 
vessel ( occasional cases). Convulsions, usually generalized and often repeated, occur in 
up to 50% of children with cerebral malaria (AA Asindi, et al., 1993). More covert 
seizure activity is common, particularly in children, and may manifest as repetitive tonic-
clonic eye movements (J Crawley, et a!., 1996). While adults rarely suffer neurologic 
sequelae, about 10% of children surviving cerebral malaria particularly those with 
hypoglycaemia, severe anaemia, repeated seizures, and deep coma have some neurologic 
sequelae when they regain consciousness; hemiplegia, cerebral palsy, cortical blindness, 
deafness, and impaired cognition and learning all of varying duration have been reported 
(ME Molyneux, et al., 1989) (DR Brewster, et a!., 1990) (FS Bondi, 1992). 
1.2.3.4 Renal Impairment: 
Renal impairment is common among adults with severe fa1ciparum malaria but rare 
among children (ME Molyneux, 1990) (XT Cao, et al., 1997a). Clinically and 
pathologically, this syndrome manifests as acute tubular necrosis; renal cortical necrosis 
never develops. Without renal replacement therapy the mortality rate may rise up to 75% 
(TT Trang, et al., 1992). In survivors, urine flow resumes in a median of 4 days, and 
serum creatinine levels return to normal in a mean of 17 days. Peritoneal dialysis or 
haemofiltration considerably improves patient's survival. 
1.2.3.5 Liver Dysfunction: 
Mild haemolytic jaundice is common in malaria. Severe jaundice is associated with P. 
falciparum infections, is more common in adults than in children (XT Cao, et at., 1997b). 
When accompanied by other vital organ dysfunction (often renal impainnent), liver 
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dysfunction carries a poor prognosis. Hepatic dysfunction contributes to hypoglycaemia, 
lactic acidosis, and impaired drug metabolism. 
1.2.3.6 Hypoglycaemia: 
An important and common complication of severe malaria, hypoglycaemia is associated 
with a poor prognosis (NJ White, et aI., 1983c) and is particularly problematic in 
children and pregnant women (S Looareesuwan, et aI., 1985b) (NJ White, et aI., 1987c) 
(TE Taylor, et aI., 1988). In severe disease, the clinical diagnosis of hypoglycaemia is 
difficult: the usual physical signs (sweating, gooseflesh, tachycardia) are absent, and the 
neurologic impairment caused by hypoglycaemia cannot be distinguished from that 
caused by malaria. 
1.2.3.7 Lactic Acidosis: 
Lactic acidosis commonly coexists with hypoglycaemia in patients with malaria and that 
is an important contributor to death from severe malaria (NJ White, et aI., 1983c) (NJ 
White, et aI., 1985). In adults, coexisting renal impairment often compounds the acidosis. 
Acidotic breathing, sometimes called respiratory distress, is a sign of poor prognosis. It is 
often followed by circulatory failure refractory to volume expansion or inotropic drugs or 
by respiratory arrest. The plasma concentrations of lactate or bicarbonate are the best 
biochemical prognostic indicators in severe malaria. The prognosis of lactic acidosis is 
poor. 
1.2.3.8 Non-cardiogenic pulmonary oedema: 
Adults with severe falciparum malaria may develop non-cardiogenic pulmonary oedema. 
(MA von Mach, et aI., 2003). The pathogenesis of this form of the adult respiratory 
distress syndrome is unclear (Y Blanloeil, et aI., 1980) (WHO, 2000b). The mortality rate 
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is >80%. This condition can be aggravated by overloaded administration of intravenous 
fluid. 
1.2.3.9 Haematologic abnormalities: 
Anaemia results from accelerated red cell destruction and removal by the spleen in 
conjunction with ineffective erythropoiesis. In non-immune individuals and in areas with 
unstable transmission, anaemia can develop rapidly and transfusion is often required (RE 
Phillips, et al., 1986a) (TT Hien, et aI., 1996). In many areas of Africa, children may 
develop severe anaemia as a result of repeated malarial infections (K Marsh, et aI., 1995). 
Anaemia is a common consequence of antimalarial drug resistance, which results in 
repeated or continued infection. 
Slight coagulation abnormalities are common III falciparum malaria, and mild 
thrombocytopenia is usual. As mentioned above, fewer than 5% of patients with severe 
malaria have significant bleeding with evidence of disseminated intravascular coagulation 
(RE Phillips, et aI., 1986a). Haematemesis, presumably from stress ulceration (TT Hien, 
et aI., 1996) or corticosteroid therapy, may also occur (DA Warrell, et aI., 1982) (SL 
Hoffinan, et al., 1988). 
1.2.3.10 Other complications: 
Aspiration pneumonia following convulsions is an important cause of death in cerebral 
malaria. Chest infections and catheter-induced urinary tract infections are common among 
patients who are unconscious for> 3 days. Septicaemia may complicate severe malaria; in 
endemic areas, Salmonella bacteremia has been associated specifically with P. jalcipal1wl 
infections (WHO, 2000b). 
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1.2.3.11 Malaria in pregnancy: 
In areas with stable malaria (hyper- and holoendemic areas) P. Jalciparum infection in 
pregnant women (semi-immune), is increased in compared with non-immume pregnant 
women (living in unstable malaria areas) in terms of frequency and density of 
parasitaemia; it is also associated with low birth weight (average reduction, ~ 170 g) and 
consequently increased infant and childhood mortality (R Menon, 1972) (F Nosten, et aI., 
1991 b) . In general, infected mothers in areas of stable transmission remain asymptomatic 
despite intense parasitization of the placenta due to sequestration of parasitized 
erythrocytes in the placental microcirculation (BJ Brabin, 1983) (YJ Garin, et aI., 1985) 
(R W Steketee, et al., 1996). Maternal HIV infection predisposes pregnant women to a 
higher prevalence of malaria and parasite density and predisposes their newborns to 
congenital malaria infection and low birth weight. The effects is greatest in women with 
1st pregnancy but they do extend to their 2nd or 3rd pregnancy (PB Bloland, et aI., 1995) 
(V Leroy, et aI., 1998) (FO ter Kuile, et aI., 2004). 
In areas with unstable transmission, malaria in pregnant women has devastating effects on 
both mother and fetus. The most common complications are high parasitaemia with 
anaemia, hypo glycaemia (S Looareesuwan, et aI., 1985b), and acute pulmonary aoedema. 
Fetal distress, premature labor, and stillbirth or low birth weight are commonly seen. 
Severe fa1ciparum malaria in those non-immune women is associated with high mortality 
(20-50%), and is often fatal to the fetus irrespective maternal outcome (TT Hien 
unpublished data). P. vivax malaria in pregnancy is also associated with a reduction in 
birth weight (average, 100 g), but, in contrast with the situation in falciparum malaria, this 
effect is greater in multigravid than in primigravid women (F Nosten, et aI., 1999). 
Congenital malaria occurs in fewer than 5% of newborns whose mothers are infected and 
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is related to the parasite density in maternal blood and in the placenta (TC Quinn, et aI., 
1982) (TV Hulbert, 1992) (B Balaka, et aI., 2000). 
1.2.3.12 Malaria in Children: 
There is one to 3 million young African children who die of falciparum malaria each year. 
Convulsions, coma, hypoglycaemia, metabolic acidosis, and severe anaemia are relatively 
common among children with severe malaria, whereas deep jaundice, acute renal failure, 
and acute pulmonary oedema are unusual (D Waller, et al., 1995) (K Marsh, et aI., 1995) 
(SJ Allen, et al., 1996) (XT Cao, et al., 1997b). Severely anaemic children may present 
with labored deep breathing, which in the past has been attributed incorrectly to "anaemic 
congestive cardiac failure" but is in fact usually caused by metabolic acidosis, often 
compounded by hypovolaemia (M English, et al., 1996). In general, children tolerate 
antimalarial drugs well and respond rapidly to treatment. 
1.2.3.13 Transfusion Malaria: 
Malaria can be transmitted by blood transfusion, needle-stick injury, sharing of needles 
by infected intravenous drug addicts, or organ transplantation. The incubation period is 
often short because the pre-erythrocytic stage of development is by-passed. The clinical 
features and management of these cases are the same as for naturally acquired infections, 
although falciparum malaria tends to be especially severe in drug addicts (TT Chau, et at., 
2002). Radical chemotherapy with primaquine is unnecessary for P. vivax and P. ovale 
infections. 
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1.2.3.14 Chronic complications ofmalaria 
Splenomegaly: 
Chronic or repeated malarial infections produce normochromic, normocytic anaemIa, 
hypergammaglobulinemia; and in certain situations, splenomegaly (GG Crane, 1986). (J 
Torres, et al., 1988), Some residents of malaria-endemic areas in tropical Africa and Asia 
exhibit an abnormal immunologic response to repeated infections that is characterized by 
maSSIve splenomegaly, hepatomegaly, marked elevations in serum titers of IgM and 
malarial antibody, hepatic sinusoidal lymphocytosis, and (in Africa) peripheral B cell 
lymphocytosis (J Van den Ende, et al., 2000). This syndrome has been associated with the 
production of cytotoxic IgM antibodies to suppressor (CD8+) lymphocytes, antibodies to 
CD5+ T cells, and an increase in the ratio of CD4+ T cells to CD8+ T cells. It is believed 
that these events lead to uninhibited B cell production of IgM and the formation of 
cryoglobulins (IgM aggregates and immune complexes) (MF Moraes, et al., 2003). This 
immunologic process stimulates reticuloendothelial hyperplasia and clearance activity 
and eventually produces splenomegaly. Patients with hyperreactive malarial 
splenomegaly (HMS) present with an abdominal mass or a dragging sensation in the 
abdomen and occasional sharp abdominal pains suggesting perisplenitis. In many cases, 
malarial parasites cannot be found in peripheral blood smears (S Puente, et al., 2000), (JR 
Torres, et al., 2003). Severe respiratory and skin infections are increased; many patients 
die of overwhelming sepsis. Persons with HMS who are living in endemic areas should 
receive antimalarial chemoprophylaxis: the results are usually good. In non-endemic 
areas, treatment is advised (MI Muniz-Junqueira. et al., 1992), (J Vanden Ende, et al.. 
1994), (F Manenti, et al., 1994) 
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Quartan Malarial Nephropathy: 
Long-tenn and repeated infections with P. malariae, and possibly other malarial species, 
(MB Abdurrahman, et aI., 1990) may cause soluble immune-complex injury to the renal 
glomeruli, resulting in the nephrotic syndrome (RG Hendrickse, 1976) (JW 
Kibukamusoke, 1986). Other unidentified factors must contribute to this process since 
only a very small proportion of infected patients develop renal disease. The histologic 
appearance is that of focal or segmental glomerulonephritis with splitting of the capillary 
basement membrane. Sub-endothelial dense deposits are seen on electron microscopy, 
and immunofluorescence reveals deposits of complement and immunoglobulins; in 
samples of renal tissue from children, P. malariae antigens are often visible. A coarse-
granular pattern of basement membrane immunofluorescent deposits (predominantly 
IgG3) with selective proteinuria carries a better prognosis than a fine-granular, 
predominantly IgG2 pattern with nonselective proteinuria (RR White, 1973). Quartan 
nephropathy usually responds poorly to treatment with either antimalarial agents or 
glucocorticoids and cytotoxic dnlgs (JW Kibukamusoke, 1968), (JA Jefferson & WG 
Couser, 2003). 
Burkitt's Lymphoma and Epstein-Barr Virus Infection: 
It is possible that malaria-related immunosuppression provokes infection with lymphoma 
viruses. Burkitt's lymphoma is strongly associated with Epstein-Barr virus. The 
prevalence of this childhood tumor is high in malarious areas of Africa (G de The, 1993), 
(LS Young & AB Rickinson, 2004) 
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1.2.4 Diagnosis of malaria 
1.2.4.1 Conventional methods 
The diagnosis of malaria relies on the demonstration of asexual fonns of the parasite in 
smears of peripheral blood. Following a negative blood smear, repeated smears should be 
made every 6-8 hours if there is a high degree of suspicion. Giemsa at pH 7.2 is preferred; 
Wright's, Field's, stain can be used. Both thin and thick blood smears should be examined. 
The thin blood smear should be dried, fixed in pure methanol, stained, and the red cells in 
the tail of the film should then be examined under oil immersion. The thick blood film 
should be of uneven thickness. The smear should be dried thoroughly and stained without 
fixing. As many layers of erythrocytes overlie one another and are lysed during the 
staining procedure, the thick film has the advantage of concentrating the parasites (by 20-
to 40-fold compared with a thin blood film) and thus increasing diagnostic sensitivity. 
Both parasites and white cells in each field are counted, and the number of parasites per 
unit blood volume is calculated from the total leukocyte count, assuming that an average 
white cell count is of 8000/uL; and a minimum of 200 white cells should be counted. 
Interpretation of thick films requires some experience because artifacts are common. 
Before a thick smear is judged to be negative, 100 to 200 fields should be examined under 
oil immersion. Phagocytosed malarial pigment is sometimes seen inside peripheral blood 
monocytes or polymorphonuclear leukocytes and may provide a clue to recent infection if 
malarial parasites are not detectable (NH Phu, et al., 1995). After the clearance of the 
parasites, malarial pigment is often evident for several days in peripheral blood 
phagocytes, bone marrow aspirates, or smears of fluid expressed after intradennal 
puncture. Staining of parasites with the fluorescent dye acridine orange allows more rapid 
diagnosis of cases in which the level of parasitaemia is low. 
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The parasitaemia is expressed as the number of parasitized erythrocytes among 1000 red 
cells, and this figure is converted to the number of parasitized erythrocytes per microliter. 
The relationship between parasitaemia and prognosis is complex; in general, patients with 
> 105 parasites per microliter are at increased risk of dying, but non-immune patients may 
die with much lower counts and semi-immune persons may tolerate parasitaemia levels 
many times higher with only minor symptoms. 
In severe malaria, a poor prognosis is indicated by a predominance of more mature P. 
!alciparum parasites (i.e., >20% of parasites with visible pigment), by the presence of 
circulating schizonts in the peripheral blood film, or by the presence of phagocytosed 
malarial pigment in >5% of neutrophils (K Silamut & NJ White, 1993),(NH Phu, et aI., 
1995). Gametocytes may remain evident for several days after treatment has begun; 
unless trophozoites are also visible on the blood film, their presence does not constitute 
evidence of drug resistance. 
1.2.4.2 Rapid diagnosis tests (RDT) 
Simple, sensitive, and specific antibody-based diagnostic stick or card tests that detect P. 
!alciparum-specific, histidine-rich protein (HRP2) or lactate dehydrogenase (LDH) 
antigens in finger-prick blood samples have been introduced. Some of these tests carry a 
second antibody, which allows distinguish fa1ciparum malaria from the less dangerous 
malarias. 
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1.2.4.3 Laboratory findings: 
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Malaria 
P . f . 
. .. 
. . . 
Normochromic, nOnllocytic anaemia IS usually documented . The leukocyte count i 
generally low to normal , although it may be raised in severe infections. The platelet count 
is usually reduced to lower than lOs/ilL. Severe infections may be accompanied by 
prolonged prothrombin and partial thromboplastin times and by severe thrombocytopeni a. 
In uncomplicated malaria, plasma concentrations of electrolytes, blood urea nitrogen, and 
creatinine are usually nOnllal. Findings in severe malaria may include metabolic ac ido i , 
with low plasma concentrations of glucose, sodium, bicarbonate, calcium, pho phate, and 
albumin together with elevations in lactate, blood urea nitrogen, creatinine, urat , mu cl 
and liver enzymes, and conjugated and unconjugated bilirubin. In adult and childr n \\ ith 
cerebral malaria , the mean opening pressure at lumbar punctur - 16 mill f 
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cerebrospinal fluid (CSF); the CSF is usually nonnal or has a slightly elevated total 
protein level [<1.0 giL (100 mgldL)] and cell count «20/uL). 
1.2.5 Treatment of malaria 
1.2.5.1 Antimalarial drugs 
Chloroquine 
Chloroquine is the most important of the 4-aminoquinoline compounds. It remains an 
effective treatment for severe malaria in those few areas where P. Jalciparum retains full 
sensitivity. 
Chloroquine IS rapidly absorbed after oral administration in healthy adults (Ll 
Gustafsson, et aI., 1983) and children with uncomplicated malaria (SA Adelusi, et aI., 
1982). In adults with malaria of moderate severity, acute bioavailability relative to 
parenteral treatment was 70% (NJ White, et aI., 1987d) compared with 75% in healthy 
adults. In children with uncomplicated malaria given an initial treatment dose of 10 mg 
base/kg as tablets, peak plasma concentrations of approximately 250 gil were reached in 
two hours (SA Adelusi, et aI., 1982). Time to peak concentrations in severe malaria is 
usually 20 minutes and can be as short as 5 minutes. This results in transiently high (500 
- 3500 gil), and potentially toxic blood concentrations if doses of 5 mg base/kg or larger 
are given (NJ White, et al., 1988). Fonnulations which retard slightly the rate of 
absorption after intramuscular or subcutaneous administration would presumably have a 
wider safety margin (S Prakongpan, et aI., 1989). Chloroquine administered by rectal 
suppositories has a bioavailabilty of approximately 30-50%, and a rate of absorption 
similar to that of oral chloroquine in healthy volunteers (F Minker & J Iran, 1991). 
Chloroquine concentrations in red cells are approximately three times higher than III 
plasma, and there is considerable concentration in granulocytes and platelets. \\'hole 
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blood concentrations are 6 to 10 times higher than plasma concentrations (Ll Gustafsson. 
et at., 1983). The enormous apparent volume of distribution results from considerable 
binding in organs such as the liver, connective tissue and melanin containing tissues such 
as the skin and retina. Chloroquine is 55% protein bound in plasma (SA Adelusi & LA 
Salako, 1982, 0 Walker, et at., 1983). Concentrations in the cerebrospinal fluid are very 
low with a mean value of 2.7% of corresponding whole blood concentrations(NJ White, 
1988). Chloroquine is concentrated slightly in breast milk with milk:plasma AUe ratios 
of2.0 to 4.3 (MD Edstein, et at., 1986). 
Chloroquine is 51 % cleared unchanged by the kidney (LL Gustafsson. et aI., 1983). The 
remainder is biotransformed by the liver, mainly to desethyl and bidose chloroquine. The 
terminal elimination half-life of chloroquine is approximately 1-2 months but in tenns of 
curative treatment (blood concentration) the real half life is about 6-10 days (M Frisk-
Holmberg, et at., 1984). The absorption and disposition of chloroquine in children 
appears to be similar to that in adults (NJ White. et at., 1988). 
Chloroquine is one of the most widely used drugs in the world. It still accounts for over 
90% by weight of the global antimalarial consumption. It has undoubtedly saved many 
patients with severe malaria. Much of the reported toxicity at therapeutic doses is 
anecdotal and poorly documented. Oral chloroquine is usually well tolerated. Nausea, 
headache, uneasiness and dysphoria are relatively common but seldom serious. Patients 
may vomit and may complain of blurred vision. Postural hypotension associated with 
malaria may be exacerbated and pruritus (NG Osifo, 1984) can be severe especially, 
though not exclusively, in dark-skinned patients. Parenteral chloroquine is a potent 
vasodilator. Hypotension is a predictable consequence of the transiently high blood 
concentrations that follow parenteral administration (S Looareesuwan. et at., 1986, NJ 
White, et al., 1988) 
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Quinine 
Quinine is still widely used for severe chloroquine-resistant malaria, although artesunate 
and artemether are effective and safer alternatives. Although quinine resistance has 
increased in areas of SE Asia and South America, there is still no high grade resistance in 
severe malaria that precludes its use. This may change and efficacy in quinine resistant 
areas needs to be monitored closely (Pukrittayakamee et ai, 1994). 
Quinine sulphate is well absorbed when given by mouth in healthy subjects, and in 
patients with malaria (G Paintaud, et ai., 1993, W Supanaranond, et ai., 1991, NJ White, 
1987). Peak plasma concentrations are reached in one to three hours (Hall et ai., 1973). 
Use of intramuscular quinine has been controversial for many years, but recent studies 
(TT Hien, et ai., 1996) suggest good bioavailability, safety profile and effectiveness even 
in very young children «2 years) with severe malaria (MB van Hensbroek, et ai., 1996, D 
Waller, et ai., 1990, NJ White, 1995) Quinine is distributed throughout most of the body 
fluids. The mean concentration in erythrocytes is approximately one third of that in 
plasma, rising to one half (presumably because of concentration within malaria parasites) 
in severe malaria (NJ White, et ai., 1983a). Concentrations in salive are one third of 
those in plasma (LA Salako & A Sowunmi, 1992). Cerebrospinal fluid concentrations are 
7 +/- 3% of those in plasma in cerebral malaria (NJ White, et ai., 1982). In healthy 
subjects and patients with malaria, quinine is predominantly (80%) eliminated by hepatic 
biotransformation (NJ White, 1985) first to 3 and 2 hydroxyquinine, and then to a series 
of more polar water soluble metabolites. Plasma concentrations of 3-hydroxyquinine are 
approximately one third to one fifth of those of the parent compound, with a lower ratio in 
malaria indicating impairment of hepatic biotransformation, but accumulation occurs in 
renal failure (P Newton, et ai., 1999). Approximately 20% of the quinine is eliminated by 
the kidney, and the remaining 80% by hepatic biotransformation. Total systemic 
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clearance is reduced in uncomplicated malaria, and further reduced in severe malaria (NJ 
White, et aI., 1982, NJ White, 1987). Renal clearance and hepatic clearance are reduced 
in parallel. Absorption of quinine is similar in adults and children. The total apparent 
volume of distribution and the volume of the central compartment is smaller in children(T 
Chongsuphajaisiddhi, et ai., 1981),(AE Greenberg, et aI., 1989, CR Newton, et aI., 1993, 
G Pasvol, et aI., 1991, D Waller, et aI., 1990),(A Schapira, et aI., 1993) and pregnant 
women (RE Phillips, et aI., 1986c) than in adults with disease of comparable severity, but 
elimination is more rapid in both groups. Systemic clearance values are therefore similar. 
Cord blood concentrations and breast milk concentrations are approximately one third of 
those in simultaneously sampled maternal plasma (RE Phillips, et al., 1986c). 
Minor adverse reactions are common with quinine therapy, but severe life-threatening 
toxicity is rare. A characteristic symptom complex known as "cinchonism" occurs with 
plasma concentrations over 5 mgll (Powell & McNamara, 1966). This consists of 
tinnitus, high tone deafness (RJ Roche, et aI., 1990), nausea, uneasiness, dysphoria and 
blurring of vision. Vomiting is likely if core temperatures are high. These symptoms of 
cinchonism are rarely sufficient to warrant stopping treatment. 
Hypoglycaemia is a more commonly encountered problem. Quinine is a potent stimulus 
to pancreatic insulin secretion (NJ White, et al., 1983c) and hyperinsulinaemic 
hypoglycaemia is particularly likely in pregnant women (S Looareesuwan, et al., 1985b), 
or patients who remain severely ill for several days. Intravenous injections may cause 
acute cardiovascular toxicity presumably because transiently toxic blood concentrations 
occur before adequate distribution (TM Davis, et al., 1988). Postural hypotension is 
common in acute malaria and this is exacerbated by quinine (W Supanaranond, et al., 
1993). Studies of intravenous quinine in severe malaria (S Looareesuwan, et aI., 1985b) 
show no evidence of an oxytocic effect. 
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Quinidine 
Quinidine is the dextrorotatory diastereoisomer of quinine. It may be more effective than 
quinine in the treatment of chloroquine-resistant falciparum malaria(NJ White, et al., 
1981), but is also more toxic. Quinidine is cleared more rapidly with a greater proportion 
of renal clearance than quinine, and the total apparent volume of distribution is larger. 
Elimination half times are shorter (NJ White, et al., 1981). Plasma concentrations of 
quinidine are therefore lower than those with equivalent doses of quinine. Much of these 
differences can be explained by the increased free fraction in plasma (J Karbwang, et al., 
1993); free concentrations are approximately twice those of quinine. Although there is 
less information, quinidine pharmacokinetic properties are affected in a similar manner to 
those of quinine in malaria i.e. clearance and volume of distribution are reduced (NJ 
White, et aI., 1981). The terminal elimination half-life in severe malaria was 12.8 hours. 
The therapeutic range for total plasma quinidine concentrations is estimated to be 
approximately 5-8mglL (KD Miller, et aI., 1989). There are no data on intramuscular 
quinidine in malaria. 
Minor toxicity with the two diastereomers is similar, although quinidine has a greater 
tendency to produce diarrhoea and has much less effect on hearing than quinine (J 
Karbwang, et al., 1993). Quinidine has a fourfold greater effect in prolonging the 
electrocardiographic QTc interval and has a greater propensity to produce hypotension(NJ 
White, et aI., 1983b ),(RE Phillips, et al., 1985). Electrocardiographic monitoring and 
close attention to circulatory status are therefore essential when parenteral quinidine is 
given for the treatment of severe malaria (KD Miller, et al., 1989). Quinidine is also 
equally likely to induce hypo glycaemia (RE Phillips, et aI., 1986b). Idiosyncratic and 
allergic reactions are not common. There are even less data for quinidine than quinine on 
which to base a recommended therapeutic range. 
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Amodiaquine 
Amodiaquine is also a 4-aminoquinoline with a similar mode of action to chloroquine. It 
is more active against resistant isolates of Pfalciparum but it is also more toxic (F 
Abacassamo, et aI., 2004, S Looareesuwan, et al., 1985a, CG Nevill, et aI., 1994, AO 
Talisuna, et aI., 2004, WM Watkins, et aI., 1984). Amodiaquine may be a useful 
substitute for chloroquine where oral treatment is required. A parenteral fonnulation of 
amodiaquine is not commercially available, but the closely related compound, 
amopyraquine, is available for intramuscular injection in many francophone countries in 
Africa. Concern that amodiaquine causes a high prevalence of agranulocytosis (CS 
Hatton, et aI., 1986) and hepatitis (KA Neftel, et aI., 1986) has tenninated its prophylactic 
use. Amodiaquine is rapidly and extensively converted to a phannacologically active 
metabolite, desethylamodiaquine, following oral administration, and it seems that this 
metabolite is responsible for most of the antimalarial activity(FC Churchill, et al., 
1985),(P Winstanley, et aI., 1987). Following intravenous administration, the fall in 
blood amodiaquine concentration is biphasic. The tenninal elimination half life is 
approximately 10 hours indicating rapid biotransfonnation to the active metabolite. Mean 
total volume of distribution was 17.4 Ukg and systemic clearance 5.5 IIkg!hr (NJ White, et 
al., 1987a). 
Su/fadoxine-pyrimethamine(SP) 
This is the most widely used of a family of drug combinations which antagonize parasite 
folic acid synthesis. They act by sequential inhibition of dihydropteroate synthetase 
(sulphonamides and sulphones) and dihydrofolate reductase (pyrimethamine and 
biguanides). A fonnulation for intramuscular injection is available. 
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Pyrimethamine and sulfadoxine are both well absorbed. In healthy subjects, peak plasma 
concentrations are reached in 2 to 6 hours (RA Ahmad & HJ Rogers, 1980),(E 
Weidekamm, et aI., 1982). Absorption in uncomplicated malaria is similar to that in 
healthy subjects(B Sarikabhuti, et aI., 1988, PA Winstanley, et aI., 1992). The 
intramuscular formulation is also well absorbed in moderately severe malaria (P A 
Winstanley, et aI., 1992) with an estimated bioavailability that was similar overall to the 
oral formulation. However, plasma concentrations in the first day after starting 
intramuscular treatment (the critical period for the treatment of severe malaria) were less 
than half those following oral administration. In severe malaria, when given together 
with quinine, pyrimethamine absorption was more rapid, but sulfadoxine was less well 
absorbed than in uncomplicated malaria (CR Newton, et aI., 1993). Pyrimethamine is 
cleared predominantly by hepatic biotransformation. Systemic clearance is approximately 
20 ml/hIkg) (RA Ahmad & HJ Rogers, 1980, E Weidekamm, et al., 1982, E Weidekamm, 
et al., 1987) and the terminal elimination half-life is approximately 90 hours. Unlike 
other sulphonamides only 5% of sulfadoxine is N-aceylated and eliminated in the urine in 
this form. Biotransformation and clearance is approximately 0.5 ml/h/kg and the terminal 
elimination half-life 180 hours. Both pyrimethamine and sulfadoxine are excreted in 
breast milk. The amounts likely to be ingested by the baby are unlikely to be effective in 
treating or preventing malaria but could cause allergic or idiosyncratic reactions. 
Intramuscular sulfadoxine-pyrimethamine (S-P) is not painful. Oral S-P is very well 
tolerated. Minor adverse effects are rare. There is now an extensive literature on the 
toxicity of these combinations, but almost all refers to continuous prophylactic use in 
prevention, and not the single dose treatment of malaria. Prolonged use of pyrimethamine 
may provoke folate deficiency in vulnerable subjects (pregnancy, malnourished patients). 
Sulphonamides should not be given in late pregnancy or to the newborn because of the 
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theoretical risk of provoking kernicterus. Prophylactic use of S-P carried an estimated 
mortality in Americas of between 1:11,000 and 1:25,000(KD Miller, et aI., 1986). Severe 
allergic cutaneous reactions are the most common serious adverse reactions. 
Agranulocytosis and other blood dyscrasias, hepatitis, pUlmonary eosinophilia, and 
neuropathy have been been reported. It is generally considered that the risks of severe 
adverse reactions in the treatment of malaria are small and do not preclude use of these 
drugs for the treatment of uncomplicated drug-sensitive infections. 
Tetracycline 
The tetracyclines are relatively slowly acting antimalarials which are used either as 
prophylactic or adjunctive drugs. They should not be used alone in severe malaria unless 
no other antimalarial drugs are available. There are extensive reviews of their clinical 
pharmacology when used as antibacterial drugs. The pharmacokinetic properties of the 
different tetracyclines vary. Tetracycline has better oral bioavailability than oxy- or 
chlor-tetracycline. Plateau concentrations following regular dosing of 250 mg six hourly 
range between 2 and 3 glmI. Oral bioavailability is increased in the fasting state, and may 
be considerably reduced by chelation to divalent cations (e.g. calcium in milk, magnesium 
and aluminium in antacids, iron preparations). Tetracycline has an elimination half-life of 
approximately 8 hours. Doxycycline has better oral bioavailability than most of the other 
tetracyclines, peak concentrations of 3.0 glml are reached within 2-3 hours. Compared to 
tetracycline food interferes less with absorption after an oral dose of 200 mg. The 
elimination half-life is 18-22 hours. All the tetracyclines are excreted by glomerular 
filtration in the urine (tetracycline 70%, doxycycline 40%, minocycline 5%) and also in 
the bile. Most of the tetracyclines accumulate in renal failure, but doxycycline, 
chlortetracycline and probably minocycline do not. Nausea, heartburn, abdominal pain, 
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vomiting and diarrhoea are not uncommon. Candida superinfections and 
pseudomembraneous colitis may occur. Hypersensitivity is rare, but photosensitivity is 
fairly common (particularly with demethylchlortetracycline). These drugs deposit in 
calcifying areas of bones and teeth and should not be used in children under 8 years or in 
pregnancy. Tetracyclines may cause nephrotoxicity by five different mechanisms; they 
may aggravate pre-existing renal failure by their antianabolic effects, very rarely they 
may cause a hepatorenal syndrome in association with acute fatty liver, outdated degraded 
tetracyclines may cause tubular damage (Fanconi-like syndrome), 
demethylchlortetracycline induces nephrogenic diabetes insipidus and on rare occasion an 
interstitial nephritis may develop. With the exception of doxycycline, these drugs are 
contraindicated in renal failure. For these reasons, tetracyclines should not be given in 
the acute phase of severe malaria. 
Antimalarial biguanides 
There has been a resurgence of interest III these compounds, which were originally 
developed over 40 years ago. They were the first of the antimalarial 
dihydrofolate-reductase inhibitors. Two compounds, proguanil and chlorproguanil, are in 
current use. There are no parenteral formulations; these drugs should not be used in 
severe malaria. Both are prodrugs for the biologically active triazine metabolites 
cycloguanil and chlorcycloguanil respectively. Biotransformation is reduced in pregnancy 
and with the oral contraceptive (R McGready, et aI., 2003). Pharmacokinetic studies have 
been reported (I Bygbjerg, et aI., 1987, WM Watkins, et aI., 1987, Y Wattanagoon, et aI., 
1987). These suggest that the elimination of the parent compounds determine the blood 
concentration profiles of the active metabolites. For proguanil estimated elimination 
half-life values (t1'2 B) range from 11 to 20 hours. Proguanil and the inactive metabolite 
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parachlorophenylbiguanide, but not cycloguanil, are concentrated in red cells. The 
combination of chlorproguanil and dapsone is an effective treatment for falcipamm 
malaria (WM Watkins, et ai., 1988) and is effective against S-P resistant parasites (T 
Lang & B Greenwood, 2003, TK Mutabingwa, et ai., 2001, P Winstanley, 2001) 
(provided the Ile164Le mutation is not present) but otherwise these dmgs are now used 
exclusively for prophylaxis. 
Mefloquine 
Mefloquine is a quinoline methanol compound, which stmcturally resembles quinine. It 
is effective against all malaria species including multi-drug resistant P. Jalciparum, 
although significant resistance has developed in Southeast Asia. There is no parenteral 
formulation. Mefloquine has no place in the management of severe malaria. Currently 
available formulations of mefloquine are well absorbed in healthy subjects and patients 
with uncomplicated falciparum malaria (J Karbwang, et al., 1987b, S Looareesuwan, et 
ai., 1987). Absolute bioavailability is not known because there is no parenteral 
formulation. The absorption profile in malaria appears to be biphasic (J Karbwang, et al., 
1987a) but with the treatment doses of 15 mglkg plasma or whole blood concentrations 
exceeding 500 ng/ml are usually reached within 6 hours. Absorption may be dose limited 
as blood levels following a 25mglkg dose are significantly higher if the dose is divided 
compared with single dose administration (R Price, et al., 1999, JA Simpson, et ai., 1999, 
JA Simpson, et ai., 2000). Absorption was rapid, but post absorption plasma 
concentrations were two to three times lower than in studies in healthy subjects or in 
uncomplicated malaria suggesting reduced bioavailability. In some assays mefloquine 
concentrations in red cells have been higher than those in plasma (DE Schwartz, et al.. 
1982, FO Ter Kuile, et ai., 1994) whereas in others blood concentrations have been 
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similar(J Karbwang, et al., 1987a). Mefloquine is highly bound (98%) to plasma 
proteins. Cerebrospinal fluid concentrations are unmeasurable «5 nglml) (P 
Chanthavanich, et al., 1985). Mefloquine exhibits a multiexponential decline in blood 
concentrations with a terminal elimination half-life of approximately three weeks in 
healthy subjects and two weeks in patients with uncomplicated malaria (J Karbwang & 
NJ White, 1990, JA Simpson, et al., 1999). Clearance is by hepatic biotransformation. 
Mefloquine is generally well tolerated, although nausea, abdominal discomfort, and 
vertigo occur in 10 - 20% of patients. Sinus arrhythmia and sinus bradycardia have been 
noted in several reports but their significance is unclear. Postural hypotension also 
occurs. There has been concern that mefloquine and quinine in combination may be 
cardiotoxic, but there is no evidence of this (W Supanaranond, et at., 1997). If patients 
develop severe malaria following mefloquine treatment then a full loading dose of 
qumme should be given, as the most likely explanation is inadequate mefloquine 
absorption. If a treatment dose of mefloquine has been taken in the 12 hours before 
severe malaria treatment starts, then electrocardiographic monitoring would be advisable 
if quinine is used. Acute psychosis or a transient encephalopathy with convulsions are 
serious occur in 0.1 % of patients in Southeast Asia (NT Hoang Mai, et al., 1996), but up 
to 1 % of Caucasian and African patients (PA Phillips-Howard & FO ter Kuile, 1995). 
The pathological mechanism underlying neurotoxicity is not understood. 
Halo/an trill e 
Halofantrine is a phenanthrene-methanol compound, it is more effective than mefloquine 
against multi-drug resistant falciparum malaria (FO ter Kuile, et at., 1993). A parenteral 
formulation has been studied (S Krishna, et at., 1993) but this is not commercially 
available. 
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The principal problem with current formulations of halofantrine is poor oral 
bioavailability. Because of erratic and variable absorption, it is currently recommended 
that the dose of halofantrine be split into three, with six hour dosing intervals. Oral 
bioavailability is increased up to six- fold if halofantrine is taken with a fatty meal (KA 
Milton, et al., 1989, GD Shanks, et aI., 1992). Mean values for tmax for halofantrine and 
its principal metabolite desbutylhalofantrine and in malaria are 15-16 hours and 55-56 
hours respectively, with corresponding cmax values of 0.9-1.2 and 0.4-0.5 mgIL 
respectively (J Karbwang, et aI., 1991); Karbwang, 1991b (JR Veenendaal, et aI., 1991). 
Halofantrine absorption is reduced by at least 50% in severe malaria (WM Watkins, et aI., 
1995). The estimated apparent volume of distribution is large (100 to 500 l/kg). 
Halofantrine is almost entirely eliminated by hepatic biotransformation. The estimated 
terminal half-life is 3.5-4.5 days (J Karbwang, et al., 1991, JR Veenendaal, et aI., 1991). 
The principal metabolite desbutylhalofantrine has equal biological activity (LK Basco, et 
al., 1992), and in malaria has a similar elimination half-life. As plasma concentrations of 
the metabolite usually exceed those of halofantrine by the third day of treatment, they are 
obviously an important determinant of antimalarial activity and drug efficacy. 
Halofantrine is extensively bound to low and high density lipoproteins in serum (B Cemli, 
et aI., 1995). 
Halofantrine is generally well tolerated. Abdominal pain and diarrhoea occur rarely but 
are usually mild and self-limited. Pruritus occurred in 13% of Nigerians taking the 
dnlg(A Sowunmi, et al., 1998). Halofantrine lacks central nervous system adverse effects 
and is better tolerated than mefloquine (FO ter Kuile, et aI., 1993) but it produces 
consistent concentration dependent delays in atrioventricular conduction and ventricular 
repolarisation (F Nosten, et al., 1993). Halofantrine has been associated with sudden 
death; and this has been attributed to lethal ventricular arrhythmias. Halofantrine should 
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not be given at doses higher than those currently recommended, to patients with a long 
electrocardiograph QT interval, to patients taking drugs known to prolong the QT interval 
i.e. quinine, quinidine, chloroquine, tricyclic antidepressants, neuroleptics, terfenadine, 
astemizole. or who have received mefloquine within 28 days(NJ White, 1996). If severe 
malaria develops after halofantrine treatment then it may be safer to use artesunate or 
artemether rather than quinine treatment. 
Lumefantrine 
Formerly called benflumetol, lumefantrine was developed by Chinese scientists. It is now 
available only in a fixed tablet combination with artemether. Each tablet contains 
artemether 20mg and lumefantrine 120mg. The combination is registered in many tropical 
countries and in Europe. It is very effective against multi-drug resistant fa1ciparum 
malaria, and it is remarkably well tolerated, with no evident adverse effects. 
Lumefantrine is lipophilic and hydrophobic. Its absorption is considerably augmented by 
taking the drug together with food (a 16 folds increase with a fatty meal). Absorption is 
reduced in the acute phase of malaria, but then increases considerably as symptoms 
resolve and the patient starts to eat (F Ezzet, et aI., 1998) The elimination half-life is 3-4 
days (F Ezzet, et al., 2000). The pharmacokinetic properties of lumefantrine are simi lar in 
adults and children (NJ White, et aI., 1999b). The principle pharmacokinetic variable 
which correlates with therapeutic response is the area under the plasma concentration 
curve (AUC) (NJ White, et al., 1999b). The plasma level on day 7 after starting treatment 
is a good surrogate of the AUC; plasma levels of lumefantrine above 500ng/mL are 
associated with a >900/0 cure rate. The treatment course which has been most widely 
evaluated approximates to 1.5/ 9mglkg (adult dose 4 tablets) given at 0, 8, 24, and 48 
hours. This is effective in patients with background immunity, but in non-immune 
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patients with multi-drug resistant infections cure rates are approximately 80% (M van 
Vugt, et aI., 1998). Increasing the regimen to six doses (i.e. twice daily on each day) 
results in >95% cure rates (M van Vugt, et aI., 2000, MV Vugt, et aI., 1999). As children 
in endemic areas are relatively non-immune the six dose regimen is a preferable regimen 
for general use. The patient should be encouraged to take the drug with food. There is no 
experience in pregnancy and therefore the drug should not be used in pregnant women. 
There is no paediatric formulation. This combination is remarkably free of adverse 
effects. Concerns about possible cardiotoxicity, have been refuted by careful studies (M 
van Vugt, et aI., 1999). Lumefantrine is not cardiotoxic. 
Piperaquine 
Also developed in China this bisquinoline compound and its hydroxy-derivative are 
active against multidrug resistant Plasmodium fa1ciparum (L Chen, 1991). Piperaquine is 
now available as a fixed combination with dihydroartemisinin (and also sometimes 
trimethoprim and primaquine). It is relatively inexpensive (adult doses just over US$ 1). 
These combinations are registered and used in China, Vietnam and Cambodia (MB Denis, 
et al., 2002, P Wilairatana, et al., 2002). Given as a four-dose (0, 8, 24, 48 hours) regimen 
comprising a total of 5120mg of piperaquine for an adult, the combination is well 
tolerated and effective, but more clinical trial information on efficacy and safety is needed 
before this exciting new drug can be recommended more widely. 
Pyron aridin e 
This naphthyridine derivative was synthesised in China in 1970 (XY Zheng, et aI., 1982). 
It has structural similarities to mepacrine and amodiaquine but unlike both these drugs it 
is highly active against multi-drug resistant P. fa1ciparum (GE Childs, et al.. 1988, S Fu, 
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et al., 1986). It has been widely used in China for over ten years. A parenteral 
formulation is available in China but has not been used widely. Originally pyronaridine 
was deployed as an enteric-coated formulation for monotherapy which had poor oral 
bioavailability and was given in a 3 day course of 1200 mg or 1800 mg (adult over 5 
days). It is active against multi drug resistant P Jalciparum (S Looareesuwan, et at., 1996, 
P Ringwald, et al., 1998). Pyronaridine is now being developed as a fixed co-formulation 
wi th artesunate 
Artemisinin and its derivatives 
The artemisinin and its derivatives are the most rapidly effective of the antimalarial drugs 
and retain efficacy even against multidrug-resistant parasites. Increasing evidence 
demonstrates that their widespread deployment leads to a reduction in transmission 
potential, and their early use in an infection may prevent the progression to severe 
falciparum malaria. 
The qinghaosu group includes the prototype artemisinin, a sesquiterpine lactone with an 
endoperoxide bridge (C-O-O-C) that IS umque among antimalarial drugs. 
Dihydroartemisinin, the reduced lactol derivative of artemisinin, is the common 
biologically active metabolite of artesunate and artemether. Artesunate and artelinate are 
the water-soluble derivatives; artemether and arteether are both oil soluble, but water 
insoluble. These four drugs are the semisynthetic derivatives of the parent artemisinin 
compound. Artemisinin is not readily available commercially outside China and Vietnam. 
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ARTEMISININ 
Artemisinin is the natural substance extracted from the leaf of Artemisia annua L. It has 
been formulated as a crystalline powder and can be administered orally as a tablet, or in a 
capsule, and rectally as a suppository. Initially, in China, it was also given 
intramuscularly as an oil suspension and as a water suspension (China Cooperative 
Research Group on Qinghaosu and Its derivatives as Antimalarials Metabolism and 
pharmacokinetics of qinhaosu and its derivatives, 1982) . 
There have been recent pharmacokinetic studies of the artemisinin derivatives using high-
performance liquid chromatography with electrochemical detection (HPLC-ECD) and 
bioassay in healthy volunteers and non-complicated malaria patients. This has shown that 
the pharmacokinetic parameters of orally administered artemisinin are similar in both 
groups: artemisinin is rapidly absorbed with the peak concentration recorded at 1-2 hours 
after administration, but the absorption is incomplete (M Ashton, et aI., 1998, A Benakis, 
et ai., 1997, P J De Vries & TK Dien, 1996, PI De Vries, et aI., 1997, M Hassan Alin, et 
aI., 1996) (Table 1.1). The plasma concentration of the drug exceeded the in vitro mean 
inhibitory concentration (MIC) of P falciparum (3-30~g1L) for more than 8 hours in all 
patients studied (LK Basco & I Le Bras, 1993, PI De Vries, et aI., 1997). The elimination 
of artemisinin is fast with an elimination half-life of 2 to 5 hours (PI De Vries, et aI., 
1997, M Hassan Alin, et aI., 1996), the AUC and the Cmax values of the 1 st day were 
about 6 times higher than that on the 5th day, indicating considerable auto induction of 
metabolic biotransformation (M Ashton, et aI., 1998, M Hassan Alin, et aI., 1996). Even a 
single dose induces metabolism. The predominant CYP450 enzyme involved is CYP 86. 
The metabolites and the potential for drug interactions have not been fully characterised. 
The rectal bioavailability is 30% relative to the oral dose although there is large inter-
individual variation. Because of the similarity in parasite clearance times between oral 
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and rectal administration, it is assumed that therapeutic concentrations could be achieved 
with artemisinin suppositories (R Koopmans, et al., 1998, JS Sidhu, et al., 1998). 
Early studies in China suggested that an optimum treatment was 3g of artemisinin given 
over 3-5 days (10-20 mglkg in the 1st day at (+0 and +4hrs) then 10mglkglday in 
subsequent days) (GQ Li, et al., 1994). However, studies using monotherapy regimens 
with less than a 7-day treatment course (oral or rectal), and designed with a 28-day 
follow-up period, confirmed that the true recrudescence rate was unacceptably high (20-
50%) (TT Hien, 1994). The combination of artemisinin (20 mglkg given on one day or 3 
day dose) and a long elimination half-life drug such as mefloquine would seem to 
overcome many of the problems of high recrudescence rates seen with artemisinin 
monotherapy. Several clinical trials have shown that this is the most effective treatment of 
multi -drug resistant P jalciparum malaria (NN Bich, et al., 1996, TT Hien, et al., 1994, 
NN Le, et aI., 1997). 
Artemisinin suppositories remain an effective treatment for Pfalciparum malaria and 
offer great promise as a life saving intervention in remote areas where facilities for 
parenteral drugs maybe limited and of course the diseases has its greatest impact. In the 
early 1990s artemisinine suppositories were shown to be as effective as parenteral 
antimalarial drugs in clinical trials for the treatment of severe malaria (XT eao, et al., 
1997 a, V Ha, et al., 1997, TT Hien, et al., 1992a) 
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Table 1.2.1: Phannacokinetic parameters of artemisinin 
de Vries PJ et al Benakis A Koopmans R 
500mg po 500 mg po 400mg 600mg 
suppository suppository 
Healthy Patients Healthy Healthy Patients 
volunteers volunteers volunteers 
Cmax (ng/ml) 391±147 364±250 360±90 100±102 108±60 
Tmax (hr) 1.81±0.73 2.88±1.71 1.07±0.73 7.1±2.1 6.5±3.9 
AUC(h.~g/L) 2,054±455 2,302±2,0 1,190±640 747±449 1080±678 
23 
T Yz el (hr) 2.8±0.9 2.72±1.76 4.34±3.46 NA NA 
ARTESUNATE 
Artesunate, the water-soluble hemisuccinate derivative of dihydroartemisinin (DHA), was 
developed as a drug for an intravenous use in the treatment of severe and complicated 
malaria. It is unstable in neutral solutions and therefore only available in powder fonn as 
artesunic acid. This powder requires reconstruction with 5% w/v sodium bicarbonate 
solution immediately before use. At neutral pH hydrolysis to DHA is rapid. Artesunate is 
the artemisinin derivative most widely used. It may be administered orally, intravenously, 
intramuscularly or rectally. 
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Artesunate is hydrolysed very rapidly after intravenous injection to DHA in 2 minutes 
(SD Yang, et al., 1985). After oral administration artesunate is also hydrolysed to DHA 
and relatively little unchanged artesunate is detectable in plasma (KT Batty, et aI., 1998a, 
KT Batty, et aI., 1998b). This hydrolysis is accelerated by plasma and red cell esterases. 
The mean absolute oral bioavailability of the drug in patients with acute malaria was 
61 %; the absorption and elimination of oral artesunate was rapid with mean elimination 
half-life of antimalarial activity of 43 minutes (P Newton, et aI., 2000b). After repeated 
oral administration of artesunate a time-dependent decline of artesunate and DHA 
concentrations in plasma occurs although it remains unclear what the mechanism for this 
decrease of concentration (NX Khanh, et aI., 1999). Artesunate has not been shown to 
auto induce metabolism in the same way as artemisinin. Despite rapid clearance of 
artesunate and DHA in patients with uncomplicated fa1ciparum malaria prompt parasite 
and fever clearance are achieved and once-daily administration to patients has been 
shown to be highly effective with similar parasite and fever clearance times to those 
treated with a twice-daily regimen (F Nosten, et al., 1994) 
Several clinical trials in South East Asia have shown that artesunate, given as single oral 
dose (2-4mg/kg) or for 3 days (4mg/kg for the 1 st day then 2mg/kg for 2nd and 3rd day) 
in combination with mefloquine (15 mg/kg as single dose) was an effective and safe 
treatment for non-complicated fa1ciparum malaria (V Ha, et aI., 1997, F Nosten, et aI., 
1994, RN Price, et aI., 1997). Very large randomized controlled studies in Thailand, Viet 
Nam and nine African countries indicate that one dose of artesunate (4mglkg) given daily 
, 
for 3 days In combination with mefloquine (25mglkg), chloroquine, 
sulfadoxine/pyrimethamine or amodiaquine is better than either a single dose of 
artesunate with these drugs or the other antimalarials given as monotherapies in terms of 
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recrudescence rates. These studies assessed efficacy for> 28 days and were supported by 
PCR genotyping; in addition, treatment with artesunate results in lower gametocyte rates 
and may thereby reduce transmission rates OF Doherty, et aI., 1999, Lorenz von Seidlein. 
et aI., 2000, RN Price, et aI., 1997). 
Unfortunately, there are insufficient data on the use of suppositories. Studies in Vietnam, 
in patients with non complicated falciparum malaria treated with a single rectal dose of 
2mg/kg of artesunate (produced in China) confirmed that fever and parasite clearance 
times obtained were similar to those seen with 20mg/kg artemisinine: FCT 100 (SD): 
29(19.1) hrs vs 38.6(26.7) hrs; PCT 100(SD): 39.8 (17.4) hrs vs 43.1(25.4) hrs (TT Hien, 
unpublished data). A clinical trial in children with non-complicated falciparum malaria in 
Gabon using single dose of 50 mg (equivalent 0.8-2 mg/kg) of a new pharmaceutical form 
of this drug [Plasmotrim® Rectocaps® MEPHA] obtained similar results (B Halpaap, et 
al., 1998) A trial in Thailand using higher doses of Rectocaps@ artesunate (l5mg/kg/day 
for 3 days) was compared with oral artesunate (6mg/kg/day); both in combination with 
mefloquine (25mg/kg). The fever clearance time (42 vs 42 hrs) parasite clearance time 
(42 vs 35 hrs) and cure rates (92% vs 100%) were similar in both groups (S 
Looareesuwan, et al., 1997, A Sabchareon, et aI., 1998). 
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Table 1.2.2: Phannacokinetic properties of artesunate 
Newton et ai, 2000 
B a t t Y e t a 1 (HPLC-ECD + bioassay) 
IV Oral (for DHA) IV Oral 
Acute Convalescence 
Crnax (ng/ml) 13,670 740 8,240 1,021 546 
Trnax(hr) 0.75 1.00 
A UC(h. ug/L) 2,280 870 3,013 1,738 886 
T ~ el (hr) 2.1 min 39 1.01 0.71 0.84 
ARTEMETHER 
Artemether is an oil soluble derivative of artemisinin. It is the methyl ether of 
dihydroartemisinin and has been used widely in China. It is more stable than artesunate. 
In healthy volunteers, artemether was absorbed rapidly after oral administration and 
underwent extensive first-pass metabolism to DHA with the concentration of this 
metabolite higher than that of the parent compound. The mean Cmax, of 310-406 nmollL, 
were reached at 1.2-2.2 hours; the mean elimination half-life was 2.0-2.6 hours(MN 
Mordi, et ai., 1997, P Teja-Isavadharm, et ai., 1996). There was no difference in 
pharmacokinetics between healthy volunteers and patients with uncomplicated malaria (K 
Na-Bangchang, et ai., 1994). In volunteers, intramuscular and intrarectal administration 
had a biovailability of approximately 25% (i.m) and 35% (i.r) compared to the oral drug. 
Plasma antimalarial activity following oral administration is significantly greater than 
following intramuscular administration (P Teja-Isavadhann, et ai., 1996) because the 
first-pass biotransfonnation is inhibited Recent studies demonstrated that grapefruit juice 
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significantly Increases the oral bioavailability of artemether and acute renal failure 
significantly modified the pharmacokinetics of intramuscular artemether with better 
absorptionlbioavailability and a reduction of systemic clearance (J Karbwang, et aI., 
1998). Bioavailability of intramuscular artemether was also shown to be highly variable 
and may be associated with an inadequate response in children with severe and 
complicated malaria especially in the presence of respiratory distress (SA Murphy, et at., 
1997). 
Monotherapy with oral or intramuscular artemether (1-4 mglkg/day for 3-5 days) results 
in rapid fever and parasite clearance but with an unacceptable recrudescence rate (25-
40%). Artemether has been given in combination with other antimalarial drugs with long 
half-lives particularly mefloquine. Again this combination has demonstrated cure rates of 
95-98% (RN Price, et aI., 1995). Since 1992, 2042 patients have been recruited to a series 
of trials using a new combination of artemether and lumefantrine (benflumetol). Four 
tablets of artemether and lumefantrine (1 tablets=20 mg of artemisinin+ 120 mg 
lumefantril) given at 0, 8, 24, 48 hours, has been shown to be very well tolerated by all 
age groups with a cure rate of 81 % (NJ White, et aI., 1999b) . The latest result from a 
double-blind trial in Thailand in which patients with uncomplicated multidrug resistant 
falciparum malaria were treated with 6 doses of 4 tablets given at 0, 8, 24, 36, 48, 60 (or 
72, 96) hours indicated that the 28 day cure rates were 96.9 - 99.1 % (MY Yugt, et at., 
1999). 
A recent meta-analysis of nine randomised clinical trials companng art em ether and 
quinine for treatment of severe malaria concluded that these two drugs were equally 
efficacious in terms of reduction in mortality rate OR (95%C1)=0. 76(0.50-1.14). 
However, pre-specified pooling of data from trials in South East Asia (mainly involving 
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adults) showed a trend towards a significant reduction of mortality OR (95%CI) = 
0.38(0.14-1.02) (MH Pittler & Ernst, 1999)" 
Table 1.2.3: Pharmacokinetic parameters of art em ether 
Bangchang Teja-Isavadharm Mordi Karbwang 
(94) (96) (97) (97) 
200 mg po 5mg.kg-l 200 mg po 300mg 
Median (range) Mean (95% CI) Mean ± SD po 1m 
Cmax (ng/ml) 118(112-127) 406(249-561 ) 310±153 474 540 
Tmax (hr) 3(1-10) 1.7(1.2-2.2) 1.88±0.21 2.0 3.9 
AUC (h.Ilg/L) 1,100 671±271 2,170 5,200 
T Y2 el (hr) 2.6(1.8-3.4) 2.00±0.59 
ARTEMOTIL (ARTEETHER) 
Arteether is the ethyl derivative of dihydroartemisinin and has been selected by the WHO 
and the US Army for full development (JM Petras, et aI., 2000). Clinical trials in India 
indicated that alpha, and beta-arteether is an effective and rapidly acting antimalarial drug 
for the treatment of acute non-complicated and severe falciparum malaria (JM Petras, et 
al., 2000, N Singh, et aI., 1998, N Valecha, et aI., 1997). There is probably little 
difference between artemether and arteether 
DIHYDROARTEMISININ (DHA) 
Dihydroartemisinin is the active metabolite of the artemisinin derivatives: artesunate 
artemether and arteether. DHA has been formulated recently as tablets and suppositories. 
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DHA has a short elimination half-life approximately 40 minutes but little is known of its 
subsequent metabolism (KT Batty, et a!., 1998a). 
Pharmacokinetic studies in volunteers indicated that the median (range) values of pooled 
pharmacokinetics of oral DHA were; Tmax 1.6 (1.1-2.2) hours, Cmax 466 (128-787) 
ng/ml, AUC 1867 (420-3535) ng.hlml, inter-individual variation was significant. The 
Tmax of DHA formulation was comparable with that of DHA metabolite of artemisinin 
derivatives. Oral dihydroartemisinin was rapidly absorbed and disappeared from the 
systemic circulation within 8-10 h (NH Le, et a!., 1999) 
Clinical trials showed oral DHA given at different dose regimens (single dose, 300 mg or 
multiple doses, 480 mg in 5 days) resulted in similar fever clearance times and parasite 
clearance times. However, short-course treatments « 5 days) have higher recrudescence 
rates (20%) (GQ Li, et a!., 1999, K Na-Bangchang, et aI., 1999). Combination with 
mefloquine demonstrated better cure rates (C Xu, et aI., 1997). 
ARTELINIC ACID 
Artelinic acid (dihydroartemisinin 4-carboxybenzyl ether) is water soluble and said to be 
more stable then artesunate in solution. It can be given orally or parenterally and is the 
only preparation that has been studied transdermally (KL Klayman, et a!., 1991). 
SAFETY OF THE ARTEMISININ DERIVATIVES 
The artemisinin-related compounds have been remarkably well tolerated in clinical 
evaluations. There has been no documented significant toxicity other than rare type 1 
hypersensitivity reactions (incidence approximately 1 :3000 treatments). In volunteer 
studies, a depression of reticulocyte counts has been noted, but increased anaemia has not 
been observed in clinical studies. In animal studies, they are much less toxic than the 
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quinoline antimalarials. The principal toxicity in animals has been an unusual dose-
related selective pattern of neuronal cell damage affecting certain brain stem nuclei. In 
animal studies, this has been related to the pharmacokinetic properties of the drug. 
Neurotoxicity is related to protracted exposure related to sustained blood concentrations, 
as follows intramuscular administration of the oil based artemether and arteether. It is 
much less following oral administration or intravenous artesunate because the drugs 
levels are not sustained. Extensive clinical neurophysiological and to a lesser extent 
pathology studies have failed to show any evidence of neurotoxicity or cardiotoxicity in 
clinical use. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Study site 
2.1.1 Geograpby 
Vietnam is the eastern part of the Indochina peninsula, which also compnses Laos, 
Cambodia. It is located between 8° and 23° North latitude and is entirely in tropical 
region. The country covers an area of 331,114 square Km, 80% of the land area is 
mountains, high plateaus and forests; the remaining 20% is the two deltas (Red River and 
Mekong River), and the coastal plains where most of the population live. 
2.1.1.1 Climate: 
Vietnam has a humid tropical monsoon climate. In the south part, there is only a small 
variation in temperature between the two seasons: the rainfall (April- November) and the 
dry season (December - March): the average temperature over the year in range of 26-
28°C. In the Northern provinces, the winter is cold (mean temperature in Hanoi is 16.5° 
C) whereas it is hot and humid in the summer (mean temperature 29°C). Most of the 
population in the northern highlands areas (the temperatures in the winter sometimes fall 
down to 10°C) lives at altitudes below 800 m where P. l'ivax transmission is not 
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interrupted during the winter months but the transmission of P Jalciparum does for 3-4 
months. The average annual rainfall over the country is around 1600 mm and may rises 
up to 200-300 mm per month in the rainy season; or to 800 mm per months in the Central 
region. Typhoons are common especially during autumn on the central coast with 10-12 
tropical storms per year. Vietnam two main rivers frequently flood the delta areas. 
2.1.1.2. Population: 
The total population in 2004 was 81,000,000 (April 2004 est.) with 33% below 14 years 
of age; 15-64 years: 62%, 65 years and over: 5% (2000 est.). The population grow rate 
was 1.49%. Life expectancy at birth in 2000 was 69.27 years, with a crude birth rate 
21.62 births/l000 population and crude death rate 6.26 deathsl1 000 popUlation. Infant 
mortality rate was 31.1311000 live births; under-five mortality was 55.411000 and 
maternal mortality was 16.611 000. 
85% of Vietnam popUlation is of the Kinh group. Apart from the people of Chinese origin 
(3%), who live in cities, the largest minority group is Kh'mer whose population is about 
one million mainly living in Mekong delta. Ten percent of Vietnam popUlation belongs to 
over 50 ethnic groups (Tay, Muong, Nung, Ede, K'hor, S'tieng) who traditionally inhabit 
in highland areas; they often live in dispersed communities, with houses on stilts, with 
livestock close to the house. These are the communities, which have been living in 
conditions of stable malaria for centuries. The H'mong people are an exception as they 
have lived as nomads above the altitude where the malaria transmission is very unlikely. 
Extensive migrations have occurred in Vietnam. It is estimated that a total of 4.3 million 
people migrated in the country covered by government-sponsored programme; but during 
the same period, about 530,000 people has migrated spontaneously. Since 1980s more 
liberal economic policies have led to increased opportunities on plantations, road 
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building, mining and public services therefore beside ordered programmes, there have 
been waves of uncontrolled migrations of smaller groups of farmers, shopkeepers, cut and 
gold and gem miners from plains to highlands. Military personnel are another group of 
short-term migrants often exposed to malaria risk. 
2.1.1.3 Environment 
Logging and slash-and-bum agricultural practices contribute to deforestation and soil 
degradation; water pollution and over-fishing threaten marine life popUlations; 
groundwater contamination limits potable water supply; growing urban industrialization 
and population migration are rapidly degrading environment big cities. 
2.1.1.4 Economy 
Vietnam is a poor, densely populated country that has had to recover from the ravages of 
war, the loss of financial support from the old Soviet Bloc, and the rigidities of a centrally 
planned economy. Substantial progress was achieved from 1986 to 1996 in moving 
forward from an extremely low starting point (GDP per capita was US$ 213 in 1994) 
growth averaged around 9% per year from 1993 to 1997. The 1997 Asian financial crisis 
highlighted the problems existing in the Vietnamese economy. GDP growth of 8.5% in 
1997 fell to 4% in 1998 and rose slightly to an estimated 4.8% in 1999. Foreign direct 
investment has fallen dramatically, from $8.3 billion in 1996 to about $1.6 billion in 
1999. Administrative and legal barriers are also causing costly delays for foreign 
investors. 
Although the economy is growing in all provinces there are important and widening 
gaps. The central and northern highlands where the incidence of malaria is the highest 
ones are still lagging behind the rest of country in terms of economic output. The ethnic 
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minority groups, living from traditional agriculture and animal husbandry, in scattered 
villages with difficult access, are the poorest. 
2.1.2 Health services 
Vietnam is committed to the primary health care approach. A strong public health sector 
involvement is considered necessary for improving health status particularly in remote 
rural areas. Vietnam has 30,000 doctors, 44,800 medical assistants and 50,000 nurses and 
11,000 midwives. The government has a major responsibility for provision of health care. 
Health services are delivered through provincial hospital, district hospitals and commune 
health stations. A commune health station covers about 10,000 people on average. That is 
the most peripheral unit for provision of health care and is where most patients with 
malaria have chance to access for diagnosis and receiving treatment. 
Private medical practice and pharmacies play an increasing role in cities and in many 
densely populated rural areas. Private pharmacies sell a wide range of pharmaceutical 
products; private doctors and medical assistants are also private treatment providers; but 
in some areas in southern and central provinces shopkeepers also provide drugs including 
antimalarials. A study, which investigated the use and quality of antimalarial drugs in the 
growing private sector of Viet Nam was conducted in 1998 by the NIMPE. The practices 
of drug vendors (called alternative treatment providers [ATPs]) as well as their stocks and 
the quality of drugs sold by them, and the local production and distribution of 
antimalarials were investigated. Antimalarials were sold by the vast majority of ATPs, 
and almost all the common antimalarials being available for sale. The practices and 
indications for sale, however, varied. Underdosing for malaria was frequent in all three 
provinces studied, and lack of knowledge of the appropriate regimen for cure was 
common among the drug-sellers. Samples of antimalarials were collected from ATP 
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outlets in the three provinces, and the drugs were assessed for their contents and expiry 
date by the Institute of Dnlg Quality Control in Hanoi. Of the 218 samples of drugs 
examined by the Institute, over 96% met the quality requirements. However, a 10% 
sample of these drugs were independently assessed by WHO and revealed a different 
picture: 70% of them failed to meet the standard specifications required. There is 
therefore an urgent need to improve the capability and monitoring procedures of bodies 
involved in assessing and regulating drugs in Viet Nam (LD Cong, et at., 1998). The wide 
distribution and extensive use of effective drugs like artesunate and mefloquine have 
probably contributed to reduction of (severe) malaria, but development of resistance to 
these drugs is to be feared. Control of drug distribution and of prescription practices is 
urgently needed (L Bont, et al., 1995). 
Most of the preventive services are run as national programmes from institutes that are 
subordinate to the Department of Preventive Medicine of the Ministry of Health (MOH) 
such as the National Institute of Hygiene and Epidemiology (NIHE) which are 
responsible for the Expanded Programme of Immunization, control of diarrhoeal diseases, 
poliomyelitis. Those programmes operate through provincial Preventive Medicine Centre, 
which are subordinate to the Provincial Health Service. 
2.1.3 National Malaria Control Programme (NMCP) 
National Malaria Control Programme (NMCP) is directed by the National Steering 
Committee chaired by a Vice-Minister of Health and responsible for planning, managing, 
monitoring and evaluating the malaria control programme. The members of the 
committee represent the southern, central and northern provinces and selected from 
central institutions. The National Institute of Malariology-Parasitology-Entomology 
(NIMPE) is responsible for the day-to-day management of the programme. The NIMPE 
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releases technical advice, conducts research, staff training data analysis and assisting 
peripheral levels in operations. It also distributes insecticides, drugs and other 
commodities. The two regional institutes in Qui Nhon city (Qui Nhon WPE) and Ho Chi 
Minh City IMPE are responsible for control activities in central and southern provinces of 
the countries, respectively. The provincial centres for malaria control (where malaria is 
endemic) or Preventive Medicine Centres (for other provinces) - attached to provincial 
health services - will conduct all malaria control activities at provincial and district le\'els. 
There are about 2000 government employees involving into the national malaria control 
programme 
2.1.4 Hospital for Tropical Diseases 
The Hospital for Tropical Diseases (HTD) in Ho Chi Minh City acts as tertiary referral 
centre for patients with infectious diseases, and serves the Ho Chi Minh city area (8 
million popUlation) and southern provinces of Vietnam (population around 35 million). 
The hospital has 500 beds, including 4 separate intensive care units (paediatric, adult, 
malaria and tetanus) and 15 wards for non-complicated infectious diseases (malaria, 
Dengue hemorrhagic fever, diphtheria, HIV/AIDS, viral hepatitis, central nervous 
infections (encephalitis and meningitis), respiratory infections, acute diarrhea. HTD has 
laboratories for haematology, biochemistry, microbiology, serology and parasitology. The 
hospital staff has involved in National Committee of Malaria Control, Dengue 
Hemorrhagic Fever Control, AIDS control, typhoid control, hospital infection and has 
also involved in WHO Malaria Programme. 
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2.1.5 Dak 0 Commune Health Station 
Dak 0 Commune is in Phuoc Long District, Binh Phuoc Province located 200 km North 
West of Ho Chi Minh City. The commune consists of 11 hamlets, with about 10,000 
people belonging mainly Kinh and S'tieng ethnic group. A minor part of the population is 
Tay and Nung people who are immigrants from the Northern provinces. The habitations 
of local people are surrounded by cashew nut or coffee tree gardens. The primitive forests 
in this area have been cleared and replaced by those trees. 
A health station, which includes one doctor assistant, one midwife and 2 microscopists, is 
responsible for local primary health care. Patients who are more seriously ill will be 
transferred to the district hospital at Thac Mo Town, the capital of Phuoc Long District, 
through a dirty path. 
The results of cross-sectional surveys conducted in this commune In 1999 and 2000 
showed that the positive blood smears rates varied from 20-30%. About 350-500 man-
times having fever come to the health station for medical consultation; 75% of those 
people carrying malaria parasite. 
2.1.6 Oxford University Clinical Research Unit 
The Oxford University Clinical Research Unit opened in 1991, funded by the Wellcome 
Trust of Great Britain. The OUCRU, located within the HTD, serves as a collaborative 
centre between HTD and Oxford University and started as an 8-bed ward for the 
treatment of patients with severe malaria. Over 10 years the Unit has expanded and now 
performs research on five core areas: malaria, dengue, typhoid, central nervous system 
infection and tetanus. 
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2.2 Aims, structure of this thesis 
While the number of malaria cases in Africa has always overshadowed those in Southeast 
Asia, the P. Jalciparum in this area is the most abysmal parasite on the world because it 
has become so difficult to treat. The multi-drug resistant malaria patients can still treated 
but by 1990s the therapeutic armoury was looking increasingly bare and the shadow of 
untreatable malaria loomed large. Viet Nam, a SEA country, has had to face to this 
challenge from the end of the war in 1975. At that moment, in addition to common 
reasons, a large population movement aggravated the malaria situation and in the 1980s, 
the control programme was drastically reduced as a result of national financial difficulties 
and dwindling external support. At the same time technical difficulties in particular multi-
drug resistance of P Jalciparum, the parasite responsible for 70% of malaria cases in the 
country become apparent and the nadir was in 1993 with 4646 fatal cases the highest 
figure ever recorded. 
The cornerstone of the change in the management of malaria in Viet Nam is the 
introduction of artemisinin and other derivatives of the Chinese herb "qinghaosu" as first 
line treatment from 1995. The early laboratory and clinical studies in China provided the 
basis for clinical trials at the Hospital for Tropical Diseases. The artemisinin used was 
initially manufactured in China but more recently in Viet Nam from locally grown 
Artemisia annua plants. Research on Artemisia annua was started in early 1980s within 
the framework of the national malaria control programme: in 1984 samples of this plant 
were collected in Lang Son Province and In 1986 the presence of artemisinin in Vietnam 
Artemisia annua with high yield (0.5-1.2% in dried leaves) was confirmed. Our studies in 
1990s have shown that artemisinin and its derivatives (artesunate or artemether) are the 
best antimalarial drugs available in terms of clearing malaria parasites. They may be 
given by the oral, parenteral or rectal routes(TT Hien & NJ White, 1993),(XT Cao, cl aI., 
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1997a). However, despite of rapid parasite clearance, the recrudescence rate of 
artemisinin and its derivatives is unacceptably high when these drugs is used In 
monotherapy less than 7 days (TT Hien, 1994) Therefore, there are a number of 
important questions that still need urgent attention: 
These are: 
+ Should artemisinin be deployed alone or in combination with other antimalarial drugs 
such mefloquine or other coumpound(s)? 
If so which is the best regimen(s) 
+ Whether artemisinin and its derivatives (artesunate or artemether) can reduce the 
mortality in severe malaria. 
+ Of possibly more relevance is the unanswered question of toxicity and the significant 
discrepancy between extensive clinical studies in patients where no adverse effects are 
seen, and animal experiments demonstrating significant brain stem damage. 
Research objectives of this thesis: 
Primary objectives 
1/ To assess the safety and the efficacy of the artemisinin based combination 
regimens for uncomplicated multi-drug resistant fa1ciparum malaria 
21 To investigate the efficacy of artemisinin and its derivatives in the treatment of 
severe malaria 
Specific objectives: 
1/ to describe the pharmacokinetic profiles of artesunate and artemether in severe 
malaria 
21 to assess the efficacy of artemisinin and its derivative (artesunate, artemether) 
in the treatment of severe malaria 
96 
Chapter 2: MATERIALS AND lltfETHODS 
3/ to compare the efficacy of artesunate + mefloquine with mefloquine 
monotherapy for acute falciparum malaria 
4/ to compare the efficacy of dihydroartemisinin + piperaquine with artesunate + 
mefloquine for acute falciparum malaria 
5/ to assess the pharmacokinetic properties of piperaquine in malaria 
6/ to evaluate the potential neurotoxicity of artemisinin 
2.3 Clinical methods 
2.3.1 Scientific and ethical approval 
HTD scientific and ethical committee approved all study protocols, and informed consent 
was obtained from each patient or accompanying relative. 
2.3.2 Patients and treatment 
All febrile patients who present to the out-patient department of the hospital at any time 
are seen by doctors and a peripheral blood smear is performed for complete blood count, 
differential count and for malaria detection (unless they are transferred from other 
hospital with laboratory results). 
Patients with positive smear for malaria will be transferred to acute or severe malaria 
ward based on their clinical symptoms and signs (WHO, 2000b). 
On admission to the ward, a thorough history will be taken and clinical examination 
made, and details will be recorded on a medical form specifically designed for infectious 
diseases. Besides the full blood count blood will also be taken for a routine biochemistry 
including blood glucose, serum creatinin, blood urea nitrogen, urine analysis, chest X-ray 
or ultrasound examination. Other laboratory investigations will be also performed for 
severe patients: blood gases, blood lactate, Na +, K +, Ca++. Anti-malarial drugs (quinine, 
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chloroquine, primaquine, artesunate) are available and free of charge. Patients will be 
treated following the national recommendations for malaria. Parasitaemia will be 
determined daily or every 12 6 hours. Axillary temperature, radial pulse rate, arterial 
blood pressure, respiratory rate will be recorded daily or every 6-12 hours as prescribed. 
Specific management for study patients will be described in individual chapters 
Diagnosis of malaria: 
The diagnosis of malaria in this thesis relies on the demonstration of asexual forms of the 
parasite in smears of peripheral blood. 
- The thin blood smear should be dried, fixed in pure methanol, stained, and the 
red cells in the tail of the film should then be examined under oil immersion. The thick 
smear should be dried thoroughly and stained without fixing. Giemsa at pH 7.2 is used; 
Field's, stain is also used for quick results (within 5-10 minutes) 
- Both parasites and white cells in each field are counted, and the number of 
parasites per unit blood volume is calculated from: 
- the thick smear: assuming that an average white blood cells (WBC) count 
is of 8000/~L; and a minimum of 400 WBC should be counted and the parasiraemia (PC) 
will be: PC = number of parasites/400 WBC x 20 
_ The thin smear: the number of parasitized red blood cell (RBC) among 
1000 RBC should be counted and the parasitaemia will be 
PC = number of parasite I 1000 RBC x 125.6 x patient's haematocrit 
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2.3.3 In vivo assessment: 
The efficacy of the antimalarial drugs is assessed by the fever clearance 
time (FCT), the parasite clearance time (FCT) and the WHO criteria for resistance to the 
aminoquinoline antimalaria drugs 
Fever clearance time: the time from starting antimalaria treatment until 
the patient is afebrile. Fever often fluctuates erratically. The method and the site of 
measurements should be standardised and the use of antipyretics recorded. One approach 
is to record when the temperature first falls below 37.SoC and when the temperature falls 
and remains below 37.SoC for 24 hours. 
Parasite clearance time: the time between starting antimalarial treatment 
and the first negative blood smear. The accuracy of the measurement depends on the 
frequency with which blood slides are taken and the quality of microscopy. The PCT is 
directly proportional to the admission parasitaemia. The time taken for parasitaemia to 
fall to half of the admission value (PCT SO) and to fall to 10% of the admission value 
(PCT 90) are also useful comparative values. 
The WHO classification of in vivo antimalarial drug sensitivity (1973) was 
used to assess the antimalarial drug efficacy: 
Rl: initial resolution of the symptoms and parasite clearance but 
recrudescence of the infection between 7 and 28 days from starting antimalarial treatment. 
R2: Reduction of parasitaemia by 7S% at 48 hours, but failure to 
clear parasites within 7 days from starting antimalarial treatment. 
R3: Parasitaemia does not fall by 7S% within .+8 hours 
We are aware that the classification of efficacy outcome for moderate transmission areas 
was introduced in 2003 
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Early treatment failure (ETF): development of danger signs or 
severe malaria on day 1, 2 or 3 in the presence of parasitaemia; parasitaemia on day 2 is 
higher than day 0 count irrespective of axillary temperature; parasitaemia on day 3 with 
axillary temperature> 37.5°C; parasitaemia on day 3 > 25% of count on day 0 
Late treatment failure (L TF): 
- Late clinical failure (LCF): development of danger 
signs or severe malaria after day 3 in the presence of parasitaemia without previously 
meeting any of criteria of early treatment failure; recurrence of parasitaemia accompanied 
by fever between 4-28 or 56 days without previously meeting any of criteria of early 
treatment failure 
- Late parasitological failure (LPF): recurrence of 
parasitaemia not accompanied by fever between 4-28 or 56 days, without previously 
meeting any of criteria of early treatment failure or late clinical failure. 
Adequate clinical and parasitological response (ACPR): no 
recurrence of parasite (with or without fever) for duration of monitoring without 
previously meeting any of criteria of early treatment failure; late clinical or parasitological 
failure. 
In order to keep the consistency of the evaluation the original classification is still in use. 
The follow-up visits were scheduled for days 2 (+48h), 7, 28, and 56 with standardized 
clinical examination, peripheral blood smear and filter paper dot. Patients were 
encouraged to return to the hospital (in hospital-based studies) or commune health station 
(in community-based studies) at any time they feel sick. Home visits were arranged for 
patients who did not come back. 
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The PCR was used to distinguish recrudescence and new infections. The failure cases will 
be treated with artesunate 3 days + one day mefloquine (25 mglkg). 
Adverse drug reactions (ADR) , defined as any symptoms and signs that occurred or 
became more severe after starting of treatment, were assessed at follow-up visits. 
Specific details of clinical assessment for individual study will be described separately in 
clinical chapters (Chapters 4, 5 and 6). 
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2.4 Laboratory methods 
2.4.1 Molecular method to differentiate re-infection from recrudescence 
2.4.1.1 Extraction of DNA from blood infected with P. falciparum 
All samples were collected on admission before the start of treatment. The diagnosis of 
Plasmodium Jalciparum infection was made by microscopic examination of Field- or 
Giemsa-stained thin and thick blood smears. During the surveys, most blood samples 
were collected and stored on filter paper. Two drops of patient's blood were spotted on 
Whatman (Maidstone, United Kingdom) 3 MM filter paper, air-dried, and stored in sealed 
plastic bags with silica gel at room temperature. With this method, the quantities of blood 
collected are small, one drop corresponding to a volume of 30 III of blood, but collection 
and storage of blood is cheap and does not require freezers. Alternatively, blood was 
collected in EDTA-tubes and stored at -30°C until DNA was extracted using a QIAGEN 
kit. 
i) DNA extraction by the chelexl boiling method, from blood spotted on to filter 
paper 
Principle: 
Saponin is a detergent, which causes lysis of the red blood cell membrane and releases the 
haemoglobin from the filter paper, which is then washed away. The DNA is bound up in 
the paper fibers and is released into the supernatant by boiling. Chelex is a chelating ion 
exchange resin with high preference for copper, iron and other heavy metals, which could 
be possible inhibitors of the PCR reaction. This method is quick, simple and inexpensi\'c, 
but it does not yield purified DNA. 
Method: 
Blood spots were cut from the filter paper using flamed forceps and scissors. The blood 
spots were soaked for 10 minutes in a sterile l.5 ml Eppendorf tube containing 1 ml of 
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1 % Saponin (w/v) (Sigma-Aldrich GmbH, Stemheim, Germany), in phosphate buffered 
saline solution (PBS; 0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 :"1 
sodium chloride, pH 7.4). The tubes were centrifuged for 4 min at 14 000 rpm in a 
microcentrifuge (Juan, France) and the supernatant was discarded. Filter spots were 
washed twice by adding 1 ml of PBS to the tubes, centrifugation for 2 min at 14 000 rpm 
and then the supernatant was discarded. 150 JlI of Molecular Biology Grade water and 
150 JlI of a 20% suspension of Chelex 100 resin (Bio Rad, Hercules, California, USA) 
were added. The tube was placed in a boiling water bath for 8 minutes and then 
centrifuged for 2 minutes at 14 000 rpm. The supernatant, which contained the DNA was 
carefully removed to avoid transfer of the Chelex resin and aliquoted into two Eppendorf 
tubes. Both tubes were stored at -200 C. When used for PCR, one tube was thawed on ice 
and after use immediately returned to -200 C storage (S Kyes, et aI., 1993). 
ii) Extraction of DNA using the QUIAamp DNA mini kit 
400 JlI of blood from the stored EDTA-blood tubes were extracted using the QIAamp® 
DNA minikit (QIAGEN, Germany) according to the manufacturer's instructions. DNA 
was eluted with 200 JlI of buffer AE. 
2.4.1.2 Genotyping of P. falciparum by Polymerase Chain Reaction using t/tree 
polymorphic marker genes: Merozoite Surface Protein 1 (MSPl), Merozoite Surface 
Protein 2 (MSP2) and Glutamate Rich Protein (GLURP). 
Polymorphic loci and oligonucleotide primer sequences 
Three parasite loci, which are single copy genes (or: exist as single copy genes in the 
parasite's genome) and exhibit repeat number polymorphisms, were used for the genetic 
analysis of the parasite population. All three genes were amplified by primary rounds of 
Polymerase Chain Reaction (PCR), which was followed by a nested round. 
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The gene for MSPI is located on chromosome 9 and can be divided into 17 
blocks according to the repetitive and conservative nature of the sequence. The region of 
amplification surrounds block 2. The primers MSPI PI: CAC ATG AAA GTT ATC 
AAG AAC TTG TC and MSPI P2: GTA CGT CTA ATT CAT TTG CAC G were used 
for the first round of PCR, which was followed by a nested round of amplification using 
the PCR primers: MSPI Nl: GCA GTA TTG ACA GGT TAT GG and MSPI N2: GAT 
TGA AAG GTA TTT GAC. 
The gene for MSP2 is located on chromosome 2 and can be divided in 4 blocks. 
The region of amplification surrounds block 2, two pairs of primers (MSP2 PI: GAA 
GGT AAT TAA AAC ATT GTC and MSP2 P2: GAG GGA TGT TGC TGC TCC ACA 
G, MSP2 Nl: CTA GAA CCA TGC ATA TGT CC and MSP2 N2: GAG TAT AAG 
GAG AAG TAT G) are used in consecutive rounds of polymerase chain reaction. 
The oligonucleotide primers used for the amplification of MSP 1 and MSP2 were 
described by Lisa Ranford-Cartwright (LC Ranford-Cartwright, et aI., 1993). 
The gene for GLURP is located on chromosome 10 and contains two repetitive 
regions, Rl and R2. The two pairs of primers used for the PCR reaction, GLURP PI: 
ACA TGC AAG TGT TGA TCC and GLURP P2: GAT GGT TTG GGA GTA ACG, 
GLURP Nl: TGA ATT CGA AGA TGT TCA CAC TGA AC and GLURP N2: TGT 
AGG T AC CAC GGG TTC TTG TGG, hybridize to the region surrounding R2. Primers 
for GLURP were described by RE. Paul and S. Viriyakasol (RE Paul, et aI., 1995) (S 
Viriyakosol, etal., 1995). 
Polymerase Chain Reaction Amplification Conditions 
PCR Conditions 
Each of the genotyping reactions for the three marker genes was carried out in separate 
tubes, with one set of primers. Each 25 /-lL reaction mixture for primary MSP 1, MSP2 and 
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GLURP and nested MSP1, MSP2 and GLURP amplification reactions contained DNA 
template (5 flL for the first round and 1 flL for the nested), 100 nM of each primer, 2.5 
mM MgCI2, PCR buffer (50 mM KCI, 10 Mm Tris-HCI), 200 flM of each 
deoxynucleoside triphosphate, and 0.6 units of Taq DNA polymerase. 
For the primary round of genotyping, the PCR conditions were as follows: step 1, 95°C 
for 5 min; step 2, denaturation at 95°C for 30 sec; step 3, annealing at 45°C for 30 sec; 
step 4, extension at 70°C for 1 min; repeat steps 2-4 29 times, followed by step 5, final 
extension at 70°C for 5 min. One microliter of the primary reaction served as the DNA 
template of the corresponding secondary reaction. Temperature profiles of the nested 
genotyping round were similar to those of the primary genotyping round, except that the 
annealing temperature was lowered to 40°C. 
In order to be able to distinguish recrudescence from a new infection with P. falciparum, 
the admission sample of the patient (sample A) and relapse sample (sample B) were 
analyzed as paired samples under exactly the same PCR conditions and run on the same 
gel next to each other. 
Controls 
Positive, negative and water controls were included in each experiment. As a positive 
control DNA from a field isolate of Plasmodium falciparum was used that showed 2 
distinctive bands for MSP1, 3 for MSP2 and one for GLURP. DNA from a healthy 
individual that was not infected with Plasmodium falciparum was used as negative 
control. 
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Sensitivity of detection of MSP 1, MSP2 and CLURP genes by PCR 
To find the sensitivity of detection, the purified DNA template was amplified by using the 
optimized PCR condition. The amount of template was varied by serial dilution to 
correspond to 1000, 500, 100, 50, 25, 10, 5, 2 and 1 parasites/~L, respectively. 
Successful nested genotyping PCR reaction was obtained reproducibly from samples 
containing as little as 1 - 10 P.falciparum genomes (ca. 0.00001 % parasitaemia). 
PCR Product Detection 
Five microliters of the amplified PCR product were mixed with 1.5 ilL of loading 
buffer (30 % glycerol (v/v), 0.4% Orange G (Bio Rad) (w/v)) and electrophoresed on a 2 
% agarose gel at 150 m V for two and a half hours. DNA size standards were run on both 
ends of the gel. After electrophoresis, the gel was stained with ethidium bromide for 15 
min so that the DNA fragments could be visualized on an UV -transilluminator and 
photographed. The size of the amplified DNA was estimated by comparing its mobility to 
a molecular weight marker (100 bp marker; Life Technologies, U.S.A.). 
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Table 2.4.1: Sequences of oligonucleotide primers used for genotyping of Plasmodium 
falciparum. 
MSP I - primary 
MSP I - nested 
MSP2 - primary 
MSP2 - nested 
GLURP - primary 
GLURP - nested 
MSPI PI 5'- CAC ATG AAA GTT ATC AAG AAC TTG TC - 3' 
MSPI P2 5' - GTA CGT CTA ATT CAT TTG CAC G -3' 
MSPI 
NI 5' - GCA GTA TTG ACA GGT TAT GG - 3' 
MSPI 5' - GAT TGA AAG GTA TTT GAC - 3' 
N2 
MSP2 PI 5' - GAA GGT AAT TAA AAC ATT GTC - 3' 
MSP2 P2 5' -GAG GGA TGTTGCTGC TCC ACAG-3' 
MSP2 
NI: 5' - CTA GAA CCA TGC ATA TGT CC - 3' 
MSP2 5' - GAG TAT AAG GAG AAG TAT G - 3' 
N2 
GLURP 
PI 5' -ACA TGC AAGTGTTGA TCC-3' 
GLURP 5' - GAT GGT TTG GGA GTA ACG - 3' 
P2 
GLURP 
NI 5' - TGA ATT CGA AGA TGT TCA CAC TGA AC - 3' 
GLURP 5' - TGT AGG TAC CAC GGG TIC TIG TGG -3' 
N2 
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2.4.2 Assay methods for antimalarial drugs 
2.4.2.1 Analysis of artesunate, dihydroartemisinin and artemether 
validated high perfonnance liquid chromatographic (HPLC) Fully or gas 
chromatographic-mass spectrometric (GC-MS) methods were used for the analysis of 
ARTS, dihydroartemisinin (DHA) and ARM. 
ARTS and DHA in plasma from patients who received i.m. ARTS were assayed by the 
HPLC method of Batty (KT Batty, et aI., 1996). The between-run coefficients of variation 
(relative standard deviations) were 5% and 6% at 900 nmol/L and 4970 nmollL 
respectively for ARTS, and 11 % and 9% at 1070 nmollL and 4730 nmollL respectively 
for DHA. Quality control samples were included with each assay batch, with a 
requirement that the run was acceptable only if the QC was within ± 15% of the nominal 
value. 
ARM and its metabolite DHA in plasma from patients who received i.m. ARM were 
quantified by the GC-MS method of Mohamed (SS Mohamed, et aI., 1999) with minor 
modifications in the GC-MS conditions. Briefly, separations and quantitations were 
achieved on a Hewlett Packard 5890 Gas Chromatograph coupled to a Hewlett Packard 
5971A Mass Selective Detector operating in selected ion monitoring mode (SIM). A J & 
W DB-5 30 m x 0.25 mm i.d. GC column coated with a 0.25mm film thickness of 5 % 
phenyl methyl siloxone (J & W Scientific Products GmbH, Koln, Germany; part # 122-
5032) was used. The gas carrier was helium at a flow rate of 1 ml/min, and the injection 
port temperature was 250°C. The oven temperature was 100°C initially and maintained at 
this temperature for 2 min, then ramped at 16°C/min to 250°C, held at the latter 
temperature for 1 min and then ramped to a final temperature of 300°C. Under these 
conditions, retention times (SIM) were 10.5 min (mlz 152; dwell time = 40 ms), 11 min 
(m/z 138; dwell time = 40 ms) and 12.4 min (mlz 166; dwell time = 40 ms) for 
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dihydroartemisinin, ARM and artemisinin (internal standard) respectively. The within-
run coefficients of variation for the assay were 3.7% and 7.8% at 35 nmollL and 352 
nmol/L respectively for DHA and 3.8% and 6.l % at 67nmollL and 671nmollL 
respectively for ARM. Similarly, between-run coefficients of variation were 16.0%, 
13.5% and 8.7% at 8 nmol/L, 39 nmol/L and 176 nmollL respectively for DHA and 
13.0% and 6.4% at 70 nmollL and 185 nmollL respectively for ARM. The limit of 
quantitation was 40 nmol/L for ARM and 3 nmollL for DHA. Quality control samples 
were included with each assay batch, with a requirement that the run was acceptable only 
if the QC was within ± 15% of the nominal value. 
2.4.2.2 Piperaquine 
Plasma piperaquine concentration assay 
Piperaquine concentrations were determined using solid phase extraction (SPE) and liquid 
chromatography (LC) (N Lindegardh, et aI., 2003). Plasma (0.5 mL) was precipitated 
with 1 mL acidic acetonitrile (acetonitrile-acetic acid 1 %,85:15 v/v) and vortex mixed for 
about 10 seconds. Five hundred ~L phosphate buffer (PH 4 0.005M) containing internal 
standard (l000 nmole/L) was added and the tubes were vortex mixed again for about 10 
seconds and left at room temperature for 10 minutes. The micro tubes were centrifuged at 
13 000 g and the supernatant was transferred to a polypropylene tube and loaded onto a 
PRS SPE column (lmL, 100 mg, Argonaut Ltd, Hengoed, Glamorgan, UK). The SPE 
column had prior to loading been activated with methanol and conditioned with acidic 
acetonitrile (acetonitrile-acetic acid 1 %-water, 42.5:7.5:50 v/v). The SPE columns were 
washed with 0.5 mL water and 2 mL methanol-phosphate buffer (PH 2.5 0.1 M) (80:20, 
v/v) before eluted with 2 mL methanol-triethylamine (98:2, v/v). The SPE eluates were 
evaporated, reconstituted and injected into a LC-system using a Chromolith Performance 
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(VWR International, Dannstadt, Gennany) and a mobile phase containing acetonitrile-
phosphate buffer pH 2.5 O.IM (8:92, v/v). The total precision for all quality controls 
during the analysis was 8.4% and 5.4% at 230 nmolelL and 1350 nmole/L respectively. 
2.4.3 Pharmacokinetic analysis 
2.4.3.1 Uncomplicated malaria 
Phannacokinetic parameters were detennined by non-compartmental analysis usmg 
STATA (release 7; Stata corporation 2001, Texas). The AUCO~24 was calculated using 
the trapezoid method in which missing drug concentrations were interpolated from the 
neighbouring points using the straight line. Maximum observed concentration Cmax and 
observed time to Cmax, Tmax were detennined from observed data. Terminal elimination 
half-life t1l2elim was detennined from the log linear fit to the final serial plasma 
concentrations. Compartmental models were fitted by weighted iterative least squares 
regression. The fundamental parameters derived were: absorption rate constant (Ka), 
apparent clearance (CLIF) and apparent volume of distribution (V IF), where F is the 
fraction of drug absorbed. In addition to the conventional compartmental and non 
compartmental analyses a population phannacokinetic analysis was also conducted. for 
piperquine data. 
In the population approach, inter-subject variability in the pharmacokinetic parameters 
were modelled with log-nonnal error models, i.e (CLlFi)=(CLIF) exp ( lli CUF), where 
CLlFi is the pharmacokinetic parameter for the ith individual, CLIF is the popUlation 
mean, lli CUF is the random effect with zero mean and variance (J'CUF, which represents the 
inter-subject variability for the parameter. 
To explain inter-subject variability, a number of covariates were investigated: presence 
of parasitaemia at day 3, weight, and gestational age. Weight and gestational age were 
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centred around their median values so that the population estimates would represent those 
of an average patient. 
The log of likelihood function, Akaike information criterion, and Schwartz criterion were 
used to determine the models that best fitted the data, firstly between different 
pharmacokinetic models and then between models with different covariates. The latter 
were compared using the backward elimination procedure. The goodness of fit of each 
model was also assessed by the examination of the scatter plots of residuals versus 
predicted drug levels. The actual time of the sampling was used in the analysis. All 
compartmental analysis was performed using the S plus programme (SPLUS 6.0 for 
Windows, Mathsoft, Inc). 
2.4.3.2 Severe malaria studies 
Data were plotted graphically and analysed using WinNonlin® 3.1 (Pharsight, Mountain 
View, CA, USA). Where possible, one- or two-compartment open models were fitted to 
the plasma concentration-time profiles. The final choice of model was based on the 
Akaike Information Criterion, and on the distribution of residuals. Conventional 
pharmacokinetic parameters (area under the plasma concentration time curve [AUC] from 
time to infinity [AUC 0-001; with extrapolation to 00 Clast/AZ, where Clast is the final 
measured concentration and AZ is the terminal elimination rate constant], tl/2, apparent 
clearance after intramuscular administration [CL or Cli,m.lf], volume of distribution at 
pseudo-distribution equilibrium (Vd), maximum concentration in plasma [Cmax] and the 
time [Tmax] to Cmax were determined from the plasma concentration-time data by both 
compartmental and noncompartmental analysis. The estimates of pharmacokinetic 
parameters for DHA assumed complete conversion of ARTS to DHA as reported 
previously (TM Davis, et aI., 2001). 
112 
Chapter 2: MATERIALS AND METHODS 
2.4.4 Statistical Analysis 
The pharmascokinetic variables were analysed using the computer package SPSS for 
Windows (version 10.0; SPSS Inc., Chicago, Ill.). Data are presented as means ± standard 
deviation (SD) or geometric means (SD range). Two-sample comparisons were by 
Student's t-test or Chi-squared test as appropriate. A two-tailed level of significance of 
0.05 was used throughout. 
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CHAPTER 3 
PHARMACOKINETICS 
In order to optimise treatment the pharmacokinetic properties of a drug need to be 
characterised. For the immediate future the artemisinin compounds are our most 
important compounds. Artemisinin derivatives have an excellent safety profile in humans 
documented in a large number of randomised controlled trials and more extensive 
community use. Dihydroartemisinin (DHA) is the active metabolite of artesunate and 
artemether, and is manufactured as an oral antimalarial drug in China. Artesunate is more 
widely used. When taken orally artesunate is almost entirely hydrolysed to DHA, and so 
has equivalent therapeutic efficacy. There are very few data on the pharrnacokinetic 
properties of the artemisinin derivatives in severe malaria, where there are different 
concerns to uncomplicated malaria. In severe malaria it is critical that therapeutic 
concentrations are achieved rapidly and so absorption parameters are critical. This is 
particularly relevant to intramuscular or rectal administration. As artemther is an oil-based 
intramusculary administered drug it was necessary to study particularly its absorption 
profile. 
Dihydroartemisinin-piperaquine IS an artemisinin-containing fixed combination 
antimalarial drug developed in China. It is being used increasingly in South East Asia. 
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and is now part of first line treatment in Vietnam. It has tremendous potential for 
worldwide use. Piperaquine, an orally active bisquinoline discovered by Rhone-Poulenc 
in the early 1960s was developed for clinical use in 1973. It is structurally related to 
chloroquine with a similar mechanism of action through the chemical inhibition of 
parasite haem detoxification (K Raynes, et al., 1995). Piperaquine phosphate (PQP) 
replaced chloroquine as the recommended treatment for fa1ciparum malaria in China in 
1978 and was used extensively for mass prophylaxis and treatment. Reported side-effects 
are generally similar to those observed with chloroquine although pruritus is uncommon 
(MB Denis, et al., 2002) 
3.1 Pharmacokinetics of dihydroartemisinin-piperaquine (DHA-PQP) 
3.1.1 Introduction 
The phannacokinetic properties of the oral artemisinin derivatives are now well 
established. All compounds are rapidly absorbed and rapidly eliminated. Although 
metabolic biotransfonnation of artemether to dihydroartemisinin via CYP 3A4 maybe 
affected by malaria this does not have a significant effect on bioactivity. Artesunate is 
readily and spontaneously hydrolysed to DHA. The DHA is then inactivated by 
glucuronidation. For piperaquine there are few data; the estimated terminal elimination 
half-life in human adults has been estimated only once and was reported as at 17 days, but 
precise phannacokinetic data in man are not yet available (TY Hung, et al., 2003). 
3.1.2 Patients and Methods 
3.1.2.1 Patients 
We recruited patients who were admitted to the Hospital for Tropical Diseases, Ho Chi 
Minh City, Vietnam, and had microscopically confirmed uncomplicated falciparum 
115 
Chapter 3: PHARMACOKINETICS 
malaria. On admission, a full clinical examination was performed and blood samples were 
taken for full blood count, biochemistry, parasite count, and baseline antimalarial drug 
assay. 
Patients were randomly allocated either 
i) regimen 1: DHA-PIP (Tonghe Pharmaceutical, Yuzhong Chongqing, People's 
Republic of China) four tablets at ° h then 2 tablets at 24 and 48 h 
OR 
ii) regimen 2: two tablets at ° h, 6 h, 24 h, and 48 h. 
DHA-PIP contains 32 mg dihydroartemisinin, and 320 mg ofpiperaquine per tablet. 
Drugs were kept in identically numbered opaque envelopes, and drug administration was 
directly observed in all cases. 
Blood samples were taken at 0, 2, 4, 6, 24, 26, 48, 50, 72, 96, 120, 144 hour and then on 
day 28 and 56. Vital signs were assessed 6 hourly and before taking blood samples. All 
blood samples were centrifuged within 10 minutes and separated plasma stored at - 20°C 
until sending to Sweden for assay. 
The study was approved by the Ethical and Scientific Committee of the Hospital for 
Tropical Diseases. We obtained written informed consent from patients or their guardians. 
3.1.2.2 Methods 
Pharmacokinetic parameters of piperaquine were determined by non-compartmental 
analysis using STAT A. The AVCo~oo was calculated from the composite of area under the 
concentration-time curve (AVC) from ° hours (time of first dose) to last drug 
measurement using cubic spline and from extrapolating the log-linear fit to the last 3 
points on the curve. The AVCo~ 48 was calculated using the cubic spline for 
concentrations measured between time ° and 48 hours. AVCs and other pharmacokinetic 
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parameters were summarised using median and 90% range and were compared between 
the two treatment regimens using the nonparametric Mann-Whitney test. 
Piperaquine pharmacokinetic characteristics were also examined using compartmental 
analysis in which the population approach was employed. Two compartment and three 
compartment models with first order absorption and first order elimination were 
considered. 
To explain inter-subject variability, a number of covariates were investigated: 
temperature, parasitaemia, weight, and age, measured at the start of the treatment (day 0). 
All covariates were centred around their median values so that the population estimates 
would represent those of an average patient. 
The log of likelihood function, Akaike information criterion, and Schwartz criterion were 
used to determine the models that best fitted the data, firstly between different 
pharmacokinetic models and then between models with different covariates. The latter 
were compared using the backward elimination procedure. The goodness of fit of each 
model was also assessed by the examination of the scatter plots of residuals versus 
predicted drug levels. 
The actual time of the sampling was used in the analysis. All compartmental analysis was 
performed using the S plus programme (SPLUS 2000 for Windows, Mathsoft, Inc), while 
the population analysis used the NLME (non-linear mixed effect) procedure 
3.1.3 Results 
A total of 25 patients with uncomplicated fa1ciparum malaria were recruited into the 
study. Two of them were excluded because of their interruption of the scheduled follow-
up. Details of admission characteristics are summarized by group of treatment in table 
3.1.1. All of the recruited patients had a negative blood smear at the last visit on day 56 
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Table 3.1.1: Baseline clinical characteristics of patients including in piperaquine PK study. 
Parameters Group 1 Group 2 p value 
(n = 10) (n = 13) 
Age (years) mean 29.4 30.7 0.83 
95%CI 22.1-36.7 22.5-38.9 
Sex male/female 10/0 1112 0.48t 
Weight (kgs) mean 54.8 46.9 0.19 
95% CI 45.5-64.1 44.1-49.6 
Temperature (OC) mean 38.5 38.7 0.48 
95%CI 37.8-39.1 38.3-39.1 
Rct (%) mean 35.9 35.0 0.83 
95%CI 32.5-39.2 30.4-39.6 
White blood cell count 106/L mean 6,544 5,571 0.74 
95% CI 3,868-9,221 4,317-6,826 
BUN (mmollL) mean 4.28 5.77 0.002 
95% CI 3.77-4.79 4.91-6.62 
Creatinine (~mo lIL) mean 83.0 73.2 0.93 
95%CI 67.2-98.8 71.6-89.3 
Glucose (mmollL) mean 6.2 6.6 0.48 
95%CI 5.16-7.29 5.56-7.64 
Parasite count on admission (/~L) geometric mean 10,836 16,358.3 0.88 
95%CI 14,270-102,150 20,092-70,267 
Mann Whitney (J te~t used 111 all tests except where specIfied: t Fisher's exact test 
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Table 3.1.2: Clinical outcomes and cure rates of patients by groups of treatment piperaquine PK study. 
Outcomes 
F ever clearance time (hrs) 
Parasite clearance time (hrs) 
Cure rate (I observed 56 day follow-up) 
Mean 
95%CI 
Mean 
95%CI 
Mann Whitney U test used in all tests except where specified; t Fisher's exact test 
119 
Group 1 
(n = 10) 
15.6 
5.7-25.6 
43.2 
23.7-62.7 
9/9 
Group 2 
(n = 13) 
19.4 
11.8-27.0 
48 
33.5-62.5 
9/9 
P value 
0.32 
0.52 
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There were 23 patients who completed the pharmacokinetic sampling, 10 of them 
received regimen 1 (3 doses: 1280, 640, 640mg of piperaquine phosphate at 0, 24,48h) 
and 13 received regimen 2 (4 doses of 640 mg ofpiperaquine phosphate, at 0, 4, 24, 48h). 
In total, there were 299 drug level measurements, median (range) of 14 (7-15) 
measurements per patient. The times of sampling were for each patient at: 0, 2, 4, 6, 24, 
26, 48, 50, 72, 96, 120, 144, and then in intervals: 284-362h for 21 patients, 640-832h for 
8 patients and 1309- 1536h for 16 patients. 
The plasma piperaquine concentration-time profile is showed separately by regimens 
group in Figure 3.1.1. 
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Figure 3 .1: The plasma piperaquine concentration-time profile is showed 
separately for the two regimens 
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Drug levels were measured in nmole/L and were converted to !lg/L by multiplyi ng by 
factor 0 .53551 (535.51 is the molar weight of piperaquine base). Dose of x !lg of 
piperaquine phosphate corresponds to the 0.58x !lg of the piperaquine base (0.58 = 
535.511927.42 = molar weight of piperaquine basel molar weight of piperaquine 
phosphate ). 
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Table 3.l.3: Phannacokinetic parameters derived from the non-compartmental analysis of 
two regimen groups in piperaquine PK study. 
Group 1 (n=10) Group 2 (n=13) 
p-value* 
Median (90% range) Median (90% range) 
T 112 elim (days) 14.5 (1-67) 24 (3-30) 0.121 
Ke (h I) 0.002 (0.0004- 0.024) 0.001 (0.00095-0.009) 0.121 
Cmax (mg/L) 
174 (77-387) 215 (45-406) 0.577 
Tmax (h) 50 (26-50) 6 (4-50) 0.035 
AUC O~OO 
22611 (4395-81018) 39468 (11697-62331) 0.063 
(~g hlL) 
AUC 0-48 
(~g hlL) 3263 (1386-15386) 5007 (1982-17333) 0.133 
* Mann-Whitney test 
tv, elim: half life, Ke(h-l): rate constant of elimination, Cmax: peak plasma concentration, Tmax: time of peak concentration, Vd: total 
apparent volume of distribution, kl 0: first order elimination rate constant, AUC: area under the plasma concentration-time curve. 
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Population approach 
Two and the three compartment models were examined. Although it looks that data may 
support the three compartment model, there is not enough data to fit such a model. 
Especially the second phase of elimination (around 200 hours and 500 hours) is not 
measured in this dataset. For these reasons, the three compartment model has been 
abandoned. 
A two-compartment model with first order absorption and first order elimination was 
selected as the kinetic model. The fundamental parameters used to characterize the two-
compartment model were: absorption rate constant (Ka), apparent clearance (CLI) from 
the central compartment, apparent clearance from the peripheral compartment (eL2), 
volume of the "central" compartment (VI), volume of the "peripheral" compartment 
(V2). Absorption rate constant Ka was only considered as a fixed effect because of 
limited individual data to characterize this phase. Random effects were considered for the 
log of the CLI, CL2, VI and V2 and a number of explanatory variables were examined in 
order to explain the random-effect variation. So in general, the model was: 
Log(CLI)ij = (PI +bli) + P2 Xl + p3 X2 + P4 X3 + p5 X4 
Log(CL2)ij = (yl +bli ) + y2 Xl + y3 X2 + y4 X3 + y5 X4 
Log(VI)ij = (81 +bli ) + 82 Xl + 83 X2 + 84 X3 + 85 X4 
Log(V2)ij = (YJ I +bli ) + YJ2 X I + YJ3 X2 + YJ4 X3 + YJ5 X4 
where XI-X4 are the explanatory variables (temperature, parasitaemia, weight, and age, 
measured at the start of the treatment ). 
When the standard model was fitted assuming the within-group errors to be E-N (0, 0'21), 
the pattern was observed in residuals plot. Therefore heteroscedacity (within-group 
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variance) was modelled proportionally to the fitted values, first assummg the linear 
relationship, and then using the best fitting power function. 
The best fit to the data was obtained with a two-compartment model with only log (VI) 
fitted as random effects and the variance increasing linearly with the fitted values (Table 
3.1.2). None of the measured covariates explained any significant proportion of the 
variation in the random effects. However, the random effects were very small, a reason 
for which may be a sparse nature of the data. 
Table 3.1.4: Estimates of piperaquine population pharmacokinetic parameters 
Parameter Estimate (95% CI) 
Ka (h-1) 1.51 (0-4.009) 
CL (L/h/kg) 0.760 (0.574-1.007) 
CLD (L/hlkg) 2.272 (1.707-3.022) 
VI (L/kg) 153.449 (105.758-222.680) 
V2(L/kg) 299.692 (204.043-440.171) 
coVl 0.81 
IT residual 143 
AVC (/-lg hlL) 41892 
TII2 abs(h) 0.46 
Ke (h-1) 0.0017 
TI/2 elim (days) 17 
Ka - absorption constant, CL - total clearance, CLD - inter-compartmental clearance, V 1- volume of the central compartment, V2 -
volume of the peripheral compartment, V=VI +V2 - total volume, AUC=DoselCL - area under the time -concentration curve, Tl/2 
abs = O.693/Ka - half life of absorption, Ke = CUV - elimination constant, TII2 elim = O.693/Ke - half-life of elimination. 
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Figure 3.2: Individual predicted concentration levels from the model (triangles) and the 
observed levels of piperaquine (circles) for concentrations measured in the first 100 hour 
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Later points in the concentration-time curve, after the absorption and distribution phase 
fini shed, describe the elimination process. A straight line may be fitted to the log-
transformed data and the slope of this line estimates the elimination rate constant. 
For four patients final measurements were negative so in the analysis (table 3) they were 
excluded. When these samples were included in the analysis as very low levels (0.05 ) the 
median (95%C1) elimination rate did not change much : 0.001525 (0.0011021 -
0.0041917). From this , we conclude that median elimination rate is Ke=O.OO 1, which 
corresponds to the estimated elimination half-life of 29 days . 
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Table 3.1.5: Slope of the final curve corresponding to the final elimination stage; 
calculated assuming first order elimination process starting at different time points 
(a) 200 hours (b) 400 hours in piperaquine study. 
Patient ID (a) Time>200 (b) Time>400 
4 0.00075 
8 0.00043 0.00026 
11 0.00199 0.00088 
12 0.00116 0.00064 
13 0.00200 0.00122 
14 0.00095 0.00071 
15 0.00146 
16 0.00127 0.00272 
17 0.00026 
19 0.00159 0.00087 
20 0.00121 0.00092 
21 0.00177 0.00131 
22 0.00100 0.00070 
24 0.00165 
25 0.00104 0.00090 
Median. 0.00121 0.00088 
(95%CI) 0.0009589 - 0.0016393 0.0006828 - 0.0012459 
90% range 0.00026 - 0.002 0.00026 - 0.00272 
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Figure 3.3: The standardised residuals from population model. 
4 
12 
3 S ml4 
(/) 'P1 1=4 8 !U 2 f6 
::J 0 0 00 
-0 0 0 
(/) 0 
Q) 0 L- 0 
-0 1 Q) 
N 0 0 
-0 0 
L- 0 
!U 0 I{)J 0 
-0 
C r !U 0 0 ..... (/) 00 
0 
-1 0 
00 0 00 0 0 0 
0 0 
-2 8 1=9 
0 100 200 300 
Fitted values 
Numerical label: patient 10 for whom the absolute value of residual was greater than 2 
127 
Chapter 3: PHARMACOKINETICS 
3.1.4 Discussion 
The phannacokinetic properties of piperaquine are very similar to those of chloroquine, as 
might have been predicted from their structural similarity. There is considerable inter-
individual variation in peak concentrations which presumably reflects the relatively small 
relative volume of the central compartment, and thus the dependence of peak 
concentration on rate of absorption. But, this is probably of no clinical relevance as no 
toxicity has been demonstrated. At this stage the main antimalarial effect is mediated by 
DBA. The tenninal elimination phase is critical for antimalarial effect. The estimated 
elimination half-life of approximately one month may still prove to be an underestimate 
with further assay refinement. The longer half-life in these studies than reported 
previously almost certainly reflects greater assay sensitivity and thus better 
characterization of the tenninal elimination phase of a multi-exponential decline. As 
might be expected this phase is unaffected by severity of malaria, as it takes place mainly 
after recovery. With drugs such as chloroquine it may not be possible to characterize 
adequately in a multi compartmental model each distinct phase of distribution and 
elimination. But unless there are major toxicity concerns, it is of greatest clinical 
relevance to concentrate on the elimination phase, as this is the phase where piperaquine 
must eradicate the individual infection, suppresses reinfections, but may also select for 
resistance. The very long elimination phase may well explain why those few 
recrudescences which do occur arise more than six weeks after treatment. More work is 
now needed to detennine the in-vivo MIC and thus the duration of post treatment 
prophylaxis that might be expected in a high transmission setting. 
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3.2 Comparative Pharmacokinetics of 1M Artesunate and Artemether in Severe 
Falciparum Malaria 
3.2.1 Introduction 
Severe malaria kills between one and two million people each year. The qinghaosu 
derivatives artesunate (ARTS) and art em ether (ARM) are being used increasingly for the 
parenteral treatment of severe fa1ciparum malaria (NJ White, 1996, NJ White, 1998). 
They are intrinsically more potent as antimalarials, have a broader stage specificity of 
action against the malaria parasite(F ter Kuile, et a!., 1993) and are simpler to administer 
and safer than parenteral quinine (Artemether-Quinine-Meta-analysis-Study-Group, 2001, 
TT Hien, et al., 1996, MB van Hensbroek, et al., 1996). Artemether has been more 
intensively evaluated, although artesunate is more widely used. ARM is formulated in an 
oil base because of its poor water solubility and can only be injected by the intramuscular 
(i.m.) route. There is evidence that i.m. ARM may not be absorbed adequately in 
severely ill children with fa1ciparum malaria who are hypotensive or acidotic (MN Mordi, 
et al., 1997) . Nevertheless, i.m. ARM has proved as effective as parenteral quinine in the 
largest randomized trials ever conducted in severe malaria (TT Hien, et a!., 1996, MB van 
Hensbroek, et al., 1996), and in adult patients with multi-organ dysfunction ARM was 
therapeutically superior (Artemether-Quinine-Meta-analysis-Study-Group, 2001). ARTS 
is a hemisuccinate artemisinin derivative formed by the addition of sodium bicarbonate to 
lyophilised artesunic acid. ARTS is water-soluble, and can be given by either intravenous 
(i.v.) or i.m. injection. Both these routes of administration give rapid therapeutic 
responses III severe malaria (TT Hien, et a!., 1992b). Data from patients with 
uncomplicated malaria suggest that i.m. ARTS is well absorbed (KF Ilett, et a!., 2002) but 
there have been no detailed pharmacokinetic studies in severely ill patients, and, despite 
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extensive use, there have been no large clinical trials comparing the efficacy of ARTS 
with other antimalarial drugs in severely ill patients. 
In areas of the rural tropics where health care facilities are basic, i.m. injection of an 
artemisinin derivative may represent the best therapeutic option for severe malaria. We 
have, therefore, investigated the pharmacokinetic properties of ARM and ARTS given by 
intramuscular injection in severely ill Vietnamese adults with fa1ciparum malaria. 
3.2.2 Patients and methods 
3.2.2.1 Patients 
We studied 19 adult patients between June 1998 and September 1999. All were admitted 
to the Malaria Ward at the Centre for Tropical Diseases, Ho Chi Minh City with 
microscopically confirmed severe fa1ciparum malaria. The diagnosis of severe malaria 
was based on modifications of World Health Organisation criteria reported previously 
(WHO, 1990) (TT Hien, et al., 1996). Briefly, severe malaria was defined as one or more 
of the following a) Glasgow Coma Score (GCS) <11, b) jaundice (serum bilirubin 
>50llmol/litre; serum aspartate aminotransferase (SGOT) more than twice the upper limit 
of the reference range), c) acute renal failure (serum creatinine >250 IlmoIlL), d) anemia 
(venous hematocrit <15%), e) hyperparasitemia (>250,000 asexual forms/ill whole blood, 
f) plasma lactate >4.0 mmollL. SUbjects who had been treated with an artemisinin 
derivative within 24 h were excluded, as were pregnant women and children under the 
age of 14 years. All patients or their attendant relatives gave informed consent to the 
study which was approved by the Ethical and Scientific Committee of the Hospital for 
Tropical Diseases and the Health Services ofHo Chi Minh City, Viet Nam. 
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3.2.2.2 Methods 
Clillical procedures 
On admission, a full clinical examination was performed and blood samples were taken 
for full blood count, biochemistry, blood culture, parasite count, and baseline antimalarial 
drug assay. An indwelling intravenous catheter was inserted into the antecubital vein of 
the arm. Patency was maintained by flushing with small volumes of heparinised saline. 
Patients were randomised to receive either 
i) ARTS (Guilin No 2 factory, Guangxi, PRC) 2.4 mglkg i.m. stat followed by 1.2 
mg/kg i.m. daily (corresponding to 6.25 and 3.13 Jlmol/kg respectively). The injection 
volumes were all 5mL. 
or 
ii) ARM (Kunming Pharmaceutical factory, Kunming, PRC) 3.2 mglkg i.m. stat 
(10.7 Jlmol/kg; injection volume 0.04mL/kg) followed by 1.6 mglkg i.m. daily (5.4 
Jlmollkg respectively; injection volume 0.02mL/kg) . 
All injections were given to the anterior thigh. After treatment was initiated, vital signs 
and parasitemia were monitored four hourly (or more frequently if indicated clinically) 
for 24 h, and then six hourly. Complications were managed as described previously (TT 
Hien, et al., 1996) 
Blood samples were taken at 0,5, 10, 15,20,30,45,60,75,90, and 120 min then at 2.5, 
3, 3.5, 4, 5, 6, 8 and 10, or 10 and 12 h following drug administration. In patients 
randomised to ARM, initial plasma concentration profiles from the first 5 patients (last 
sample 10 h in two patients and at 12 h in three patients) showed that further samples 
were needed to characterise the terminal elimination phase, and hence sampling in this 
group was extended mid-way through the study to include 12, 18, 20 and 24 h. At each 
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time point, 4 mL of whole blood was collected in lithium heparin tubes (L.I.P 
Northampton UK). These samples were centrifuged immediately at 1500rpm for 5 
minutes at 4°C and aliquots of separated plasma and frozen at -80°C in Coming 1.8ml 
cryotubes (Coming BV Life Sciences Netherlands) until analysed. 
Thick blood films were stained with Giemsa. The number of asexual parasites per 
micro litre of blood was determined by counting the white blood cells (WBC) in a high 
powered field containing a total of 500 parasites in which the ratio of parasites/WBC was 
less than 1. The parasitemia was calculated as the product of the parasite/WBC ratio and 
the WBC count. The time to a 50% reduction in the original parasite count was 
determined by linear interpolation of the parasite count-time data. Fever clearance time 
was taken to be the time of the first two axillary temperature readings <37.5°C. 
Analysis of ARTS, DHA, and ARM: as described in chapter 2 
3.2.3 Results 
Of the total of 19 patients studied, 9 were allocated to ARTS and 10 to ARM. There were 
no adverse reactions to either drug. One patient received peritoneal dialysis in the ARM 
group. Two patients died, both from the ARM group. The first, a 34 year old male was 
admitted obtunded (GCS 7), jaundiced, acidotic (plasma lactate 11 mmollL) , in acute 
renal failure, and in shock. He died 39 h after admission. The parasitemia (proportion of 
red cells parasitised) was 46% on admission, rose to a peak of 61 % at 4 hours, and was 
still above the admission value at 24 hours. Plasma ARM levels remained below 100 
nmollL during the first 10 h following admission. The second, a 42 year old male, was 
admitted jaundiced, comatose (GCS 6) and in shock, and died after 30 hours post 
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admission. The admission parasitemia was 47%, falling to 2% at 24 hours. Plasma ARM 
levels remained below 20 nmolll for the first 10 h, and did not rise above 50 nmollL 
during the first day. The other 17 patients made an uneventful recovery. The median 
(range) times to fever and parasite clearance time were similar in the two groups: 34 (15-
60) hand 48 (21-60) h respectively in the ARTS group and 35 (15-60) hand 48 (30-60) h 
in the ARM group respectively. The baseline characteristics of the patients in the two 
groups are summarized in table 3.2.1 
3.2.3.1 Pharmacokinetics ofintramuscular artesunate 
ARTS was absorbed very rapidly with peak concentrations measured in the first sample 
(5 min) in 5 of the 9 patients. A one-compartment model was fitted satisfactorily to the 
plasma concentration-time data for both ARTS and DHA (Figure 3.2.1). No significant 
improvements in fit were obtained using a two- compartment model, with mean Akaike 
information criteria for one and two compartmental models 101 and 95 respectively (95% 
CI for the difference -4.3 to 16.8). 
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Table 3.2.1: Patient characteristics on admission artesunate -artemether PK study 
Parameter ARM ARTS p 
Number of patients (male) 10 (6) 9 (7) 
Mean age (years) 36.7 31.6 0.47 
Range 24 - 60 17 - 62 
Mean tem£erature on admission (oC) [SD] 38.9 [1.1] 38.7 [1.0] 0.73 
Mean hematocrit (0/0) [SD] 33.0 [8.9] 33.8 [9.6] 0.83 
Mean white blood cell count (l09/L) [SD] 8.4 [3.5] 7.4 [2.4] 0.52 
GCS<8 1 0 1.0 6 
GCS 8-11 2 0 0.4 6 
GCS 12-15 7 9 0.2 6 
Serum creatinine (f..1mollL) [SD] 106.0 [36.3] 185.6 [238.6] 0.32 
Blood lactate (rnrnoI/L) [SD] 5.1[4.2] 6.4 [6.7] 0.67 
Total plasma bilirubin (f..1mollL) [SD] 147.0 [119.7] 63.2 [76.9] 0.09 
Parasitemia on admission If..1La 225,944 57,747 0.32 
(range) (30,144 - 1,775,230) (360 - 816,750) 
Fever clearance time (hours) [SD] 56 [34.7] 65 [67.9] 0.72 
Parasite clearance time (hours) [SD] 48 [11.5] 38.2 [13.5] 0.14 
~-~ --------
Mortality 2 (20%) 
_.-
0(0%) 0.4 b 
a = geometric meanb = Fisher 2-tailed results 
134 
Table 3.2.2: Artesunate and dihydroartemisinin pharmacokinetics following intramuscular artesunate injection in severe malaria 
ARTS DHA 
Parameter median (range) Parameter median (range) 
Cmax (nmoVL) 5,710 (1,362-8,388) Cmax (nmoVL) 3,060 (1,718-7,080) 
Vd (L/kg)I -- - - 1.09 (0.47-4.58) Vd/f(L/kg)I 1. 79 (0.63-3.53) 
kl0 (/h) I 1.39 (0.62-120) Tmax (min) 35 (10-86) 
tY2 (min) 1-- - -- - 30 (67-3.5) kOl (/h)1 2.34 (0.70-17.9) 
MRT (min) 43 (5-97) klO (h)l 0.79 (0.60-1.59) 
AUC (nmol.h) IL)2 2,228 (533-4,672) Elimination tY2 (min) 52.7 (69.3-26.2) 
CLi.m (LI h /kg) 2.84 (1.33-11.73) AUC (nmol.hlL)2 5,262 (3,812-7,436) 
CL/f (LI h /kg/) 1.18 (1.64-0.84) 
Cmax: peak plasma concentration, Vd: total apparent volume of distribution, kl0: first order elimination rate constant, t12: half life, MRT: 
mean residence time, AUC: area under the plasma concentration-time curve, CL: clearance, Tmax: time of peak concentration, kO 1: first 
order formation rate constant, f: fraction of parent drug converted to DHA (assumed to be 100%). 
1: Estimated from one compartment modeling (DHA values assume 100% bioavailability) 
2: None of the artesunate AUC was extrapolated (0-10% of the DHA AUC was extrapolated) 
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Derived pharmacokinetic parameters are summarized in Table 3.3.2. There was a wide 
variation between individuals in peak plasma ARTS concentrations (range 1,362 to 8,388 
nmoI/L). Elimination rates were rapid and varied relatively little between patients (c.v. 
11.6%). ARTS was converted rapidly to DHA. By the first sample (5 min) DHA levels 
were a median (range) of 21 % (5 to 122%) of the parent compound concentration.The 
molar AUC values for dihydroartemisinin were almost double those for artesunate (mean 
(95% CI) difference 727 (321 to 1132) nmol/L.h). DHA was eliminated significantly 
more slowly (p =0.018). The median (range) estimated elimination half-life for 
dihydroartemisinin was 52 (26-69) minutes compared with 30 (3-67) minutes for 
artesunate. These two values were significantly correlated (r = 0.79; P = 0.012) 
3.2.3.2 Pharmacokinetics of artemether 
Plasma concentrations of ARM and DHA fluctuated widely following i.m. injection of 
ARM (see Figures 2 and 3). As a result, compartmental modeling was not possible. In 
general the absorption profile was biphasic with a relatively rapid initial absorption phase 
during the first 30 min, followed by a more gradual rise to a peak concentration at a 
median of 10 hours (see upper panel, Figure 2). Thereafter, mean ARM concentrations 
tended to decline slowly, but the levels at 24 h were still higher than those during the first 
4 h of sampling. In individual patients (lower panel, Figure 2), peak plasma ARM 
concentrations ranged between 67 and 1631nmoi/L (median 574 nmoVL) and occurred at 
a median (range) of 10 (1.5 - 24) h. The mean plasma DHA concentration-time profile 
followed the same pattern as ARM (upper panel, Figure 3) but at much lower 
concentrations. The mean ratio of parent drug to metabolite varied between 10 and 30 
throughout the 24-hour sampling period, consistent with relatively little metabolism of 
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ARM to DHA. In only 2 patients did peak DHA concentrat ions exceed 25 nmoVL and in 
6 patients, the concentration did not rise above 5 nmo VL. 
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Figure 3.5: Individual concentration-time profiles for ARM (A) and its metabolite DHA 
(B) following the first i.m. dose of 10.7 /lmol (3.2 mg)/kg of ARM to 10 patients with 
severe P Jalciparum infection. For ARM, two patients had samples collected to 10 h, 
tlu·ee to 12 h and five to 24 h. For DHA, two patients had samples collected to 10 h, three 
to 12 h and five to 24h. In 5 of the profiles some of the concentration-time points shown 
were w1detected (zero), or below the assay limit of quantitation. 
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3.2.4 Discussion 
Severe malaria carries a high mortality which can only be reduced by effective 
antimalarial therapy (WHO, 1990) (NJ White, 1998). It is therefore essential that 
parasiticidal concentrations of antimalarial drugs are achieved as soon as safely possible 
following admission to hospital or health clinic. ARM is the most widely assessed of the 
parenteral artemisinin derivatives. Although it is an oil-based formulation that can be 
given only by the i.m. route, it has proved at least as effective as i.m. quinine in the 
treatment of severe malaria in large randomized trials which have enrolled collectively 
nearly 2000 patients both in Asia and Africa (Artemether-Quinine-Meta-analysis-Study-
Group, 2001). The dose regimens recommended for both ARM and ARTS, and used in 
these studies, were developed empirically before valid analytical techniques were 
available that allow detailed pharmacokinetic-pharmacodynamic evaluation. 
Despite the generally good clinical results with ARM, our data suggest that the absorption 
of intramuscular ARM is erratic and unpredictable. Indeed the plasma concentration 
profiles were so variable that we were unable to perform pharmacokinetic modelling. In 2 
of the 10 ARM-treated patients studied, one of whom died, plasma concentrations of 
ARM did not exceed 50 nmol/L within 6 h of dosing. Furthermore, conversion to the 
more active principal metabolite DHA was minimal, and thus antimalarial efficacy 
depended almost entirely on the parent ARM. 
Although malaria parasites are exquisitely sensitive to artemisinin derivatives, these low 
levels are very close to the highest reported 50% inhibitory concentrations (IC50) for 
Plasmodium Jalciparum isolates taken from patients with primary or recrudescent 
infections on the north-western border of Thailand (up to 60 nmollL for ARTS, 58 
nmollL for ARM and 29 nmollL for DHA (A Brockman, et aI., 2000), and therefore 
below the concentrations required for maximum parasiticidal effect. In general in-\'itro 
139 
Chapter 3: PHARMACOKINETICS 
mInImUm inhibitory concentrations are lower than those extrapolated in VIVO partly 
because of differences in protein binding, and because drug concentrations are constant in 
vitro whereas they fluctuate in vivo. Poor absorption was documented previously in a 
study in African children with cerebral malaria (TM Davis, et at., 2001), in which the 
combined plasma levels of ARM and DHA peaked at less than 100 !J.g/L (336 nmoIlL). 
Taken together these observations give rise to the concern that some severely ill patients 
may not absorb intramuscular ARM adequately for maximum parasite killing in the 
critical early hours following the start of treatment. The superior intrinsic antimalarial 
potency of ARM compared with quinine, therefore, may be counter-balanced by its 
erratic absorption in the most severely ill patients. 
There are few other reports of ARM pharmacokinetics after i.m. injection, mostly in 
healthy subjects. In one, 8 volunteers received a dose of 300 mg, with a geometric mean 
Cmax of 540 /-lg/L (1812 nmol/L) and mean half-lives of absorption and elimination of 2 
and 6.9 h respectively (J Karbwang, et al., 1997). The corresponding mean peak for DHA 
was greater than that of ARM (646 /-lg/L or 2275 nmollL) but the elimination tl/2 was of 
similar magnitude (5.1 h). In another, 8 subjects received 5 mg/kg by i.m. injection and 
mean peak concentrations were 588 /-lg/L (1973 nmol/L) and 142 /-lg/L (500 nmol/L) for 
ARM and DHA respectively (Y Suputtamongkol, et al., 2001). The erratic absorption of 
ARM prevented accurate estimation of elimination half-lives (Y Suputtamongkol, et al., 
2001), as in the present investigation. It is difficult to know why the results of these two 
published studies differ so markedly, as the same dose of the same formulation of ARM 
was given and the same assay methodology (HPLC with electrochemical detection) was 
used. 
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A third study involving 17 Thai adults with severe malaria, carried out by the same group 
as the first volunteer study described above (J Karbwang, et aI., 1997), reported that the 
dose-adjusted AUC of ARM was increased in severe malaria, especially in patients with 
renal impairment (J Karbwang, et aI., 1998). All subjects had plasma concentration 
profiles of both ARM and DHA that exhibited the same pattern as observed in healthy 
subjects (J Karbwang, et aI., 1997), with tmax values all close to 4 h and plasma 
concentrations that fell progressively thereafter to levels that were below, or close to, the 
limit of detection at 24h (J Karbwang, et at., 1997). These findings are in marked 
contrast to those in our patients and the other reported studies with artemether (MN 
Mordi, et at., 1997); (P Teja-Isavadharm, et at., 1996) and the closely related compound 
arteether (S Looareesuwan, et aI., 1999) which suggest that the absorption of the oil based 
drugs from an i.m. depot is prolonged and erratic, and biotransformation to DHA much 
reduced compared with that after oral dosing. 
Comparison of these results with studies of oral administration(Y Suputtamongkol, et aI., 
2001), suggests that extensive first-pass metabolism of ARM occurs when the drug is 
given by mouth compared to parenteral routes. Following oral administration the AUC of 
the metabolite considerably exceeds that of the parent compound, whereas the reverse is 
seen following intramuscular administration. The plasma DHA concentrations measured 
in our patients with severe malaria were, after adjusting for the the lower dose used (3.2 
vs 5 mg/kg), still considerably lower than those measured in healthy volunteers following 
intramuscular administration (Y Suputtamongkol, et aI., 2001), suggesting that hepatic 
metabolism of ARM, mainly by CYP3A4, but also 2B6 and 3A5 (JM Grace, et aI., 1998, 
SA Murphy, et aI., 1997) is reduced by malaria infection. Acute malaria reduces the 
hepatic biotransformation of many drugs (P Newton, et at., 2000a). The metabolism of 
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quinine (also largely via CYP3A4) has been shown to be reduced in proportion to the 
severity of malaria (P Teja-Isavadharm, et at., 1996). The effect of severe malaria on 
ARM pharmacokinetics may be even more pronounced, as both absorption from the 
intramuscular injection site and hepatic conversion to the active metabolite are reduced. 
In contrast to ARM, the absorption of ARTS was rapid and reliable. The plasma 
concentrations for ARTS and DHA in our patients (median peak values: 5707 and 3223 
nmollL respectively) were generally similar to those reported previously in 
uncomplicated malaria (KT Batty, et al., 1996, KF Hett, et al., 2002, SA Murphy, et al., 
1997). Peak concentrations of ARTS and DHA are 50-100 times higher than those 
required for full activity against the parasite. Both are eliminated rapidly, even in severe 
malaria, yet this brief exposure to the infecting parasite population (several hours) is 
sufficient for maximum antiparasitic effect in all cases. There are also important 
pharmacokinetic differences between the two artemisinin derivatives follwing oral 
administration in malaria. In a recent cross over study in uncomplicated malaria in which 
oral ARTS was compared with oral ARM, the relative oral bioavailability of oral ARM 
was 58% compared to that of ARTS (S Pukrittayakamee, et al., 1997). 
Unfortunately, there is still only one manufacturer of parenteral ARTS, and this 
formulation is not yet prepared to an internationally recognised Good Manufacturing 
Practices standard. Parenteral ARTS has considerable pharmacokinetic advantages over 
ARM in the treatment of severe fa1ciparum malaria. Since these drugs have a similar cost 
and are both widely available in the tropics, ARTS is the preferred choice for the 
treatment of severe fa1ciparum malaria, particularly in those patients who are most 
seriously ill and in whom absorption from an i.m. depot may be compromised. These 
findings should be formally assessed by a randomised clinical trial. 
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CHAPTER 4 
SAFETY OF 
ARTEMISININ AND DERIVATIVES 
The Qinghaosu (artemisinin) group of drugs, first isolated by Chinese scientists from the 
plant Artemesia annua in 1972, are now in widespread use throughout South East Asia 
and are used increasingly elsewhere in the tropical world for the treatment of both 
uncomplicated and severe malaria (China Cooperative Research Group on qinghaosu and 
its derivatives as antimalarials, 1982), (D Klayman, 1985, P Newton & NJ White, 1999). 
Several different compounds are available including the parent compound artemisinin, 
and the derivatives artesunate, artemether and arteether. Several million patients have 
now been treated with this group of drugs and, to date, no unequivocal drug-attributable 
toxicity has been reported. Recent large comparative studies of patients with severe 
falciparum malaria have confirmed artemether to be an acceptable, well-tolerated 
alternative to quinine. No significant adverse effects were found. In a double blind trial 
of 560 Vietnamese adults treated with artemether, which included thorough neurological 
evaluation and double blind audiometry, no evidence for iatrogenic neurotoxicity was 
found. In large studies of uncomplicated malaria in Thailand again no evidence of 
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significant toxicity was found (TT Hien, et aI., 1996, P Newton, et al., 1999, MB van 
Hensbroek, et aI., 1996). Two recently completed meta-analyses of the use of artemisinin 
derivatives in uncomplicated and severe malaria conducted under the auspices of the 
Cochrane group and the World Health Organisation have provided no evidence of 
neurotoxicity (H McIntosh & P Olli aro , 1998a),(H McIntosh & P Olliaro, 1998b) . The 
excellent safety profile of the qinghaosu compounds contrasts with the relatively frequent 
minor toxicity reported with the quinoline, antimalarials, quinine, chloroquine and 
mefloquine(P A Phillips-Howard & FO ter Kuile, 1995). However, concerns have been 
raised by in vitro and animal studies. In laboratory experiments using the oil-based 
parenteral artemisinin derivatives arteether and artemether, selective neurotoxicity was 
noted in the brain stem nuclei with a dose-related site-specific necrosis primarily in the 
pons and medulla of rats, dogs and monkeys (TG Brewer, et aI., 1994a, TG Brewer, et aI., 
1994b, RF Genovese, et aI., 1998, J Petras, et aI., 1997). Use of the water-soluble 
qinghaosu compound, artesunate, and oral administration of all the compounds produced 
considerably less neurotoxicity in animal experiments. 
Despite the lack of clinical reports of neurotoxicity, these data from animals is a cause for 
concern. In order to rule out neurotoxicity in man there is a need of investigations at the 
bedside and in more sophisticated facilities. 
4.1 Clinical and neurophysiological study of the effect of multiple doses of 
artemisinin on brain-staim function in Vietnamese patients 
4.1.1 Introduction 
In order to evaluate the possibility of brainstem neuropathology in patients who have 
received multiple treatment courses of the qinghaosu compounds, we assessed the 
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auditory pathway of the brainstem with studies of brain stem auditory evoked potentials 
(BSAEP) together with thorough audiometric and neurological examinations. 
The BSAEPs occur in the brainstem during the first 10 ms after a transient auditory 
stimulus. The potentials are recorded as a characteristic series of waveforms. These are 
detected by scalp electrodes and correspond to anatomic structures in the auditory 
pathway of the brainstem. Specifically, the auditory nerve and the cochlear nucleus are 
the generators of peaks I and II, the superior olivary complex generates peak III, the 
lateral lemniscus generates peak IV, and the inferior colliculus generates peak V (Figure 
4.1) (A Moller, 1994). Together, the series of waveforms encompass these nuclei and the 
relays between them. BSAEPs are used to demonstrate the integrity of the neuronal 
pathway from the cochlea, via the auditory nerve to the brain stem, and they allow 
localization of dysfunction within this pathway. The neuropathological damage reported 
in experimental animals treated with artemisinin is highly localized to the auditory, 
vestibular nuclei, and trapezoid body. If there was significant iatrogenic damage to these 
centres then measurement of BSAEPs in patients treated with repeated doses of 
artemisinin or its derivatives would be expected to be abnormal. 
The purpose of this study was to determine whether there was clinical or 
neurophysiological evidence of neurotoxicity in humans exposed to multiple doses of the 
qinghaosu compounds. 
4.1.2 Materials and methods 
4.1.2.1 Study Site 
The study was carried out at the Khanh Phu Medical Station between May and November 
1997. Khanh Phu is in the Central Highlands of Vietnam 450kms north of Ho Chi Minh 
City. Malaria transmission is very high and Khanh Phu village has the 
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highest incidence of malaria reported in Vietnam. The entomological inoculation rate 
(EIR) is approximately 100 per year; 70% of infections are P Jalciparum, 25% P. vivax, 
and 5% P.malariae. Sporozoite rates are 3-4%. The artemisinin drugs became available 
in the village from 1995 onwards, and they are supplied free from the health clinic. Every 
patient attending the clinic with fever has a blood smear examined, and is treated with 
antimalarial drugs at the clinic if the blood smear is positive and there are also clinical 
features of malaria. Asymptomatic parasite positive patients are not treated. If the patient 
lives far from the clinic they are given a course of treatment to take at home, if they live 
close they return daily for supervised administration of drugs. All attendances at the 
clinic are recorded along with basic clinical information, result of smear, and drugs 
dispensed. All the treatment episodes from 1995 until May 1997 had been recorded. 
There is little incentive in this extremely poor village to seek external medical help or to 
purchase drugs elsewhere. Thus the details of all malaria episodes from the introduction 
of artemisinin in 1995 are likely to include all antimalarial treatments. 
4.1.2.2 Drug Usage 
Both artesunate (Guilin No 1 factory, Guangxi, PRC) and artemisinin (Factory 19, Ho Chi 
Minh City) were used. The treatment regimen for artesunate in use by the Health Clinic 
since 1995 has been: less than 1 year of age 150mg total dose; 1-5 years 300mg; 5-13 
years 550mg; more than 13 year 600mg. For artemisinin the total doses used have been: 
less than 1 year of age 750mg total dose; 1-5 years 1500mg; 5-13 years 2750mg; more 
than 13 year 3000mg. Both were given as five day regimens. 500 mg/kg artemisinin as 
the total cumulative dose of drug received was selected (a priori) to look at the very 
heavily exposed in an analysis suited to a binary outcome. 
146 
:...,~~~~ter 4: SAFETY OF ARTEMISININ AND DERIVATIVES 
Mefloquine was given as antimalarial treatment between July and December 1995 at a 
time when artemisinin derivatives were not available. This was as 15mglkg 
monotherapy. Mefloquine was not used at any stage as a combination therapy with an 
artemisinin derivative. Using the dates of drug administration and present age of the 
subject, the age of each patient at the time of receiving drug was back calculated. Using 
these ages and a standardized height and weight growth chart (for Vietnamese children) 
for ages ranging from birth to 18 years the total weight adjusted dosage was calculated for 
all subjects who had previously received anti-malarial treatment. Demographic details of 
the subjects and controls are shown in Table 4.1.1 A 
For the subjects aged eighteen years or younger and whom received antimalarial therapy 
the mean difference in the estimated weight (from height and weight growth charts) and 
the weight recorded was 1.88 kg (95% normal range:- -5.69 up to 9.45 kg). The 
magnitude of the difference between the measured and estimated weight was significantly 
positively correlated with age (Spearman Rank correlation coefficient = 0.524, p-
value<0.001). Table 4.1.1B shows the mean difference in estimated weight (from height 
and weight growth charts) and the weight measured during the study. 
4.1.2.3 Study Design 
Fully informed consent was obtained from the subjects and their parents for the 
neuro-otological evaluation. Subjects were selected randomly from the village population 
of 1764 people, the controls were the total number of people in the village who had 
received no artemisisin derivative. All subjects were assessed clinically using a standard 
neurological examination. Particular emphasis was placed on identifying abnormalities in 
hearing, vestibular and cerebellar function, and the control of voluntary movement. The 
presence of nystagmus or tremor was noted, and abnormalities in auditory localisation, 
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finger-nose movement, Romberg test, gait, repetitive alternating movements, and fine 
motor control were assessed. Otoscopic examination of the external auditory canal was 
performed, with particular reference to the presence of scarring, perforation, or pus. 
Audiological examinations were performed on both ears on those over 4 years old 
(Kamplex Screening Audiometer AS7 Japan). The initial screen was done at 40dB with a 
frequency of 250Hz, subsequently increasing to 500Hz, 750Hz, 1000Hz, 1500Hz, 
2000Hz, 3000Hz, 6000Hz, and 8000Hz. All the data were recorded together with the 
patients' clinical history and exposure to all drugs. The neurological, otoscopic, and 
audiological assessments were performed blinded to the treatment histories of the 
subjects. 
The BSAEP measurements were performed throughout by a single investigator (EK) 
using a Bio-Logic Traveller® Express E Auditory Evoked Potential Machine according to 
manufacturer's instructions. Briefly, surface electrodes were applied to the vertex and to 
both mastoids, and the subject asked to lie down. Electrical impedance was checked and 
kept below 10kOhm for all recordings. The 100Jls click stimulus was delivered to each 
ear in tum via the headphones at a rate of 11.1 per second with an intensity of 80dB. The 
contralateral ear was masked with noise delivered to this ear at 40dB. The bipolar 
BSAEPs of 1024 clicks were amplified, averaged and recorded. At least two recordings 
were made on each ear to ensure reproducibility. The wave forms were identified 
subsequently and marked by a single investigator (LK), blind to inforn1ation regarding 
drug exposure. All the wave forms and markings were subsequently checked, again blind 
to all subject details, by a single experienced neurophysiologist (CM) and these values 
accepted. Interpeak wave latencies were calculated and the wave forms assessed for other 
abnormalities. Subsequently all BSAEP measurements were checked (again blind to all 
subject details) by the neurophysiologist (CM). The accuracy of the Bio-Logic 
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Traveller® Express E Auditory Evoked Potential Machine is 0.1 ms; variation below this 
level was considered not significant. The interpeak latencies between waves III and V 
were considered prospectively to be most likely to be affected if the same pattern of 
neurological toxicity observed in experimental animals was found in the subjects. The 
analysis concentrated on the I to V and III to V latencies. 
4.1.2.4 Statistical Analyses 
Data were analyzed using SPSS for Windows (SPSS Inc., Release 7.5.1). Categorical data 
were compared using the X2 test. Normally distributed continuous data were compared by 
the Student's t test. Data not conforming to a normal distribution were compared by the 
Mann Whitney U test. A p-value of <0.05 was considered statistically significant. In 
comparisons with published normative data a value of the mean plus 2.5SD was regarded 
as within the normal range. 
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Figure 4.1: The brain-stem auditory evoked potentials generated from a single patient 
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4.1.3 Results 
Neurological and otoscopic examinations, auditory localization, audiometry, and BSAEPs 
were assessed in 242 subjects who had received previous antimalarial treatment with 
artemisinin or artesunate alone (QHS), 98 who had received both artemisinin and 
mefloquine (QM), and 10 who had been treated with mefloquine alone (M), and 108 
controls from the same location who had never received these drugs before. The controls 
were older (median[range] age 13.5 [4 to 65] years) compared with the other groups: 
QHS 10 [1 to 57], QM 8 [4 to 48], and M 10 [7 to 17] years: p<O.OOl, and they had a 
larger body mass index (BMI) (median[range] 16.0 [11.75 to 34]) compared with the 
other groups: QHS 15.63 [6.85 to 25.95], QM 14.72 [11.34 to 21.37], and M 15.12 [13.42 
to 17.85]. The controls also had a lower body temperature (mean [sd] °C: 36.9[0.4tC) 
compared with the other groups; QHS 37.0 [0.5], QM 37.0 [O.4],and M 36.9 [0.2]. The 
groups were otherwise comparable (Table lA). 
4.3.1.1 Intensity of Drug Exposure 
The qinghaosu compounds dispensed by the Health Station were either artemisinin or 
artesunate depending on availability. The median (range) number of treated episodes in 
individual patients over the previous two years was 2 (1-21) separate courses of 
artemisinin. Artemisinin is approximately five times less potent in terms of antimalarial 
activity compared with artesunate. The weight adjusted (milligram per kilogram) dosing 
regime for each treatment course of artemisinin was therefore five times that for 
artesunate, and artesunate dosage was multiplied by five in order to express all treatment 
in terms of artemisinin. The median (range) of treatment dose was 168 mglkg [11,2705]. 
Overall 20% of subjects received total doses of artemisinin (or the adjusted equivalent of 
artesunate) exceeding 500 mglkg (see Table 4.1.2 and Figure 4.1.2). 
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Figure 4.2: Percentage of subjects receiving a total dose of QHS of either <200, 201-
500,501-1000, or> 1 000 mg/kg 
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Table 4.1.1 A: Demographic details BS AEP study 
Controls Qinghaosu Qinghaosu Mefloquine 
compound alone compound + alone 
(n=108) (n=242) mefloquine 
(n=98) (n=10) 
Median age 13.5 10.0 8.0 10 
(range) 4-65 1- 57 4-48 7 - 17 
n(%) 
2-5yrs 2 (1.9%) 67 (27.7%) 31 (31.6%) 0 
6-15yrs 70 (64.8%) 94 (38.8%) 58 (59.2%) 9 (90%) 
16+ 36 (33.3%) 81 (33.5%) 9 (9.2%) 1 (10%) 
Male sex n(%) 50 (46.3%) 108 (44.6%) 45 (45.9%) 5 (50%) 
Temperature N=105 N=222 N=79 N=9 
Mean(SD) 36.9(0.4) 37.0(0.5) 37.0(0.4) 36.9(0.2) 
Range 36.1- 38.0 36.0 - 46.0 36.1 - 37.8 36.5-37.1 
Body Mass Index 
Median 16.0 15.63 14.72 15.12 
Range 11.75 - 34.0 6.85 - 25.95 11.34 - 21.37 13.42 - 17.85 
Otoscope Exam 
Dry perforation 10.4% (11/106) 19.7% (45/229) 19.4% (18/93) 12.5% (1/8) 
Otitis Media 13.4% (141106) 11.4% (26/229) 8.6% (8/93) 12.5% (1/8) 
Otitis&/or perforation 23.6% (25/106) 31.0% (71/229) 28.0% (26/93) 25.0% (2/8) 
Audiometry N=102 N=153 N=60 N=9 
Right 4000 Hz 
::;;30 dB 89(87%) 123(80%) 47(78%) 7(78%) 
35-45 dB 11 28 12 2 
50-55 dB 1 0 1 0 
~ 60 1 2 0 0 
Left 4000 Hz 
::;;30 dB 81(79%) 124(81%) 53(88%) 8(89%) 
35-45 dB 18 20 5 1 
50-55 dB 3 6 2 0 
~60 dB 0 3 0 
0 
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4.1.3.2 Neurological Exam Results 
A detailed neurological examination was conducted in 375 (81.5%) of the study subjects. 
This total was limited by ability to follow commands. There was one subject with 
nystagmus in the control group. Otherwise no abnonnalities were found on neurological 
examination in any of the treatment groups or controls. 
Table 4.1.1 B: Mean difference for estimated weight (from height and growth charts) 
minus recorded weight (95% nonnal range) BS AEP study. 
Age group Mean difference, kgs (95% nonnal range) 
1 - 4 years 
5-9 
10 -14 
15 - 18 
4.1.3.3 Otoscopic Exam Results 
0.08 (-2.43, 2.59) 
1.61 (-2.33, 5.55) 
2.36 (-5.97, 10.69) 
4.28 (-8.73, 17.29) 
Overall, there was a high prevalence of middle ear infection. Of the 436 otoscopic exams 
124 (28%) were found to have pus and/or perforation. Consistent with the natural history 
of otitis media, the rates of otitis as detennined by pus in the external canal and at the 
tympanic membrane were much higher in younger children. 16% (15 of 92) in the 2 to 5 
year age group, 14% (31 of221) in the 6 to 15 year old age group, and 2.4% in those over 
16 years. As there were no controls in the youngest age group, comparisons cannot be 
made between rates of infection in control versus treatment groups in the very young. For 
children over 5 years of age, the rates of dry perforation were as follows, 10.6% (111104) 
in controls, 17.90/0 (30/168) in the QHS group, 14.1 % (9/64) of the QM group and 12.5% 
(1/8) of the M group (p-value = 0.43). The rates of otitis were 11.5% (121104) of controls, 
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9.5% (16/168) of the QHS group, 7.8% (5/64) of the QM group and 12.5% (l/8) of the M 
group (p-value = 0.87). 
Audiometry Results 
There were no differences between the groups (Table 4.1.1 A). 
4.1.3.4 Auditory Evoked Potentials 
Analysis of the inter-peak latencies (IPLs) was performed separately for each ear. (Table 
3). No differences in the IPLs of the left ear were observed between the qinghaosu 
compounds and the left ear of the controls. On univariate analysis the IPLs I-V and I-III 
of the right ear were significantly longer for those patients in the QM group compared to 
the controls. Patients in the QHS group had a significantly longer I-V IPL of the right ear 
compared to right ear of the controls. There were no differences for the left ear. 
As age is related to IPLs, and there were only two subjects less than 5 years of age in the 
control group (see Table lA), a sub-analysis was performed in which IPLs of the 
treatment groups were compared with those of the control group in those study subjects 
greater than five years old (see Table 4). This revealed very small but statistically 
significant prolongation for the right IPLs I-ill (2.03 vs 1.98 (p=0.027)) and I-V (3.82 vs 
3.74 (p=0.007)) in the QM group compared to the control group. In each case, the 
difference from controls was less than the accepted O.lms measurement accuracy range of 
the equipment. Again there were no differences for the left ear. 
In those individuals less than 4 years of age (for whom there were no controls in the 
popUlation studied) the IPLs were also compared with published normative age matched 
data (normal values for IPL I-V 1 year old <5.01, 2 year old <4.76,3 year old <4.75; for 
IPL III-VI year old <2.9, 2 year old <2.688, 3 year old <2.664). One patient had an IPL 
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longer than 2.5SD from the mean IPL for their age (2 year old IPL ill-V 2.78). This child 
also had pus in the external auditory canal obstructing the tympanic membrane. 
Throughout the analysis there were no differences between the right and left ear within 
the treated groups, the apparent prolongation of the right IPL I-III and I-V is due to the 
shorter IPL in the right ear of the controls (Table 3 ). 
Table 4.1.2: Frequency of qinghaosu total doses (weight adjusted) given to subjects 
All Qinghaosu 
compounds 
N=337* 
Weight adjusted total dose§ 
Median [range] 168 [11,2705] 
0-200 mg/kg 188 (55.8%) 
201 - 500 82 (24.3%) 
501 - 1000 44 (13.1 %) 
>1000 23 (6.8%) 
MQF: mefloquine 
§:The artesunate dose multiplied by 5 
*: 3 subjects without weight measured 
4.1.3.5 Effect of total drug exposure on IPL 
Qinghaosu Qinghaosu 
compound compound + MFQ 
alone n=97 
N=240 
130 [11,2705] 237 [19,2646] 
148 (61.7%) 40 (41.2%) 
47 (19.6%) 35 (36.1 %) 
29 (12.1%) 15 (15.5%) 
16(6.7%) 7 (7.2%) 
A comparison was made of the effects on cumulative quantity of drug received (less than 
or equal to 500 mglkg or >500 mglkg of artemisinin or artesunate dose times five). There 
was no significant difference in the IPLs between these two groups except for IPLs I-III 
(2.07 ms in the greater than 500 mglkg group versus 2.00 ms in the less than or equal to 
500 mglkg group [p=0.014]) and I-V (3.89 ms versus 3.79 ms [p=0.014]) of the right ear. 
However, because of the effect of age on IPL, a sub-analysis was undertaken (see Table 
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5A and 5B). We compared the IPLs between those who received less-than or equal to 500 
mglkg with those who received more 
Table 4.1.3: Descriptives of inter-peak latencies (msec) BS AEP study 
Inter-peak Controls All Qinghaosu Qinghaosu Qinghaosu 
latencies a compounds compound compound 
alone + mefloquine 
Right I-III 1.98 (0.15) 2.02 (0.17) 2.01 (0.17) 2.03 (0.17) 
1.66 - 2.44 1.52 - 2.60 1.56 - 2.52 1.52 - 2.60 
p* = 0.035 p* = 0.075 p*=0.029 
Right I-V 3.74 (0.18) 3.81 (0.22) 3.81 (0.23) 3.81 (0.19) 
3.20 - 4.12 3.20 - 4.74 3.20 - 4.74 3.43-4.40 
p* = 0.006 p* = 0.011 p* = 0.011 
Right III-V 1.78 (0.17) 1.79 (0.17) 1.80 (0.18) 1.78(0.14) 
1.28 - 2.28 1.40 - 2.78 1.40 - 2.78 1.44 - 2.32 
p* = 0.324 p* = 0.254 p*=0.758 
Left I-III 2.00 (0.16) 2.02 (0.17) 2.02 (0.18) 2.04 (0.16) 
1.64 - 2.64 1.52 - 2.76 1.52 - 2.76 1.54 - 2.48 
p* = 0.289 p* = 0.507 p*=0.108 
Left I-V 3.78 (0.20) 3.81 (0.21) 3.80 (0.21) 3.83 (0.22) 
3.40 - 4.24 3.16-4.72 3.16 - 4.72 3.32 - 4.56 
p* = 0.219 p* = 0.364 p*=0.122 
Left III-V 1.78 (0.16) 1.79(0.18) 1.80 (0.18) 1.78 (0.18) 
1.44 - 2.30 1.32 - 2.54 1.36 - 2.54 1.32 - 2.24 
p* = 0.690 p* = 0.552 p*=0.900 
a - mean (sd), range 
*- treatment group vs controls, unpaired t-test 
than 500 mg/kg in those older than five years of age. The same comparison was made 
separately for those younger than or equal to five years old. In each case, when 
correcting for age there was no significant differences in IPLs between the group 
receIvmg higher cumulative dosages and the group receiving the lower cumulative 
dosage. 
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Table 4.1.4: Descriptives of inter-peak latencies for subjects> 5 years of age 
Controls All Qinghaosu Qinghaosu Qinghaosu 
Inter-peak compounds compound compound 
latencies a N=106 N=241 alone + mefloquine 
N=174 N=67 
Right I-III 1.98 (0.15) 2.00 (0.16) 1.99 (0.16) 2.03 (0.15) 
1.66 - 2.44 1.56 - 2.48 1.56 - 2.48 1.72 - 2.40 
p* =0.180 p* = 0.511 p*=0.027 
Right I-V 3.74 (0.18) 3.80 (0.21) 3.79 (0.22) 3.82 (0.20) 
3.20 - 4.12 3.20 - 4.64 3.20 - 4.64 3.43-4.40 
p* = 0.018 p* =0.069 p* = 0.007 
Right III-V 1.78 (0.17) 1.80 (0.17) 1.81 (0.17) 1.80 (0.15) 
1.28 - 2.28 1.40 - 2.40 1.40 - 2.40 1.44 - 2.32 
p* = 0.178 p* = 0.178 p*=0.420 
Left I-III 2.00 (0.17) 2.02 (0.17) 2.01 (0.17) 2.03 (0.16) 
1.64 - 2.64 1.52 - 2.44 1.52 - 2.44 1.54 - 2.44 
p* = 0.409 p* = 0.551 p*=0.321 
Left I-V 3.78 (0.20) 3.81 (0.20) 3.80 (0.20) 3.84 (0.22) 
3.40 - 4.24 3.16 - 4.56 3.16-4.52 3.48 - 4.56 
p* = 0.225 p*=0.515 p*=0.063 
Left III-V 1. 78 (0.16) 1.79 (0.17) 1.79 (0.17) 1.80 (0.18) 
1.44 - 2.30 1.36 - 2.44 1.36 - 2.44 1.48 - 2.24 
p* = 0.624 p* = 0.699 p*=0.595 
a - mean (sd), range 
*- treatment group vs controls, unpaired t-test 
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Table 4.1.5 A: Mean (SD) inter-peak latency (msec) for subjects in the artemisinin group 
:::;5 years of age 
Right I-III 
I-V 
III-V 
Left I-III 
I-V 
ill-V 
:::; 500 mg/kg 
N=30 
2.03 (0.18) 
3.79(0.19) 
1.76 (0.15) 
1.99 (0.17) 
3.80 (0.20) 
1.81 (0.22) 
Drug dosage 
> 500 mg/kg 
N=36 
2.08 (0.18) 
3.89 (0.29) 
1.80 (0.24) 
2.07 (0.20) 
3.85 (0.27) 
1.79 (0.18) 
p-value 
0.258 
0.125 
0.436 
0.105 
0.456 
0.764 
Table 4.1.5 B: Mean (SD) inter-peak latency (msec) for subjects in the artemisinin group 
> 5 yrs of age 
Right I-III 
I-V 
III-V 
Left I-III 
I-V 
III-V 
Controls 
N=106 
1.98(0.15) 
3.74 (0.18) 
1.78 (0.17) 
2.00 (0.17) 
3.78 (0.20) 
1.78 (0.16) 
Drug Dosage 
:::; 500 mg/kg 
N=165 
1.99 (0.16) 
3.79 (0.22) 
1.80 (0.18) 
2.01 (0.17) 
3.80 (0.20) 
1.80 (0.17) 
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> 500 mg/kg 
N=8 
2.01 (0.21) 
3.88 (0.15) 
1.85 (0.17) 
2.07 (0.15) 
3.79 (0.22) 
1.73 (0.15) 
p-value 
0.782 
0.113 
0.308 
0.627 
0.789 
0.476 
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4.1.4 Discussion 
The artemisinin (Qinghaosu) group of compounds are now first line antimalarial drugs in 
South East Asia, and they are being used increasingly in Africa and South America. Their 
use has increased because of their ease of drug delivery, lack of adverse effects and rapid 
therapeutic responses even against multidrug resistant falciparum malaria (S 
Looareesuwan, et aI., 1998). The demonstration, in experimental animals, of a 
reproducible pattern of selective damage to the brain stem following large doses of 
artemisinin derivatives has been a major concern (S Meshnick, 1996). Neurotoxicity in 
rats, dogs, and rhesus monkeys, has resulted from the administration of large 
intramuscular doses of arteether (AE), or artemether (AM), two lipophilic derivatives of 
artemisinin. Following administration of 10-50mg/kglday AE for eight to twenty eight 
days, a dose dependent, region specific pattern of damage was noted in the pons and 
medulla of beagle dogs and Sprague-Daw ley rats (TG Brewer, et aI., 1994a, TG Brewer, 
et aI., 1994b, J Petras, et al., 1997). In rhesus monkeys no pathological effects could be 
demonstrated after 7 days treatment with arteether (8-24mg/kglday), but dose dependent 
neuropathological lesions were noted in the reticular, vestibular and auditory nuclei after 
14 days of treatment. Foci of neurotoxicity were also found in the brainstem nuclei of the 
reticular formation, the vestibular system, and the auditory system (including the superior 
olivary nuclear complex and most consistently, the trapezoid nuclear complex) (J Petras, 
et aI., 1997). A marked species variation was noted with a ranking of susceptibility of 
nervous system the species examined; dog>rat>rhesus monkey. In cell culture, toxicity 
has been demonstrated against neuronal cell types (J Fishwick, et aI., 1995, D L Wesche, 
et aI., 1994). It has also been noted that considerably higher doses of oral artemether or 
arteether, or the water soluble artemisinin derivatives given by any route, are required to 
produce neuropathological lesions. This suggests that the development of neurotoxicity 
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with parenteral AE and AM results from slow release of drug following intramuscular 
injection and thus sustained exposure of the central nervous system. 
Khanh Phu village, the site for this study is a remote community in a region of high 
transmission for malaria with an entomological innoculation rate of 100 per year and 
sporozoite rates of 3-4%. The population may have had a higher cumulative dose of 
artemisinin or artesunate than any other group of people in the world. The subjects had 
received up to 21 separate treatment courses. This provided an unusual opportunity to 
assess possible neurotoxicity. The treated group was younger than the control group, but 
there were no other significant differences in demographic details, or in the results of 
otoscopic examination and audiometry. The clinical examination concentrated on the 
assessment of hearing, vestibular function, cerebellar and control of voluntary movement, 
as these were considered a priori to be most likely to be affected by neurotoxicity. No 
significant differences were found between cases and controls. 
Brain stem auditory evoked potentials (BSAEP) are a sensitive non-invasive 
technique to assess the integrity of the auditory pathways from the cochlea to the mid-
brain. The interpeak latencies (IPLS) are the least variable and most independent of 
subject, stimulus and recording parameters compared with other measures derived from 
the BSAEP, and were therefore used throughout this study (J Jacobsen & J Hall, 1994, D 
Schwartz, et al., 1994) .The accuracy of the recording system in this study was O.lms; 
variation below this level cannot be assessed accurately. In this study a very small, but 
statistically significant differences in IPLS were found in recordings from the right side of 
subjects over four years old who had received artemisinin or artesunate compared to those 
versus those who had not. No differences were found on the left side. The differences 
were below the accepted sensitivity of the recording device. As there is no reason to 
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believe neurotoxicity should occur preferentially on one side of the brain, these findings 
are not considered of pathological significance. 
In this study there were no untreated controls under 5 years of age and therefore, for those 
subjects less than 5 years old, IPL values were compared with published normative data 
(D Schwartz, et al., 1994). Using a conservative definition of the upper limit of normal as 
2.5SD greater than the mean, only one subject in the treatment group had an IPL outside 
the accepted normal range for their age. This was a two year old child with pus in the 
external auditory canal (EAC) such that the ear drums could not be visualized, and in 
whom the rest of the clinical neurological assessment was normal. Whilst we cannot rule 
out absolutely a neuropathological process in this individual, severe inflammation in the 
unilateral EAC in a two year old would be an acceptable clinical cause of a prolonged IPL 
I-V. The contralateral ear was normal and had normal IPLs. All other subjects had IPL 
within the normal range for their age. 
If artemisinin and its derivatives are neurotoxic with cumulative exposure, there should be 
some relationship between total dose, and effect. There was no evidence for dose-
dependency in IPLS. This provides further support for lack of neurotoxicity. 
The artemisinin derivatives have been deployed mainly in China and South East Asia, 
where the main at-risk popUlations live in areas of low malaria transmission and 
infrequent infection. The situation in Khanh Phu is unusual in its transmission intensity, 
and thus exposure of the popUlation to the artemisinin derivatives. This study aimed at 
careful neurological evaluation of the population exposed to multiple treatments with the 
artemisinin derivatives. As a field study in a small rural community it could not meet the 
rigorous criteria of a drug-safety study. However, the lack of any convincing clinical or 
neurophysiological evidence of brain stem neurotoxicity, despite thorough examination in 
subjects receiving up to twenty-one treatment episodes in a two year period, is reassuring. 
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It is possible that the combination of detailed clinical assessment plus brain stem 
neurophysiology used in this study is not sensitive enough to detect covert 
neuropathology. The BSAEP measures neuronal activity from the acoustic nerve through 
the cochlear nucleus, the superior olivary complex, the lateral lemniscus, the inferior 
colliculus and finally via the medial geniculate body to the primary auditory cortex. This 
pathway is directly adjacent to the structures damaged by arteether in male rhesus 
monkeys; the reticular formation (pontine nuclei, medullary gigantocellular nuclei), the 
vestibular system, and the auditory system (superior olivary and trapezoid nuclear 
complex) (J Petras, et aI., 1997) . These nuclei and their projections are intimately 
connected to the neuronal pathway assessed by the BSAEP. If the combined clinical and 
neurophysiological assessments conducted in this study are not sensitive enough to detect 
a potential lesion, then these defects would have to be very subtle indeed. This study 
provides further reassurance, in addition to the recent Cochrane Group meta-analysis (H 
McIntosh & P Olli aro , 1998b), that there is no evidence of neurotoxicity from studies in 
man that would lead one to restrict the use of appropriate antimalarial treatment regimens 
with these drugs. The safety of these drugs in continuous use (e.g. prophylaxis) has not 
been established and cannot be inferred from these data. 
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4.2 Neuropathological assessement of artemether-treated severe malaria 
4.2.1 Introduction: 
Artemisinin and its derivatives are the most rapidly acting antimalarial drugs. 
They are reliably effective against multidrug-resistant falciparum malaria and are used 
increasingly throughout the tropical world. In a large randomised trial, intramuscular 
artemether (an oil-based artemisinin derivative) proved very well tolerated and effective 
in people with severe falciparum malaria compared with parenteral quinine (Artemether-
Quinine-Meta-analysis-Study-Group, 2001). In Southeast Asian adults, mortality was 
lower in artemether recipients (TT Hien, et aI., 1996). Despite excellent tolerability, a 
main concern has been that, in studies in animals, high doses of intramuscular 
artemether-and the closely related artemotil-produce an unusual selective pattern of 
damage to certain brainstem nuclei, especially those implicated in hearing and balance (J 
Petras, et aI., 1997). In a randomised double-blind comparison of intramuscular quinine 
and artemether (TT Hien, et aI., 1996), full autopsies were done on patients who died, if 
informed consent was obtained from attendant relatives. After the concerns over possible 
neurotoxic effects emerged from studies in animals, we decided to preserve the entire 
brains of these patients who died specifically with the aim to ascertain whether similar 
neurotoxic findings were present. 
4.2.2 Methods and material 
This study was done at the Hospital for Tropical Diseases, Ho Chi Minh City, 
Vietnam. Patients received either intramuscular quinine dihydrochloride (20 mg saltlkg 
followed by 10 mg/kg every 8 h) or artemether (4 mg/kg followed by 2 mglkg every 8 h). 
The doses used in this trial were more than double those generally recommended. 
Protocols for autopsy and specimen collection were approved by the Scientific and Ethics 
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committee of the Hospital for Tropical Diseases. We fixed brains in 10% buffered 
formalin saline until sectioning. We removed brainstems at the midbrain level and 
sectioned them, beginning at the pontomedullary junction. Serial transverse sections were 
taken at 5-mm intervals both rostrally and caudally. We then prepared standard forrnalin-
fixed wax-embedded sections for histopathological examination, with haematoxylin and 
eosin, solochrome-cyanin, and periodic acid-Schiff staining. We examined sections with a 
light microscope, while masked to clinical details. Pathological changes associated with 
toxic effects of the drug were sought specifically. We particularly examined the neurons 
in the nuclei in which neuropathological changes had been noted in animals (J Petras, et 
al., 1997). These included the trapezoid nucleus, red nucleus, superior and inferior olivary 
nuclei, cochlear and vestibular nuclei, and the cerebellar dentate nuclei. Neuronal 
changes, which were qualitatively assessed, included frank neuronal necrosis, apoptosis, 
Nissl substance swelling, nuclear chromatin changes, size and placement of the nucleolus 
within the nucleus, intracellular neuronal oedema, and presence of peri neuronal 
microglial cell satellitosis (neuronophagic nodules). Parenchymal changes assessed 
included a generalised increase in number or shape of activated microglia, foci of axonal 
swelling, and focal white-matter necrosis. In a subset of patients, we did 
immunohistochemical staining for glial fibrillary acidic protein and CD68 to examine 
astrocyte and microglial responses (IM Medana, et aI., 2001),4 and for p-amyloid 
precursor protein (P-APP) to assess axonal injury. For neuronal chromatolysis, results 
were subdivided by brainstem nuclei: 
i) oculomotor nucleus; 
ii) motor nucleus ofVth nerve; 
iii) vestibular nucleus; 
iv) reticular nucleus and raphe nuclei; and 
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v) other nuclei (lateral cuneate, trigeminal nuclei, and xth nerve). 
Axonal injury was expressed as the proportion of the section area showing P-APP 
staining. Pathological features were reviewed by four neuropathologists (JC, AD, RW, 
and WB) before unmasking drug treatments. Comparisons of variables between treatment 
groups were done with Student's t test, Kruskall-Wallis test, or Fisher's exact test as 
appropriate. 
4.2.3 Results 
Clinically, the percentages of the patients with cerebral malaria and other complications 
were comparable in two treatment groups. Time from admission to death in Artemether 
group was 76.6 h (median) and Quinine was 3.1 h (median) (p-value = 0.17) (table 4.2.1). 
No evidence was recorded of neurotoxic effects of artemether despite receipt of 
intramuscular doses up to 44 mg/kg (table 4.2.2). 
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Table 4.2 1: Baseline characteristics by drug treatment group 
Artemether Quinine p 
(n=6) (n=IS) 
Variable 
Age (years, mean [SD]) 37 (21) 34 (12) 
Male/female 4/2 1114 
Admission GCS 11 (8-lS) 10·S (7-14) 
(median [IQR]) 
Coma on admission 3 (SO%) 7 (SO%) 
Jaundice at any time S (83%) 12 (86%» 
Acute renal failure 4 (67%) 11 (79%) 
Hypoglycaemia 2 (330/0) 8 (S70/0) 
Haemodynamic shock S (83%) 13 (93%) 
Severe anaemia 3 (SO%) 9 (64%) 
Admission parasite 148000 120000 
count / /-lL (geometric (42 000-S17 000) (33 000-441 000) 
mean [9S% CI]) 
Time to death from 76·S (8·0-331) 31·1 (8·6-63) 0·17 
admission (h, median 
[IQR]) 
Data are number of patients (%l) or median (IQR), unless otherwise stated. 
GCS=Glasgow coma scale. 
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O·SI 
0·99 
0·99 
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Table 4.2.2.: Neuropathological findings 
Artemether Quinine p 
(n=6) (n=15) 
Frank neuronal necrosis 0 1 (7%) 0·99 
Glial response 6 (100%) 13 (88%) 0·99 
Demyelination 1 (17%) 6 (40%) 0·61 
Axonal injury 0·01 (0-0·3) 0·02 (0-4) 0·62 
Neuronal chromatolysis 
1 1 (17%) 3 (20%) 0·67 
2 2 (33%) 1 (7%) 0·18 
3 1 (17%) 6 (40%) 0·61 
4 2 (33%) 12 (80%) 0·12 
5 2 (33%) 2 (13%) 0·54 
Data are number of patients (%) or median (range). 
4.2.4 Discussion 
In animals, high doses of intramuscular artemether or artemotil are much more neurotoxic 
than are comparable doses administered orally, or when water-soluble artesunate is given 
by any route (A Nontprasert, et at., 2000). Neurotoxic effects result from sustained 
exposure of the eNS to artemether, and its principal metabolite dihydroartemisinin, which 
follows slow absorption of intramuscular injections. In primates, daily doses of artemotil 
of 8 mg/kg or greater for 14 days were neurotoxic, whereas 8 mg/kg for 7 days was not (J 
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Petras, et aI., 1997). Neuropathological abnonnalities in animals associated with 
artemether and artemotil neurotoxic effects were reported as frank neuronal necrosis, 
associated astroglial responses, pallor of myelin staining, axonal damage, and 
chromatolysis (J Petras, et aI., 1997) . In this series, chromatolysis was evident in all 
patients, axonal injury and astroglial activation were frequent, and focal pallor of myelin 
staining was noted in some cases, but these findings were similar in recipients of 
artemether and quinine. Widespread neuronal stress responses and axonal injury have 
been reported previously (lM Medana, et aI., 2001). No evidence was recorded for either 
irreversible neuronal injury or the selective distribution of neuropathological 
abnonnalities confined to certain brainstem nuclei, which was such a consistent feature in 
animals (J Petras, et aI., 1997). These findings suggest that the neuropathological 
abnormalities resulted from severe malaria itself, and not artemether treatment. This 
series is small, and the quality of neuropathological assessment that is possible-even 
from rapid autopsy-will always be inferior to that of perfusion-fixation in animals. 
However, complete absence of neuronal death in artemether recipients and the similarity 
of the other neuropathological findings between the two different treatments, together 
with normal neurological and audiometric findings in survivors (TT Hien, et aI., 1996), 
all suggest that no relevant neurotoxic effects are associated with intramuscular 
artemether in severe falciparum malaria. These data provide reassurance that therapeutic 
doses of these important antimalarial drugs do not damage the nervous system. 
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CHAPTERS 
TREATMENT OF 
UNCOMPLICATED FALCIPARUM 
MALARIA IN VIETNAM 
5.1 Mefloquine vs single day artesunate+mefloquine vs 3 day artesunate + 
mefloquine 
5.1.1 Introduction 
In Vietnam although the malaria situation has improved compared to the 1980's and the 
early 1900's, hundreds of thousands of people still suffer from this debilitating infection 
each year and the resistance to the available antimalarial drugs is particular problematic. 
Since 1991 because of the increased resistance of conventional drugs as chloloquine, 
sulfadoxine-pyrimethamine and quinine, mefloquine (l5mglkg) was introduced as a first 
line antimalarial drug in areas of multi-drug resistant Pfalciparum. Until 1994 the cure 
rate of mefloquine (MSP) was still 100% (TT Hien, et al., 1994). However in other 
countries in South East Asia, especially in Thailand, at the same time, the resistance to 
mefloquine was evident on the western and eastern borders and this has increased steadily 
170 
'-"'~l""-' 5: TREATMENT OF UNCOMPLICATED Pf MALARIA 
despite the dose of mefloquine was raised from 15 to 25 mglkg (NJ White, 1994b). In 
addition, results from 2 other studies conducted in 1997 and 2001 in Vietnam have also 
shown that the cure rates of single dose of mefloquine (500 mg) or combination 
mefloquine - artesunate were critically low (NN Le, et aI., 1997, TN Trung, et aI., 2001) . 
In order to be able to assess the response of multi-drug resistant Pfalciparum to 
mefloquine and mefloquine in combination with artesunate in this region we conducted 
this study at the Hospital for Tropical Diseases by comparing 3 regimens recommended 
by the national malaria control project in Viet Nam in 1997: mefloquine monotherapy (15 
mglkg), combined therapy including one day of artesunate (AM) and 3 days of artesunate 
+ mefloquine (15 mg/kg) (A3M) 
5.1.2 Materials and methods 
5.1.2.1 Objective 
This study, conducted at the Hospital for Tropical Diseases of Ho Chi Minh City 
in Vietnam, was designed to detect a difference in cure rate of 20 % with 95% confidence 
and 80% power. The cure rate of artemisinin (comparable to artesunate) single day + 
mefloquine (15mglkg) was 95% in the study carried out in 1994 (TT Hien, et aI., 1994) at 
the same hospital. 
5.1.2.2 Patients 
Consecutive patients with non-complicated malaria admitted to the malaria ward D were 
recruited in the study if they were aged at least 12 years old and < 60 years old, having 
the typical symptoms and signs of acute uncomplicated malaria (>3705C) and/or at least 
one constitutional malaria symptom; having asexual forms of P. Fa1ciparum in the 
peripheral blood smear on the admission. Patient were excluded if they received 
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antimalarials during the last 48 hours; having mixed infections (with P. vivax) 
concomitant chronic infections. Fully informed consent was obtained from patients before 
entry into the study. The study was approved by the Scientific and Ethical Committee of 
the hospital. 
Patients were assigned to receive one of 3 regimens: M: a single dose of oral mefloquine 
750 (Lariam® Hoffmann - La Roche, Basel Switzerland), or AM, a single dose of 200 
mg oral artesunate (Artesunate tablet, Guilin No 1 Factory, Guangxi, China) and 
mefloquine 750 mg, or A3M, artesunate (200 mg for the 1st day then 100mg the 2nd and 
3rd day) and mefloquine 750 mg in the 3rd day of treatment). The drug for each patient 
was contained in opaque, sealed and coded envelopes which were randomised in block of 
6. Once a patient was enrolled in the study the envelope was opened. The treating 
physicians and the technicians who performed the patient's parasitaemias were blinded to 
the treatment. 
5.1.2.3 Clinical procedure 
After randomisation, a detailed history was taken from the patient and full clinical 
examination conducted. Venous blood was taken for a pretreatment investigation included 
blood smear, full blood count, blood glucose, serum creatinin, blood urea nitrogen and 
mefloquine level. Patients were reassessed every 6 hours for vital signs as axillary 
temperature, pulse, blood pressure during febrile period then daily until discharge. The 
peripheral blood smear should be taken and the number of asexual forms per 400 WBC 
on thick films or per 1000 RBC on thin films are to be counted, and the results recorded 
in terms of number of parasites per micro litre of blood. Parasitological checks are to be 
performed at baseline (hour 0) and every 12 hours after treatment, if possible also on days 
14, 21, 28, 35, 42, 49 and 56. Efficacy will be expressed in time to clearance (time until 
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first negative slide) and as parasitological cure rate. Patients whose parasitemia cleared 
within 7 days but who became smear positive again during the follow up period (days 7-
56) with the same genotype of either P. jalciparum, or a mixed infection including the 
same genotype of P. jalciparum, were defined as treatment failures. Treatment failures 
were retreated with artesunate 4 mglkg/day once daily for 3 days, plus mefloquine 25 
mg/kg given in divided doses on day 3. 
5.1.2.4 peR for reinfections: 
The study primary end point was the incidence of reappearance of parasites within 56 
days in the three treatment groups. Blood samples on filter paper were taken on 
admission to the study and on the day of reappearance of parasites. Recrudescence was 
distinguished from re-infection by parasite genotyping of three polymorphic loci (MSP 1, 
MSP2 and GLURP) using the polymerase chain reaction (PCR). Genotyping was 
performed blind to the clinical details of the patients. 
5.1.2.5 Statistical analysis: 
Analysis of variance was used for normally distributed data, and the Mann-Whitney U 
test was used to compare data that were not normally distributed. The Chi-square test with 
Yate's correction or the Fisher's exact test was used to compare proportions. Fever and 
parasite clearance time was assessed by survival analysis and by the log rank test. 
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5.1.3 Results 
Between November 1999 and June 2000, 216 patients were enrolled (70 received M, 72 
received AM, and 73 received A3M) all of them are non- immune to malaria. No patient 
was taking malaria prophylaxis. There were 48 patient excluded (13 received M, 16 
received AM, and 19 received A3M) because of mixed infection with P. vivax, or 
incomplete treatment course, or unable to be followed. Finally, 167 patients were 
analysed (57 received M, 56 received AM, and 54 received A3M). Baseline 
characteristics are similar in 3 groups (Table 5.1.1). 
The initial responses to the three treatment groups were different. Mean fever clearance 
times were similar in all three groups 25.2 (3.1) hours in the group M, 21.5 (2.5) hours in 
AM and 22.6 (2.1) hours in A3M. But the parasite clearance times were significantly 
different, 64.6 (4.4) hours in M, 48.2 (3.8) hours in AM and 44.5 (3.4) hours in A3M. 
There are 4 patients in the M group whose peripheral parasiteamia were not cleared at the 
seventh day of the treatment course (R2). There were 23 patients in the M group, 16 in the 
AM group and 6 in the A3M group had fever and parasitaemia confirmed by microscopy 
during the 28-day follow up period. In addition, 3 in M group, 9 in AM group and 4 in 
the A3M group had also fever and positive blood smear during the time elapsed between 
the 28th and 56th day of the follow up. Of those 5 patients in the group M, 2 patients in 
the AM group and 2 in the A3M group had a recrudescence of the original infecting 
parasite, confinned by PCR-genotyping representing a treatment failure. Therefore the 
failure rates at 56th day adjusted for re-infections are 36.8%, 44% and 14.8% for the M, 
AM and A3M group respectively. The recrudescence of the original genotype occurred 
on days 35, 35, and 28. The new infections were seen on days 28, 29, 34. 
The most common side effect was nausea. All side effects in both groups were self 
limiting and in no patient was it necessary to repeat the dose of the tablets. 6 (16%) 
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patients III the A3M group had significant adverse events possibly related to their 
treatment regimen. Four patients (10%) had vomiting, 3 patients (8%) had dizziness 
and 1 patient had a transient neurological syndrome of ataxia, dizziness, and slurred 
speech lasting 24 hours. All of these reactions were short lived and settled spontaneously. 
There were no significant differences in the liver function tests between the two groups 
carried out on all patients on day 3, 7, and 28. 
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Table 5.1.1: Patients characteristics on admission by drug treatment groups (M- AM- A3M) 
Characteristic Treatment P value 
M (n=57) AM (n=56) A3M (n=54) 
Age (yr) mean (95% C.I) 31.07(27.8-34.3) 32.30(28.9-35.7) 32.10(28.4-35.8) 0.866t 
Gender MalelF emale 47110 47/9 43111 0.798t 
Weight (kg) mean(95% C.I) 50.3(47.9-52.7) 51.0(48.7-53.4) 51.3(48.0-54.5) 0.788t 
Temperature eC) mean(95% C.l) 38.7(38.5-39.0) 38.7(38.4-38.9) 38.7(38.4-39.0) 0.915t 
Haematocrit (%) mean(95% C.l) 36.2(34.0-38.4) 35.2(33-37.4) 37.0(34.9-39.1) 0.531 t 
White blood cell 106 IL mean(95% C.I) 6034(5534-6535) 5638(5177-6100) 5703(5262-6146) 0.679t 
Blood glucose (mmoI/L) mean(95% C.I) 5.9(5.4-6.3) 6.0(5.6-6.4) 5.8(5.2-6.4) 0.415t 
Serum creatinine (~moIlL) mean(95% C.l) 94.5(89.2-99.8) 93.7(88.4-98.1 ) 90.1 (86.6-94.5) O.689t 
BUN (mmoIlL) mean(95% C.I) 4.9(4.5-5.3) 5.3(4.7-5.8) 4.4(4.0-4.8) 0.094t 
Parasite count on admission 1 ~L Geometric mean 14,693 16,766 13,755 0.753t 
t Kruskal Wallis Test t Chi-Square test T Fisher exact test 
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Table 5.1.2: Patient outcomes by drug treatment groups (M- AM- A3M) 
Patients M* AM* A3M* 
Patients recruited 70 72 73 
Excluded £ 13 16 19 
Fever clearance times (h) t 25.2 21.6 22.6 
(18.9-31.6) (16.5-26.6) ( 18.4-26.8) 
Parasite clearance time (h) :t: 64.7 48.2 44.5 
(55.8-73.5) (40.6-55.9) (37.7-51.4) 
Failure of parasite clearance 4/57 0/56 0/54 
within 7 days ( R 2) (7.00/0) (0%) (0%) 
23/57 16/56 6/54 
Failure rates at 28 day-follow-up 
(40.3%) (28.5%) (11.1%) 
3/57 9/56 4/54 
Failure rates at 56 day-follow-up 
(5.2%) (16.0%) (7.4%) 
Total failure cases 26/57 25/56 10/54 
Re-infection (by PCR) 5 2 2 
21/57 23/56 8/54 
Real failure rates § 
(36.8%) (41.0%) (14.8%) 
* AM = artesunate 1 day (4mg/kg) + mefloquine (15 mg/kg) single dose; 
A3M = artesunate 3 days (4mg/kg then 2 mg/kg) + mefloquine (15 mg/kg) single 
dose; 
M = mefloquine 15 mg/kg single dose. 
£ Mis-diagnosis (P. vivax) or discontinue the treatment, or unable to follow- up 
t Kruskal Wallis test p=0.834 
:t: Kruskal Wallis test p=O.OOI 
§ Chi-Square test p=0.003 
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5.1.4 Discussion: 
Mefloquine and combination artemisininlartesunate + mefloquine have been used in 
southern provinces of Viet Nam since 1991. Those drugs were introduced into the country 
in early 1990s with high cure rate> 95% (KA Trinh, et aI., 1990). But since 1991, reports 
from Thailand have shown that P fa lcipa rum has developed resistance to mefloquine 
rapidly, despite the addition of sulphadoxine and pyrimethamine but there is no 
information on the resistance of the parasite to mefloquine in Vietnam, particularly in 
vivo studies. This is a first randomized comparative trial conducted in Vietnam assessing 
the effectiveness of mefloquine and the combination mefloquine + artesunate since 1995. 
Although there were 2 studies conducted between 1997 and 2000 but the dose of 
mefloquine and artemisinin used was rather low (500 mg) than the ones recommended by 
the national malaria control programme. 
This study revealed that there is a dramatic decrease in mefloquine efficacy in southern 
provinces of Viet Nam since it was first introduced as one of dnlgs of choice in treatment 
of uncomplicated malaria in 1991. The cure rate has declined from 100% in 1990 (KA 
Trinh, et aI., 1990) to 45.5% in 2000 with 4 R2 response cases. While the main source of 
pressure for development of resistance in Thailand was thought coming from the use of 
mefloquine (F Nosten, et al., 1991 a), the frequency of exposure of P falciparum to this 
drug was rather low in Vietnam (approximately 300,000 doses of mefloquine was 
distributed each year since 1992 but it was used in combination with artemisinin or 
artesunate) (Annual report of NIMPE). Worryingly, the efficacy of the combination of 
mefloquine (15 mglkg) + one day artesunate (AM) which was proved very effective in 
1995 (TT Hien, et aI., 1994) has also declined to a similar level. This result indicated that 
the dosage of components of the artemisinin based combination therapy (ACT) should be 
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revised and optimised. So far, the combination of mefloquine (25 mglkg) + artesunate (-+ 
mglkg x 3 days) is still the gold standard regimen (with nearly 100% cure rate) for 
patients whose initial treatment failed with lower dose of mefloquine (Hien TT, 
unpublished data). The level of immunity of patients involved in this study is probably 
different from previous ones: all patients recruited were non-immune people it may 
contribute to the higher failure rates of the 3 regimens of treatment. 
In order to measure the mefloquine levels at different timing during the treatment and the 
follow-up, a 5 ml of blood specimen were taken on admission, at 4th and 8th week from 
admission. Unfortunately, because of different reasons, results of those specimens were 
not available at the time of data analysis. It should be emphasized that mefloquine used in 
this study is Lariam (Roche) which is considered to have the best bioavailability amongst 
the different formulations. 
In contrast with artemisinin group, mefloquine did not reduce rapidly parasitaemia (table 
5.1.2) and that may put patients with falciparum malaria at risks of lethal complications. 
We have ruled out false RII due to delayed parasite clearance with mefloquine described 
elsewhere (F Nosten, et al., 1987) by monitoring those patients for further 3-5 days before 
re-treatments 
This study has also confirmed that the duration of follow up is an important factor being 
considered when assessing antimalarial drug efficacy (NJ White, 2003). Our result has 
indicated that the cure rate would decrease by 0.2 -2 fold (table 5.2) if we double the 
duration of follow up from 28 days to 56 days. Thanks to the peR we can easily rule - out 
re-infection even as patients going back home in malaria areas. 
This study confirms P Jalciparum in Southern provinces III Vietnam has developed 
resistance to mefloquine rapidly. The results support the suggestion that mefloquine 
should no longer be used alone but only in combination with appropliate doses of 
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artemisinin or derivatives. There is also an urgent need to investigate newer combination 
with artemisinin. 
5.2 Assessment of the efficacy of the combination Dihydroartemisinin-piperaquine 
5.2.1 Introduction 
Resistance to antimalarial drugs is increasing nearly everywhere in the tropical world, 
confounding global attempts to "Roll Back Malaria"(F Nosten & P Brasseur, 2002) 
Southeast Asia has the most resistant malaria parasites in the world, which has limited 
treatment options in this region. To combat the further spread of resistance, it is generally 
accepted that combinations of antimalarial drugs that include an artemisinin derivative 
should be used, and, if possible, that preparations should be formulated in a single 
tablet(NJ White, et aI., 1999a, WHO, 2001). There is only one combination available that 
meets these criteria: artemether-Iumefantrine (MV Vugt, et aI., 1999). 
In 1978, piperaquine-a bisquinoline antimalarial- replaced chloroquine as the 
antimalarial recommended by the national control programme of the People's Republic of 
China. Over the next 14 years, 214000 kg of piperaquine phosphate-ie, about 140 
million adult doses-were used for mass prophylaxis and treatment. In 1990, a group of 
Chinese scientists began development of fixed-dose artemisinin-based combinations with 
piperaquine. The prototype, CV 4, included four drugs: dihydroartemisinin, trimethoprim, 
piperaquine, and primaquine. These combinations were tested in small non-randomised 
clinical trials in China, Vietnam, and Cambodia. Modification of the doses of the 
individual components led to a new version (CV8), which was subsequently tested, 
marketed, and manufactured. CV8 was introduced to the Vietnamese National Malaria 
Control Programme in 1998. Concerns about the risklbenefit ratio of primaquine in the 
combination led to its removal and to the use of the triple combination. This preparation 
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contained dihydroartemisinin (32 mg/tablet), trimethoprim (90 mg/tablet), and 
piperaquine (320 mg/tablet). Uncertainties about the contribution of the trimethoprim 
component and dose then led to an increase in the dose of dihydroartemisinin to 40 
mg/tablet, and removal of the trimethoprim. This new two-drug fixed combination 
antimalarial is quite inexpensive; in 2003 it cost about US$1 for an adult treatment. 
Other effective treatments against multidrug-resistant Plasmodium fa1ciparum malaria are 
much more expensive (2:$2·40 per treatment) than widely used, but increasingly 
ineffective, drugs such as chloroquine and sulphadoxine-pyrimethamine (:::;$0'20). Cost is 
a major factor deterring countries and international donors from providing artemisinin-
based combinations to combat the worsening global malaria situation. (F Nosten & P 
Brasseur, 2002, NJ White, et aI., 1999a) (WHO, 2001). There is an urgent need for 
alternative combination antimalarial drugs in fixed doses that are effective, safe, and 
affordable. 
To assess the safety and efficacy of dihydroartemisinin-piperaquine combinations, we did 
two randomised trials in Vietnam. The first, a pilot study of dihydroartemisinin-
trimethoprim-piperaquine (DHA-TP) versus the standard recommended regimen of 3 
days' artesunate and a split dose of mefloquine (A3M) was based in a tertiary referral 
hospital in Ho Chi Minh City. The second study was a large open community-based 
randomised trial of DHA-TP, dihydroartemisinin-piperaquine (DP), and A3M in a 
provincial health station in Binh Phuoc Province. 
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5.2.2. Methods 
5.2.2.1 Patients and randomisation 
Pilot study 
We recruited patients who were admitted to the Hospital for Tropical Diseases, Ho Chi 
Minh City, Vietnam, and had microscopically confirmed uncomplicated fa1ciparum 
malaria. Patients were randomly allocated either DHA-TP (Tonghe Phannaceutical, 
Yuzhong Chongqing, People's Republic of China) two tablets at 0 h, 6 h, 24 h, and 48 h 
(one tablet if the patient was younger than 15 years), or A3M (artesunate, Guilin 
Pharmaceutical Factory No 1, Guilin, China; mefloquine, Hoffman-La Roche, Basel, 
Switzerland) in a ratio of 2 (DHA-TP) to I(A3M). DHA-TP contains 32 mg 
dihydroartemisinin, 90 mg of trimethoprim, and 320 mg of piperaquine per tablet. 
Patients allocated A3M received artesunate 4 mg/kg/day once daily for 3 days, plus 
mefloquine 25 mg base/kg given as two split doses, 6 h apart on day 3. Randomisation 
was in blocks of six. 
Drugs were kept in identically numbered opaque envelopes, and drug administration was 
directly observed in all cases. We excluded women who were pregnant or breastfeeding, 
and children younger than 2 years. 
The pilot study was approved by the Ethical and Scientific Committee of the Hospital for 
Tropical Diseases. We obtained written informed consent from patients or their guardians. 
Community based study 
Patients in the community based study were seen at the Dac 0 Health Station, Phuoc 
Long District, Binh Phuoc Province. The Dac 0 commune is in the southwestern region 
of Vietnam on the border with Cambodia, about 200 km from Ho Chi Minh City. There 
are roughly 9000 people living in the community served by the health station. 
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Transmission of malaria in this region is low and seasonal. Nearly all fa1ciparum malaria 
infections there are symptomatic. 
Adults and children older than 2 years presenting to the Dac 0 Health Station with 
microscopically confirmed uncomplicated fa1ciparum malaria were eligible for the study. 
We excluded patients who had any evidence of organ dysfunction (impaired 
consciousness, severe anaemia [packed cell volume <0·20], oliguria, shock, convulsions, 
hypoglycaemia, respiratory distress, or tachypnoea [>50 per min]). Patients were also 
excluded if they were known to be pregnant, unable to tolerate oral medication, or were 
unable to return for follow-up. To control for the contribution of immunity to the 
treatment response, we did not include patients who had been resident in Dac 0 for more 
than 2 years. 
Patients were randomly allocated one of three treatments: DHA-TP (two tablets at 0 h, 6 
h, 24 h, and 48 h [one tablet if the patient was younger than 15 years]), or 
dihydroartemisinin-piperaquine (Holleykin Pharmaceutical, Guangzhou, People's 
Republic of China) (two tablets at 0 h, 6 h, 24 h, and 48 h [one tablet for children younger 
than 15 years]), or artesunate plus mefloquine in a ratio of2 (DHA-TP):2 (DP):I(A3M). 
Patients allocated A3M received artesunate 4 mglkg/day once daily for 3 days, plus 
mefloquine 25 mglkg given as two split doses, 6 h apart on day 3. Drugs were kept in 
identically numbered opaque envelopes and drug administration with water was observed 
in all cases throughout the treatment regimen. Patients were monitored for 6 h after taking 
the drugs. A case report form was used to record the exact time that every dose was given. 
The contents of the randomisation envelopes were concealed from investigators and 
patients. 
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The Scientific and Ethical Committee of the Hospital for Tropical Diseases, and the 
Health Services of Binh Phuoc Province approved the study. Patients, or their guardians, 
gave written infonned consent. 
5.2.2.2 Procedures 
Pilot study and community based study 
At enrolment (day 0), patients had a full medical examination and we recorded all 
infonnation on a standard case fonn. Blood was taken for quantitative parasite counts and 
routine haematological and biochemical analyses. In the pilot study, blood smears were 
taken every 12 h until patients were free of parasites, and they were then followed up 
every week until day 56. At each visit, a blood smear was taken and a questionnaire about 
symptoms and adverse effects was completed. Parasite counts were done from Giemsa-
stained thick and thin blood films. If the count on the thick film exceeded 500 parasites 
per 500 white blood cells, we recorded the thin film result (expressed as the number of 
infected erythrocytes per 1000 red blood cells). In the community based study, blood 
smears were taken on admission (day 0), at the completion of treatment (day 2), and at 
day 7. All patients were followed up until day 56. 
The primary endpoint for both studies was the reappearance of parasites within 56 days 
(ie, parasitological failure). Secondary endpoints were the parasite clearance time, fever 
clearance times, and the occurrence of side-effects. As reinfection during the follow-up 
period was possible, we took blood samples on filter paper at admission to the study and 
on the day that parasites reappeared. Recrudescences were distinguished from reinfections 
by PCR genotyping of three Plasmodium falciparum polymorphic loci (MSP I, MSP2, 
and GLURP) by standard methods (A Brockman, et aI., 2000) For patients whose 
parasitaemia cleared within 7 days but who had a recurrent infection at 56 days with the 
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same genotype of either P falciparum, or a mixed infection including the same genotype 
of P falciparum, treatment was deemed to have failed. People whose treatment had failed 
were retreated with artesunate 4 mg/kg/day once daily for 3 days, plus mefloquine 25 
mg/kg given in divided doses on day 3. 
5.2.2.3 Statistical analyses 
In the pilot study, we calculated that a sample size of 114 patients allowed a difference 
between 750/0 efficacy (DTP) and 95% efficacy (A3M) to be detected with 80% power 
and 95% confidence, assuming a 10% dropout rate. 
In the second community based study, randomisation was done in accordance with the 
ratio 2 DHA-TP:2 DP:l A3M. A sample size of 160 patients in the DHA-TP and DP 
groups allowed for a cure rate of 95% in either arm to be estimated with 5% precision, 
and also to show efficacy equivalence with a maximum allowable difference in cure rates 
between groups of 100/0 in either direction with 80% power and 95% confidence, taking 
into account a drop-out rate of up to 30%. We used the Wilson procedure with a 
continuity correction to calculate 95% CI for efficacy differences (RG Newcombe, 1998). 
ANOV A was used for normally distributed data, and the Mann-Whitney U test was used 
to compare data that were not normally distributed. We used X2 test with Yates' 
correction or Fisher's exact test to compare proportions. Fever and parasite clearance time 
were assessed by survival analysis and by the log rank test. Analysis was by intention to 
treat. 
5.2.3 Results 
5.2.3.1 Pilot study 
Between February and July, 2001, 114 patients were enrolled. Of these, 107 (94%) lived 
outside malaria endemic areas and contracted their malaria when travelling into an 
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endemic region. No patient was taking malaria prophylaxis. The average dose (based on 
the number of tablets taken and bodyweight) of dihydroartemisinin was 2-4 mglkg on the 
first day and 1·2 mg/kg on subsequent days, the average dose of piperaquine was 24 
mg/kg on the first day and 12 mg/kg on subsequent days, and the average dose of 
trimethoprim used was 6·8 mglkg on the first day followed by 3-4 mglkg on subsequent 
days. 
At admission, all patients were febrile (temperature >37·5°C), and the median (95% CI) 
fever clearance times were similar in both groups: 24 h (12-50) in A3M, and 24 h (2--49) 
in DHA-TP. Parasite clearance times (95% CI) were not significantly different at 72 h 
(23-97) in A3M and 48 h (22-98) in DHA-TP. 
No patient developed severe malaria, none was lost to follow-up, and no patients were 
excluded. Five patients in the DHA-TP group had a reappearance of parasites within the 
56-day follow-up period: two were recrudescences; and in three patients, a new genotype 
was confirmed by PCR, thus indicating reinfection. After adjustment for reinfections, the 
56-day cure rate was 97-4% (74/76) after treatment with DHA-TP. The two 
recrudescences arose on days 29 and 30. New infections were noted on days 28, 34, and 
35. There was no reappearance of parasites in the A3M group-ie, cure rate was 100% 
(38/38). 
DHA-TP was well tolerated and no adverse drug reactions were noted or reported, 
whereas six (16%) patients in the A3M group had important adverse events that we 
judged to be related to treatment (p=0·01). Four patients (10%) had vomiting, three (8%) 
complained of dizziness, and one had a transient neurological syndrome of ataxia, 
dizziness, and slurred speech lasting 24 h. All of these reactions were short lived and 
settled spontaneously. There were no differences between the results of liver function 
tests done on days 3, 7, and 28. 
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Table 5.2.1: Admission characteristics of patients in A3M-DTP pilot study. 
Number of patients (Female) 
Mean age (years) ; range 
Mean admission temperature (Oct 
Mean haematocrit (% t 
Mean white blood cell count (1 09/L) a 
Blood urea nitrogen (mmoVL) a 
Serum creatinine (/-lmoI/L) a 
Blood glucose (mmoI/L) a 
AST (aspartate aminotransferase) (U/L) 
AL T (alanine aminotransferase) (U/L) 
Admission geometric mean parasitaemia 
Fever clearance time (hours) a 
Parasite clearance time (hours) a 
Result of treatment assessed at D56 
(cure) b 
A3M 
38 (6) 
3l.7(8-56) 
39.0 (38.6 - 39.3) 
38.0 (36.0 - 40.0) 
5.161 (4080-5656) 
4.7 (4.2-5.2) 
99.1 (83.9-97.2) 
5.8 (5.3-6.4) 
23.1 (15.8-30.4) 
6.4 (4.6-8.1) 
24,747 
24 (12 - 50) 
72 (23 - 97) 
38/38(100%) 
Data are median (95% CI) unless otherwise stated 
DTP 
76 (11) 
32.9(5 - 67) 
39.0 (38.7-39.3) 
36.3 (34.3-38.3) 
4.481 (4082-4815) 
5.4 (4.9-5.9) 
95.4 (90.1-99.0) 
5.6 (5.1-6.0) 
28.2 (16.0-40.3) 
6.2 (4.9- 7.4) 
19,127 
24 (2 - 48) 
48 (22 -98) 
74 I 76 (97.4%) 
AM = artesunate (4mglkglday) at 0, 24, 48 hours + mefloquine (25 mglkg split in two 
doses) at 48 and 56 hours, DTP=dihydroartemisinin 32 mg + piperaquine phosphate 320 
mg + trimethoprim 90 mg; for adult : 4 tablets at 0, 8, 24, 48 hours; for children: age 
adjusted; a: Median (95% Confidence Interval), b: Fishers 2 - tailed test, all 
characteristics of 2 treatment groups are comparable unless otherwise stated 
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5.2.3.2 Community based study 
Between November, 2001, and March, 2002, 1204 patients attended the health station in 
Dac 0 with fever and a positive blood smear for P Jalciparum. Of these, 30 were 
excluded because they were pregnant, and 774 were not enrolled because they were not 
able to return for follow-up, or they had been resident in Dac 0 for more than 2 years. 
Thus, we enrolled 400 patients in this community-based study, including 51 who were 
younger than 15 years. Of these children, 19 received DHA-TP, 21 DP, and 11 A3M. No 
patient was taking antimalarials for the present illness. Patients' baseline characteristics 
and outcomes were similar in all treatment groups (Table 5.2.2). In the DHA-TP group 
the average dose of dihydroartemisinin was 2·66 mg/kg on the first day and 1·33 mg/kg 
on subsequent days; the average dose of piperaquine was 26 mg/kg on the first day and 13 
mg/kg on subsequent days; the average dose of trimethoprim was 7· 5 mg/kg on the first 
day followed by 3·8 mglkg on subsequent days. In the DP group, average dose of 
dihydroartemisinin was 3-4 mglkg on the first day and 1·7 mglkg on subsequent days and 
the average dose of piperaquine was 27 mg/kg on the first day and 13·5 mglkg on 
subsequent days. 
The initial responses to the three treatment groups were similar. On admission, all 
patients were febrile (temperature >37'5°C), but by day 2 (at the completion of treatment) 
fever had resolved in all cases. 17 (22%) in the A3M group, 50 (32%) in the DHA-TP 
group, and 45 (27%) of the DP group still had positive blood smears but with low 
parasitaemia at 48 h (Table 5.2.2). All patients were smear negative at day 7. 
No patient developed severe malaria, none was lost to follow-up, and no patients were 
excluded. There were seven patients in the A3M group, 13 in the DHA-TP group, and 16 
in the DP group who had fever and parasitaemia confirmed by microscopy during 
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Table 5.2.2: Admission characteristics of patients in A3M-DTP community based study: 
Number of patients (Male) 
Mean age (years) 
Range 
Mean admission temperature (Oc) 
Serum creatinine (!J.mollL) a 
AST (Aspartate aminotransferase) 
(U/L) 
ALT (Alanine aminotransferase) 
(U/L) 
Geometric mean parasitaemia on 
admission (/!J.L) 
Mean temperature at 48 hours (Oct 
Geometric mean parasitaemia at 48 
hours /!J.L) 
Result of treatment (cure) b 
Assessed at 56 days follow-up 
DPT 
157(124) 
26 (24.6-27.7) 
(7 - 60) 
38.6 (38.7-38.8) 
70.4 (17.6-114.4) 
26.1 (19.9-32.3) 
18.1 (7.6-28.6) 
7789 
37 
100 
153 (97.4%) 
Data are median (95% CI) unless otherwise stated 
DP 
166(121) 
26.7(24.9-28.5) 
(10 - 65) 
38.7(38.5-38.9) 
79.2 (17.6-149.6) 
19.2(13.8-24.6) 
12 (7.6-16.3) 
6544 
37 
358 
164 (98.7%) 
A3M 
77(53) 
27.1 (24.4-29.9) 
(8 - 52) 
38.5 (38.3-38.8) 
70.4 (17.6-123.2) 
31.0(21.6-40.3) 
14 (7.6-20.3) 
6272 
37 
62 
76 (98.7%) 
AM = artesunate (4mg/kg/day) at 0,24,48 hours + mefloquine (25 mg/kg split in two doses) at 48 
and 56 hours; DTP =dihydroarternisinin 32 mg + piperaquine phosphate 320 mg + trimethoprim 90 mg. 
DP = dihydroarternisinin 40 mg + piperaquine phosphate 320 mg 
For adults: 4 tablets at 0, 8, 24, 48 hours; for children: age adjusted 
a: Median (95% Confidence Interval) b: Fisher's 2 - tailed test all characteristics of 2 treatment groups are 
comparable unless otherwise stated 
the 56-day follow-up period. Of these, one patient in the A3M group, four in the DHA-TP 
group, and two in the DP group had a recrudescence of the original infecting parasite 
confirmed by PCR-genotyping. Therefore, the 56-day cure rates, adjusted for re-
infections, were 97-4% for DTP (1531157), 98·7% for DP (1641166), and 98·7% for A3M 
(76/77); P=l. The recrudescences and the new infections all occurred between days 28 
and 35. The difference in efficacy between A3M and DHA-TP treatments was 1·2% 
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(95%CI -5,7 to 5'7%) and between A3M and DP treatments was -0,1 % (-6'9 to 3'6%). 
Both CIs lie entirely within the equivalence range. 
DHA-TP and DP were well tolerated. three (2%) and five (3%) of the DHA-TP and DP 
group, respectively, had minor adverse effects, mostly transient nausea. All side-effects in 
both groups were self limiting and resolved with the abatement of fever. No patient 
needed to repeat the dose of the tablets. In the A3M group, 12 (16%) patients had 
significant adverse events that might have been related to treatment (p=0·002). Ten 
patients (13%) had vomiting, and two (3%) had dizziness. All of these reactions were 
short lived and settled spontaneously. There were no significant differences between the 
three groups in the results of liver function tests done on all patients on days 3, 7, and 28. 
5.2.4 Discussion 
Our hospital and community based studies have shown that a combination of 
dihydroartemisinin and piperaquine, is an effective and safe treatment for multi-drug 
resistant fa1ciparum malaria in Vietnam. In this country, P fa1ciparum is resistant to 
chloroquine and antifolates and there has been a decline in sensitivity to mefloquine (A 
Brockman, et a/., 2000); (NM Huong, et a/., 2001). The use of the artemisinin derivatives 
has been central to successful malaria control efforts in Vietnam (F Nosten, et aI., 1998); 
(TT Hien, 1994). The dihydroartemisinin-piperaquine combinations used in these studies 
were very well tolerated by adults and children. This reassuring safety profile accords 
with experience with the individual components. Dihydroartemisinin, both as a drug 
itself, and as the main biologically active metabolite of artesunate and artemether, and 
piperaquine have been used in millions of patients (TT Hien, 1994); (K Raynes, 1999). 
The bisquinoline piperaquine has a similar mode of action to other quinoline antimalarials 
(K Raynes, 1999). Some resistance did develop in China when piperaquine was used 
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widely as a monotherapy, and in mass prophylaxis, against already chloroquine-resistant 
P Jalciparum (X Guo & L Fu, 1989); (L Changxiong, et al., 1989); (C Lin, et al., 1982). 
However, piperaquine is clearly making an important contribution to controlling 
multi drug-resistant P. Jalciparum in Vietnam, since 3-day regimens of artemisinin 
monotherapy in Vietnam are associated with failure rates of more than 40% (TT Hien, et 
aI., 1994), and elsewhere 3-day regimens of artesunate were associated with 80% failure 
rates, compared with only 4% seen in this study. Combination with an artemisinin 
derivative would be expected to delay the emergence of resistance. The efficacy of 
dihydroartemisinin-piperaquine was equivalent to that of artesunate-mefloquine, the 
current treatment of choice for multidrug-resistant fa1ciparum malaria in Southeast Asia. 
This combination has retained excellent cure rates (>95%) on the northwestern border of 
Thailand over a 10-year period, despite being introduced when mefloquine monotherapy 
failure rates had reached 50%. Dihydroartemisinin-piperaquine has several advantages 
over artesunate-mefloquine. It is a fixed-dose coformulation, which improves adherence, 
it is better tolerated, and it is around three times less expensive. In Vietnam, this 
combination is available for about $1 for an adult treatment course. This cost is generally 
regarded as the absolute upper limit of affordability for an antimalarial treatment in most 
countries affected by malaria. The cost of artesunate-mefloquine in Vietnam is $6, and the 
discounted price for artemether-Iumefantrine after approval by WHO is $2-40. 
Much remains to be learnt about dihydroartemisinin-piperaquine. Although there has been 
extensive clinical experience with the individual drug components, detailed large-scale 
adverse effect reporting (phase IV assessment) will be needed to confirm that rare adverse 
effects do not arise with the new combination. There are few pharmacokinetic data for 
piperaquine in human beings, although indirect evidence would suggest that it has a long 
terminal elimination half-life. The potential for resistance has already been shown when 
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used as a monotherapy, and a long terminal elimination half-life is a predisposing factor 
for the emergence of resistance. The dose of dihydroartemisinin is still low by 
comparison with other artemisinin-based regimens. Despite an increase in the amount of 
dihydroartemisinin per tablet in DP, the adult treatment dose still provides only of 3-4 
mg/kg of dihydroartemisinin on the first day and 1· 7 mg/kg on subsequent days. This 
amount may still be too low. The average dose of piperaquine used in this study was 27 
mg/kg on the first day and 13· 5 mg/kg on subsequent days. Increasing the dose of 
piperaquine may be limited by patients' nausea and vomiting (K Raynes, 1999). The late 
recrudescences confirm earlier suggestions that piperaquine has a long terminal 
elimination half-life. Clearly, the trimethoprim component did not make any contribution 
to the combination therapy, as would be expected from the high prevalence of antifolate 
resistance in this region, and is not necessary. Thus, further dose adjustments might still 
be necessary before the optimum combination of this antimalarial drug is found. 
Nevertheless, our results provide promise of a generally affordable treatment for 
multi drug-resistant falciparum malaria and lend support to the findings from a non-
randomised trial in Cambodia (MB Denis, et aI., 2002). 
Quite small investments are needed to facilitate further development of this and the other 
already available artemisinin-based combinations such that they can become generally 
available. If used widely, this inexpensive, fixed-dose artemisinin-based combination 
antimalarial could make important contributions to "rolling back malaria". 
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CHAPTER 6 
TREATMENT OF SEVERE MALARIA 
6.1 A double blinded controlled comparative trial of artemether or quinine in 
Vietnamese adults with severe falciparum malaria. 
6.1.1 Introduction 
Since the cinchona alkaloids were introduced as a specific treatment for agues 350 years 
ago, the treatment of severe malaria has changed little. Quinine and quinidine remain the 
drugs of choice for severe chloroquine-resistant malaria due to Plasmodium falciparum, 
and with the spread of these resistant parasites, the usage of these drugs is increasing 
(WHO, 1990). In 1972 scientists in China discovered the antimalarial properties of a 
group of sesquiterpene lactone peroxides derived from the qinghao plant (Artemisia 
annua) (Qinghaosu Antimalaria Coordinating Research Group, 1979). The principal 
component, qinghaosu (artemisinin), and two derivatives - the water-soluble 
hemisuccinate artesunate and the oil-soluble artemether - are the most rapidly acting and 
potent of all antimalarial drugs (TT Hien & NJ White, 1993, Qinghaosu Antimalaria 
Coordinating Research Group, 1979, NJ White, 1994a); (GQ Li, et ai., 1994); (TT Hien, 
1994, S Looareesuwan, 1994);(GQ Li, et at., 1982b). These compounds retain activity 
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against all malarial parasites, including multi drug-resistant strains of P. Jalciparum. Over 
2 million people have received antimalarial treatment with artemisinin, artesunate, or 
artemether (N White, 1994a). These drugs have proved rapidly effective in the treatment 
of severe malaria and remarkably nontoxic (GQ Li, et aI., 1994);(TT Hien, et al., 1994); 
(GQ Li, et aI., 1982b); (J Karbwang, et aI., 1992b); (J Karbwang, et aI., 1995); (K Win, et 
aI., 1992b). Artemether has been reported to reduce the mortality rate for cerebral malaria 
caused by chloroquine-resistant P. Jalciparum by a factor of 3 (WHO, 1994). 
6.1.2 Materials and methods 
This study was conducted in a special research ward at the Hospital for Tropical Diseases 
in Ho Chi Minh City, Vietnam, and was approved by the center's ethics and scientific-
review committee. A full-time study team of specially trained physicians and nurses 
provided medical care. All laboratory measurements made during the acute phase of 
illness were conducted on site. A three-month pilot study was conducted before the main 
study to familiarize staff members with the clinical and laboratory procedures. 
6.1.2.1 Objectives 
The study was designed to detect a difference in mortality of 33 percent with 95 percent 
confidence and 80 percent power. The mortality rate for severe malaria was 
approximately 30 percent before the study. Except where indicated the secondary end-
points were defined prospectively. 
6.1.2.2. Drugs 
Patients were randomly assigned to receive artemether (50 mg per milliliter) or quinine 
dihydrochloride (250 mg per milliliter) for a minimum of 72 hours. The drugs were issued 
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In packs of 10 identical 3-ml ampUles by the Kunming Phaffilaceutical Company 
(Kunming, People's Republic of China). Randomly selected ampules were checked for 
sterility and potency. The initial dose of both drugs was 0.08 ml per kilogram of body 
weight (4 mg of artemether per kilogram and 20 mg of quinine salt per kilogram), half of 
which was injected into the anterior thigh of each leg. The maintenance dose was 0.04 ml 
per kilogram for each drug (2 mg of artemether per kilogram and 10 mg of quinine salt 
per kilogram) and was given every eight hours. 
When the patient could take oral medication reliably, a second independent 
randomization was perfoffiled. Patients received either a single oral dose of 15 mg of 
mefloquine per kilogram (Lariam, Hoffmann-LaRoche, Basel, Switzerland) or oral 
quinine sulfate (Government Phaffilaceutical Organization of Thailand, Bangkok) at a 
dose of 10 mg per kilogram three times daily for up to four days (i.e., for a total of seven 
days of antimalarial treatment). Treatment with quinine was followed by two tablets of 
pyrimethamine-sulfadoxine (Fansidar, Hoffmann-LaRoche). 
6.1.2.3 Randomization and Blinding 
The drugs for each patient were placed in a coded sealed envelope, and the envelopes 
were randomized in blocks of 20. Once a patient was enrolled in the study the envelope 
was opened. Subsequent analysis of efficacy was on an intention-to-treat basis. Although 
the ampules, drug volumes, and administration schedules of artemether and quinine were 
identical, the viscosity and color of the two drugs were slightly different. To maintain 
blinding, a separate team of nurses, who were not otherwise involved with the care of the 
study patients, drew up and gave the injections. The drugs were kept in an opaque packet 
in a locked cabinet during the study. 
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6.1.2.4 Clinical Procedures 
Patients were included in the study if they (or an accompanying relative) gave informed 
consent, had asexual forms of P. falciparum on a peripheral-blood smear, were older than 
14 years, were not in the first trimester of pregnancy, were not intravenous drug users, 
had received less than 3 g of quinine or two doses of artemisinin or a derivative in the 
previous 48 hours, and had one or more of the following: a score on the Glasgow Coma 
Scale of less than 11 (indicating cerebral malaria); anemia (hematocrit, <20 percent), with 
a parasite count exceeding 100,000 per cubic millimeter on a peripheral-blood smear; 
jaundice (serum bilirubin, >2.5 mg per deciliter [50 Jlmol per liter]), with a parasite count 
of more than 100,000 per cubic millimeter on a peripheral-blood smear; renal impairment 
(urine output, <400 ml per 24 hours; and serum creatinine, >3 mg per deciliter [250 Jlmol 
per liter]); hypoglycemia (blood glucose, <40 mg per deciliter [2.2 mmol per liter]); 
hyperparasitemia (> 10 percent parasitemia); and systolic blood pressure below 80 mm Hg 
with cool extremities (indicating shock). 
Each patient underwent a full clinical examination that included a detailed neurologic 
assessment. A complete blood count, count and estimation of the life-cycle stage of the 
parasites, biochemical analyses, measurements of plasma glucose and lactate, and blood 
cultures were done, and plasma was stored for measurement of cytokines, plasma quinine, 
and coagulation indexes. Arterial-blood gases and pH were measured on admission 
beginning in April 1992 (when 234 patients had been enrolled). Blood was obtained by a 
finger-prick for hematocrit measurements and blood smears every 4 hours for the first 24 
hours and every 6 hours until three consecutive smears were negative for asexual stages 
of P.falciparum. The degree of parasitemia was determined on the basis of the number of 
parasitized red cells per 1000 red cells (thin film) or the number of parasites per 400 
leukocytes (thick film). 
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6.1.2.5 Management and Clinical Monitoring 
Patients were cared for according to standard recommendations (WHO, 1990). All 
patients were gIVen isotonic saline to restore fluid balance, and fluid balance was 
maintained with saline or 5 percent dextrose in water. When necessary, a central venous 
catheter was inserted and the central venous pressure maintained at 5 cm of water. Blood 
was transfused if the hematocrit fell below 20 percent. Hypoglycemia was corrected with 
a bolus injection of 50 ml of 30 percent dextrose in water and a subsequent maintenance 
infusion of 5 to 10 percent dextrose in water. Detailed clinical and nursing observations 
were recorded a minimum of every 4 hours for the first 24 hours and every 6 hours 
thereafter. 
In all patients blood glucose, lactate, and cytokine levels were measured 4, 8, 12, and 24 
hours after admission. Beginning in June 1992 (after the enrollment of 259 patients) an 
electrocardiogram with a rhythm strip (paper speed, 50 mm per second) was obtained 
before treatment, 12 hours after treatment was begun, 4 hours after the last parenteral 
dose of antimalarial agent, and at discharge. Standard intervals were recorded, and the QT 
interval was corrected with the use of Bazett's fonnula (QT/v'RR). A diagnostic lumbar 
puncture was performed if the score on the Glasgow Coma Scale was below 14. Opening 
cerebrospinal fluid pressures were measured, the cerebrospinal fluid was analyzed 
microscopically, and levels of protein, glucose, and lactate were detennined. Peritoneal 
dialysis was started in patients with established renal failure. Beginning in September 
1993 (after the enrollment of 427 patients) hemofiltration was also available. There were 
no facilities for ventilation. Acetaminophen was given for a temperature above 39°C, and 
intravenous diazepam, intramuscular phenobarbital, and if necessary, intravenous 
phenytoin were given for convulsions. Antibiotics with no clinical antimalarial activity 
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(i.e., not tetracyclines, macrolides, trimethoprim-sulfamethoxazole, or chloramphenicol) 
were prescribed for suspected cases of bacterial sepsis. 
On discharge a detailed neurologic examination, electrocardiography, and beginning in 
November 1993 (after the enrollment of 441 patients), audiography (frequency range, 250 
to 8000 Hz) were performed. A full autopsy was performed on patients who died of 
malaria if permission could be obtained from relatives. All information was recorded in 
the patients' records and then triple-entered in a computer data base. 
6.1.2.6 Statistical Analysis 
The study was reviewed continuously by an outside monitor. Categorical data were 
analyzed by Fisher's exact test, and continuous data by the Kruskal-Wallis test with the 
statistical programs Statview v.4.1 (Abacus Concepts, Berkeley, Calif.) and Stata V.4 
(Stata, College Station, Tex.). The lengths of time to recovery were compared in the two 
groups by survival analysis with the Peto and Peto modification of the Wilcoxon test (R 
Peto & J Peto, 1972). Cox regression analysis was used to determine the contribution of 
different variables to recovery. 
6.1.3 Results 
Between May 1991 and January 1996, 561 patients were enrolled in the study. Only one 
patient was excluded from the analysis, because a review of the admission blood smear 
did not confirm the presence of malarial parasites. He died of an intracranial hemorrhage. 
There was a steady decline in the number of patients recruited during the study that 
paralleled the overall decline in the incidence of malaria in Vietnam. After reviewing the 
results of an interim analysis conducted in October 1994 (after 500 patients had been 
recruited), we decided to continue the study for one more year. 
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Table 6.1.1 Characteristics of the artemether quinine patients on admission. 
Ca .... RACTERISTIG.<; OF THE PATIENTS ON ADMISSION, ACCORDING TO TR.EATMENT GROUP. 
CHARACTERISTIC· 
Age - yr 
1vledjan 
Range 
Intcrquarrilc r.lnge 
Sex- M/F " 
Pn:vious trcaunent wie.h quinin ... for 
ClilTene episode of mal.1.ria -
no. of patients (%) 
Pre"iolls trc,1tlllcnt wieh anemisinin or 
<.kri,·atin: I~ .• r clIrrent cpisode of 
l1ul.u·i.l - no. of patients (''h;) 
Convulsion~ - no. e,f pati ... nt~ (%) 
Te 1l1per.lturc - ·:·c 
1vledian 
Range 
Intc.'qu,ll·tik l'ang.: 
Pul!Oc r,ltc/min 
l\lcdi,Ul 
Range 
Intcn.luar'tik range 
Rcspir,norr ratc/ min 
lYkdian 
R.lnge 
IlItcrql1.1ftik \'ang ... 
C~la~go\\· Conl.l !>.:on: 
l\lcdi,ll1 
R.lnge 
Inte.·quartlk f.lnge 
(,;Iasgo,,, c .. nl.l "':0"'" <11 -
no. (Jfp~Hl..:n{~ (f;~"1 
(')penil1g pl'c",urc "f c ... rcbn .~p.n.ll 
fluid - Inl11 of w.Her 
Median 
R.lJw;c 
Intc~qll'lnik f.lng~' 
ARTEMETHER 
(N = 284) 
30 
15-79 
22-40 
212/72 
155 (55) 
30 (ll) 
30 0: 11) 
38.2 
,=\(),3-41 
37.5-.N 
102 
70-160 
96-120 
2H 
16-()4 
24-32 
10 
3-1:=;' 
8-15 
142(:=;'0) 
1()0 
;0-340 
125-1lJO 
QUININE P 
(N=276) VALIJE 
30 
15-78 
22-41 
0.99 
213/63 0.49 
14lJ (54) 0.93 
22 (8) 0.46 
33 (12) 0.59 
0.3 
38,;::' 
36.5-41 
37.5-39.2 
105 
60-188 
95-120 
28 
16-48 
24-32 
10 
3-15 
8-15 
(U~7 
0.59 
0.14 
148 (;4) 0.4 
16; 
40-5111 
130-200 
0.45 
CHARACTERlSllC" 
Shod" - no, of patients (%) 
Hypo~l\'<:enlia - nn. of 
, p'ar'i.::nts (%) 
H'::1l1,tto.:rit - % 
,\h'dLlll 
R~Ulg.: 
Illr,"£'qu.1.nilc f·.J.n~(,· 
l\lI'a"ite .:ount - XIO-3/ IUIl13 
.\lcdi.ln 
Range 
Inte;:quartile r.mgc 
VVhitt.'-.:dl count - X 10-3/mm3 
.\-kdial1 
Ra.nge: 
Illrerqll.ll"tilc- 1·.J.nge 
S.::rUI11 '::£''''.\[il1ll1e - mg/dl 
.\k.:li,\I1 
R<lng~' 
Int,·rqll.Htile f.l 11 g;<..' 
Tor.t1 bilirubin - 1l1g/dl 
.\.kdi.ln 
Rang .. , 
Inr ... rqu,1nile r.lnge 
Asp.ln.He 'lIl1in()trall~fen\se-
JL.ll1 ()J/hr/ dl 
.\·kdi.lI1 
Range 
Int,,·rqll.lnile r.J.ngc 
Pbsl1l.l bet.Ht.· - rnnlnl/lit<.'l· 
.\i ... dl.lIl 
Rallg ... 
Int .. 'rqll.1rtile f';'}I1~(' 
ARTEMETHER 
(N=284) 
18 (6) 
23 (8) 
30 
10-60 
24-35 
90.4 
O,02-16S0 
16.8-339 
8,35 
9-3:-
(> .2-1 1.4 
2.0 
0.3-11.8 
1.5-3.7 
3.6 
0.5-20 
1.8-7.lJ 
1;3 
20-630 
95-248 
3.2 
OA- IlJ.3 
2-5.5 
QUIMNE 
(N= 276) 
25 (9) 
18(7) 
31 
6-53 
25-37 
86.9 
(1.04- 3690 
19.3-343 
lJ.08 
3~5- 38,5 
6.;- 12.b 
2.0 
0.5-1 :u~ 
1.4-3.2 
3.3 
0,5- 1<) 
I.6-~.6 
160 
30-~3U 
100-23; 
3.4-
0.4-18 3 
2.1-47 
P 
VALUE 
0.27 
0.52 
0.18 
0.71 
lU)6 
0.25 
11.71 
0.78 
0.lJ4 
.'1'" nlln'crt values t~)r n·~·.ltinil1e to IniCfOIlI.)ks 1''''\" Iit ... 'r. 11111ltipl\' hr 88.4; t.) con\'ert \'.)Ill~·~ t,)r rot.,1 bilirubin to l11icrnmnles per lit .... " 111ultiplr lw 17.1. 
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The characteristics of the patients on admission are shown in Table 1. There were no 
significant differences in any of the major variables between the two treatment groups. 
The median total dose of antimalarial agent given parenterally, including that given 
before the study, was 120 mg of quinine per kilogram (range, 20 to 246) and 20 mg of 
artemether per kilogram (range, 4 to 44). 
6.1.3.1 Outcome 
The overall mortality rate was 15 percent (83 of 560 patients). The difference in the 
mortality rate between the art em ether group and the quinine group was not significant (13 
percent vs. 17 percent, P = 0.16) (Table 6.1.2). Four patients had neurologic sequelae 
(three in the artemether group and one in the quinine group), and thus there was also no 
significant difference in the combined number of deaths and cases of neurologic sequelae 
between the groups. In a multiple logistic-regression model that incorporated factors 
identified at the outset as associated with outcome, treatment with artemether was 
associated with a lower mortality (P=0.028) (Table 6.1.3). Among patients with cerebral 
malaria (score on the Glasgow Coma Scale, <11), the overall mortality rate was 16 
percent (45 of 290 patients): 15 percent in the artemether group (21 of 142) and 16 
percent in the quinine group (24 of 148, P = 0.75). 
6.1.3.2 Causes of Death 
The cause of death was often multifactorial. Of the 83 patients who died, 59 had acute 
renal failure (dialysis had been started in 30 of these patients), 56 had intractable shock, 
35 had a terminal respiratory arrest with continued pulse, 25 had serious gastrointestinal 
bleeding, and 12 had pulmonary edema. A full autopsy was performed on 50 of the 
200 
Chapter 6: TREATMENT OF SEVERE A1ALARIA 
patients who died. Serial measurements of arterial-blood gas were begun In 1992 and 
showed that 42 of the 50 (84 percent) had metabolic acidosis 
Table 6.1.2: Assessement of outcome after treatment with artemether or quinine 
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Table 6.1.3 The factors associated with death from severe falciparum malaria 
~'lULTIV.-'\.R.L":rE LOGISTIC -REGRE-;SIO~ 
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6.1.3.3 Recovery 
Artemether treatment was associated with quicker clearance of parasites from the 
peripheral blood but slower resolution of fever, slower recovery from coma, and longer 
hospitalizations (P<0.005 for all comparisons) (Figure 6.1 and Table 6.1.4). We used a 
Cox proportional-hazards model to assess the contribution of different variables evaluated 
at admission (score on the Glasgow Coma Scale, creatinine and lactate values. log 
parasite count, and the presence of jaundice, hypoglycemia, and shock) to the time to 
recovery from coma (defined as the time to reach a score of 15 on the Glasgow Coma 
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Scale). In patients with cerebral malaria , qumme treatment remained significant! 
associated with a more rapid recovery than artemether treatment (hazard ratio, 1.39; 
Figure 6.1: Kaplan Meier plots of overall survival (A), time to recovery from coma (B) 
parasite clearance time (C) and fever clearance time (D). 
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In Panel C the four patients in whom clearance of parasites took longer than 250 hours Itvvo ill the artemether group and two In 
the quinine group) are not shown. 
95 percent confidence interval, 1.06 to 1.81; P = 0.017), and this difference became 
evident after 48 hours (Figure 6.1 A, B, C, and D). The markers of disease se erity at 
admission in patients with impaired consciousness that lasted more than 48 hours v ere 
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similar in the two groups. In a similar model, the differences in the time to resolution of 
fever between the two groups could not be explained by the occurrence of supervening 
bacterial infections. 
6.1.3.4 Hematologic Recovery 
There was no significant difference between the artemether group and the quinine group 
in the fall in the hematocrit from base-line values (median reduction, 27 percent vs. 30 
percent; range, 0 to 71 vs. 0 to 68; P = 0.48), blood-transfusion requirements (Table 
6.1.2), or the hematocrit values at discharge (22 percent vs. 24 percent; range, 10 to 40 vs. 
13 to 41; P = 0.18). However, patients in the artemether group had significantly lower 
mean reticulocyte counts one week after treatment (2.3 percent vs. 5.6 percent; range, 0.1 
to 16.1 vs. 0.0 to 28; P<O.OOI). Blackwater (red or black urine caused by hemoglobinuria 
but not hematuria) developed in 11 patients: 7 in the artemether group and 4 in the 
quinine group (2 percent vs. 1 percent; relative risk, 2.7; 95 percent confidence interval, 
0.86 to 8.3; P = 0.11). The overall incidence of blackwater in patients who had received 
quinine either before or during the trial was 4.9 percent (21 of 431; 95 percent confidence 
interval, 3.0 to 7.4 percent). 
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Table 6.1.4: Assessement of recovery after treatment of artemether or quinine 
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Ct )>:TI>:VED, 
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6.1.3.5 Adverse Effects 
Quinine was associated with hypoglycemia: hypoglycemia developed in 25 percent of the 
quinine-treated patients as compared with 11 percent of the artemether recipients (relatiye 
risk, 2.3; 95 percent confidence interval, 1.6 to 3.4; P<O.OOl), There was an increased 
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incidence of culture-negative pyuria in the artemether group (P = 0.03), but the incidence 
of urinary tract infections was not significantly different between groups. There were no 
other definite systemic adverse effects. There were no significant electrocardiographic 
abnormalities in the patients in whom recordings were made, although in 60 of the 
quinine recipients (45 percent), as compared with 38 of the artemether recipients (25 
percent), the corrected QT interval was prolonged by more than 0.5 second (relative risk, 
l.8; 95 percent confidence interval, l.3 to 2.5; P = 0.001). Only 12 patients in the quinine 
group (9 percent) and 11 in the art em ether group (7 percent) had a corrected QT interval 
that was prolonged by more than 25 percent (P = 0.67). Prolongation of the corrected QT 
interval was not associated with any other clinical finding, including the development of 
shock or the duration of coma. There were no differences between the two treatment 
groups in auditory acuity on discharge from the hospital. 
6.1.3.6 Oral Treatment 
Overall, 247 patients were randomly assigned to receive oral mefloquine and 224 to 
receive oral quinine; 89 patients did not receive oral antimalarial agents because they had 
either died (74) or had received seven days of parenteral treatment (15). Nine patients 
died after receiving oral antimalarial agents (four given mefloquine and five given 
quinine). The oral antimalarial agents had no effect on recovery times or parasite 
clearance as assessed by Cox regression analysis. 
6.1.4 Discussion 
Our results show that artemether is a safe and effective treatment for severe fa1ciparum 
malaria in Vietnamese adults. The mortality rate among artemether-treated patients was 
26 percent lower than that among quinine recipients, but the 95 percent confidence 
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interval ranged from a 50 percent reduction to an 11 percent increase in mortality. 
However, in our prospectively designed multivariate analysis, which took into account 
other factors that contribute to outcome, treatment with artemether was associated with a 
significantly lower mortality rate than treatment with quinine. This suggests that 
artemether is at least as good as, and may be better than, quinine for severe chloroquine-
resistant malaria. In a setting of relative quinine resistance (S Pukrittayakamee, et aI., 
1994), similar to that in Vietnam (K Arnold, et ai., 1990), artemether proved considerably 
superior to quinine in smaller, open trials of severe malaria conducted in Burma and 
Thailand (J Karbwang, et aI., 1992a, K Win, et ai., 1992a) (J Karbwang, et aI., 1995). The 
large differences in mortality observed in these studies were not substantiated in our large 
and detailed double-blinded, randomised trial. This cannot be ascribed to differences in 
clinical severity or drug administration, since the clinical and laboratory features of severe 
malaria in our trial were similar to those reported previously and the doses of artemether 
were higher than those usually recommended. 
Although treatment with artemether resulted in a more rapid reduction in the level of 
parasitemia as reported previously (TT Hien & NJ White, 1993), the overall times to 
defervescence, recovery of consciousness in patients with cerebral malaria, and discharge 
from the hospital were longer in artemether-treated patients. Survival analysis indicated a 
significant divergence in the times to recovery from coma among patients who remained 
unconscious for more than two days. In these patients, treatment with artemether was 
associated with slower recovery. There are three possible explanations for this unexpected 
finding: the play of chance, neurotoxicity, or a consequence of the beneficial effect of 
artemether - patients who would have died if they had received quinine survived 
because they received artemether and took longer to recover. Although there was no other 
evidence of neurotoxicity (TG Brewer, et ai., 1994a, TG Brewer, et aI., 1994b), an acute 
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reversible drug effect cannot be excluded, particularly since the difference in the times to 
recovery from coma became evident after 48 hours, after a total of 14 mg of artemether 
per kilogram had been given. In support of the third explanation, the times to recovery 
from coma were strongly associated with other measures of disease severity, and these 
measures were similar in all patients whose recovery from coma took longer than 48 
hours. 
In uncomplicated malaria, the artemisinin derivatives consistently shorten all aspects of 
recovery, whereas in severe malaria, in which the processes that cause organ dysfunction 
and death may already be largely irreversible (WHO, 1990), they do not. Pharmacokinetic 
factors may contribute to this difference. Parenteral artemether is dissolved in groundnut 
oil and administered by intramuscular injection. As compared with orally administered 
artemether, intramuscularly administered artemether is absorbed slowly and incompletely. 
This delay in achieving therapeutic blood levels may offset any intrinsic 
pharmacodynamic advantage of artemether. In general, the water-soluble artesunate has 
resulted in the most rapid therapeutic responses. Artesunate is given intravenously and is 
also rapidly bioavailable after intramuscular or oral administration (TT Hien & NJ White, 
1993, N White, 1994b). Artesunate may be more effective than artemether in severe 
malaria. By contrast, absorption of intramuscular quinine in severe malaria is regular, and 
its plasma-concentration profiles are similar to those seen after intravenous 
administration(D Waller, et aI., 1990) (G Pasvol, et aI., 1991). 
The intramuscular administration of quinine is painful and causes local tissue damage, 
which sometimes results in sterile abscesses (W Fletcher & S Visuvalingam, 1923, R 
Ross, 1914) and, occasionally, tetanus (LM Yen, et at., 1994). In this study, both 
treatment regimens were well tolerated and only nine quinine-treated patients (3.2 
percent) had abscess formation, difficulty walking because of local pain, or both, despite 
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the use of a concentrated solution (250 mg per milliliter, with a pH of 2). Thus, the risks 
of serious local reactions from intramuscular quinine are low, provided a scrupulous 
aseptic technique of injection is used. Quinine causes hypotension if given too quickly by 
intravenous injection, and it also prolongs ventricular repolarization, but substantial (>25 
percent) prolongation of the corrected QT interval occurred in only 12 patients (9 
percent), and no serious toxic effects were associated with the use of a loading dose of 
quinine despite the fact that the majority of patients had been treated previously with 
quinine (K Silamut, et aI., 1995). Indeed, there were no serious cardiovascular or nervous 
system effects with either drug. 
Quinine is a potent stimulator of the secretion of insulin by pancreatic beta cells (NJ 
White, et aI., 1983c) and was associated with an increased risk of hypoglycemia. Overall, 
our results confirm that intramuscular administration of quinine is an acceptable 
alternative to intravenous administration and that the principal adverse effect of quinine in 
severe malaria is hypoglycemia (NJ White, et aI., 1983c) . In rodents, dogs, and primates, 
artemether (and the related compound, arteether) induced an unusual and selective pattern 
of damage to certain brain-stem nuclei (TG Brewer, et al., 1994a, TG Brewer, et aI., 
1994b); This has been the main concern overlying the further development of these 
compounds. With the possible exception of prolonged recovery from coma in patients 
given artemether, we did not detect any evidence of permanent damage to the central 
nervous system despite the use of maintenance doses that were three times higher than 
those now usually recommended. The auditory nuclei are among the most sensitive to 
damage by these compounds, but there was no evidence of residual hearing impairment. 
Artemether is an effective alternative to quinine for severe malaria. It is simple to 
administer, equivalent in overall cost to quinine, and has no apparent local or serious 
systemic adverse effects. It is one of a family of new antimalarial agents that are active 
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against quinine-resistant parasites. These new drugs should not be used in an uncontrolled 
or unregulated way, or resistance to them will develop. 
6.2 Assessement of IR artemisinin, IV 1M artesunate and 1M artemether 
in the treatment of severe and complicated malaria in Vietnam 
6.2.1 Introduction 
In recent years, artemisinin and its derivatives have been used widely in Vietnam and 
other developing countries to treat uncomplicated malaria caused by Plasmodium 
falciparum. They have also been used in severe and complicated malaria with good 
results (NJ White, 1994a). Recent studies have compared individual preparations of 
artemisinin with quinine, but direct comparisons between all the artemisinin derivatives 
have not been made. Consequently, it is not known which preparation and route of 
administration are preferable. In 1992, we reported a study comparing artemisinin 
suppositories with intravenous (i.v) artesunate and iv quinine in the treatment of cerebral 
malaria. However there were few cases in the group treated with artemisinin 
suppositories, owing to discontinuation of the supply from manufacturer(TT Hien, et aI., 
1992a). We also showed that intramuscular(im) artesunate and iv artesunate were equally 
efficoacious (TT Hi en, et al., 1992b). We conducted the present study to compare the 
efficacy of different regimens of artemisinin and its derivatives in the treatment of P. 
falciparum severe and complicated malaria in a rural hospital setting. 
6.2.2 Patients and methods 
The study was an open randomized comparative study, conducted in Tan Phu regional 
hospital, which is responsible for health care in 2 districts, Tan Phu and Dinh Quan, in the 
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rural area of Dong Nai province, southern Vietnam. In this region, malaria is endemic 
throughout the year and the major employment is rice farming and forestry. 
6.2.2.1 Patients 
The patients were recruited into the study if 15 years of age or older, of either sex, with 
clinical symptoms and signs of malaria and the presence of asexual form ofP. falciparum 
in their peripheral blood. In addition, they must have had at least one of the following 
signs: i) unarousable coma (Glasgow Coma Score (GCS) <11, ii) hypoglycaemia (blood 
glucose <2.2 mmol/L [40 mg%], iii) acute renal failure (plasma creatinine >265.2 
/-lmoVL) [3 mg%] with or without oliguria, iv) jaundice (total bilirubin >51.3 /-lmoVlitre [3 
mg%] with parasitaemia > 100,000//-lL or with plasma creatinin > 1.5 mg %, v) anemia 
(hematocrit <20% with parasitaemia. 100,0001 uL), vi) shock ( systolic arterial blood 
pressure < 80 mm Hg with a thready pulse and cold clammy extremities, and vii) 
hyperparasitemia (>250,000 asexual forms//-ll whole blood (Hien et all 1996). 
Patients were excluded from the study if prior treatment with more than 3 g of quinine or 
two doses of artemisinin or a derivative had benn recorded by the peripheral health care 
worker. Pregnant women in the first trimester and patients with concomitant diseases 
(active tuberculosis, bacterial meningitis, ect.) or mixed infections with P. vivax, were also 
excluded from the study. 
Informed consent for participation was obtained from the patients or their relatives (in the 
case of comatose patients). The study was approved by the scientific and ethical 
committee of the Hospital for Tropical Diseases ofHo Chi Minh City Vietnam 
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6.2.2.2 Methods 
Clinical procedures 
On admission, a thorough history was taken and full clinical examination made, and the 
details were recorded on a standard form. Peripheral blood film was prepared for parasite 
counts every 6 hours, until 3 consecutive films had failed to reveil parasites. Blood was 
also taken a complete blood count and routine biochemistry (blood glucose, serum 
creatinine, serum bilirubine). The parasitaemia was determined as the number of 
parasitized red blood cells per 1000 red blood cells (thin film) or the number of parasites 
per 400 leucocytes (thick film). Axillary temperature, pulse, arterial blood pressure, 
respiratory rate and Glasgow coma scale were recorded every 6 hours. 
Treatment 
When a patient fulfilled the enrolment criteria, a sealed envelope containing the code for 
the treatment regimen was opened to allocate himlher to one of the following 4 treatment 
groups: 
i) Artemether (Kunming Pharmaceutical factory, Kunming, People's 
Republic of China - PRC) 200 mg i.m initially then 100mg at 24, 48, 72. 
ii) Artemisinin suppositories (Vietnam Industrial Development of 
Pharmaceutics, Ho Chi Minh City, Vietnam) 1200 mg initially, then 400 
mg at 4, 24, 48, 72. The same dosage of artemisinin was re-administered 
if the suppositories were expelled within 2 hours of insertion 
iii) Artesunate (Guilin No 2 factory, Guangxi, PRC) 120 i.m. initially, then 60 mg 
at 4, 24, 48, and 72 hours. 
iv) Artesunate (Guilin No 2 factory, Guangxi, PRC) 120 i.v. initially, then 60 
mg at 4, 24, 48, and 72 hours. 
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All patients received 750 mg mefloquin (Lariam@, Roche) as a single dose after 
regaining consciousness or at 72th hour. Fluid and electrolyte replacement, antipyretics, 
and other ancillary treatment were given when needed, as guided by the World Health 
Organisation(WHO, 1990). Patients with acute renal failure requiring dialysis were 
transferred to the Hospital for Tropical Diseases in Ho Chi Minh City for peritoneal 
dialysis. 
We allocated the first 120 cases randomly to the treatment groups. When 30 patients had 
been recruited to the i.v. artesunate group, we stopped recruitment of patients into this 
group and randomly allocated the next 60 to the remaining 3 groups 
Assessment of results 
We assess fever clearance time (FCT) - time for axcillary temperature to fall to, and 
remain for> 24 hours at, 37.5 °c or lower, parasite clearance time, time to regain full 
consciousness(in comatose patients) and fatality rate. 
Statistical analysis 
The Kruskal-Wallis test was used to compare continuous variables, the X2 test for 
categorical variables, the Kaplan-Meier procedure with log rank tests for survival analysis 
of fever clearance time, parasite clearance time, and time to recovery of consciousness. 
Epi Info version 6.0 and SPSS for Windows version 6.0 packages were used. All values 
ofp < 0.05 were considered significant. 
6.2.3 Results 
Overall 180 patients were enrolled. Five patients were excluded from the analysis (one 
each in the im and iv artesunate groups, 2 in the im artemether group, and one in the 
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artemisinin suppository group) because a review of admission blood film showed that 
their parasite counts were below 500,0001 !J.L and there was no additional criterion of 
severity. Therefore, 175 patients, 51 in the artemisinin suppositories group, 45 in the i.m. 
artemether group, 49 in the i.m artesunate group and 30 in the i.v. artesunate group, were 
included in the analysis. There was no significant difference in any of the major 
admission clinical and laboratory characteristics of patients between the 4 treatment 
groups (Table 6.2.1) 
6.2.3.1 Mortality 
The overall mortality rate was 13.7 % (24 cases) and it was similar in each groups: 10.2% 
(5 cases) in the i.m. artesunate group, 11.5% in the i.m. artemether group, 16.6% ( 5 
cases) in the i.v artesunate group, 17.6% in those receiving artemisinin suppositories (X2 
= 1.66 P = 0.64). Post mortem examination was unavailableand so the exact cause of 
death could not be established. 
6.2.3.2 Recovery 
The feverclearance time, parasite clearance time, and the time to regain full consciousness 
(in comatose cases) are presented in Table 6.2.2. The differences between the 4 groups 
were not significant. There was no neurological sequel among those who recovered from 
comatose state. 
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Table 6.2.1: Admission clinical and laboratory characteristics of the 4 artemisinin - treatment groups 
Artemether Artemisinin Artesunate Artesunate 
intramuscular supposi tories intramuscular intravenous pa 
No of patients 45 51 49 30 
Gender (female/male) 17/28 16/35 18/31 7/23 
Age (year) b 28 (16-65) 28 (16-62) 24 (15-66) 30 (15-60) 0.7 [22-37] [21-41 ] [18-39] [22-37] 
Admission temperatureCC) b 38 (37-41.5) 38 (37-40.6) 38 (37-41) 38 (37-41) 0.9 [37.5-39] [37-39] [37.5-38.5] [36.5-40] 
Haematocrite(%) b 34 (11-45) 31.5 (10-57) 30.5 (15-48) 32 (16-42) 0.8 [25-38] [26-38] [24.5-36] [26-36] 
Leucocytes ( x 109/L)b 7500 (4200-19000) 7500 (5000-25300) 7500 (2000-14400) 7000 ( 4100-10500) 0.8 [700-9000] [6700-8200] [6500-8550] [ 6800-8000] 
Parasitaemia (/~Lt 20178 (140-1044000) 34538(40-1065000) 33174 (60-1751000) 17159 (20-1217000) 0.5 [2000-151976] [ 18212-286368] [3893-244794] [1520-364742] 
Cerebral a 34 35 36 24 
Anaemia a 7 10 9 5 
Jaundice a 7 6 10 1 
Acute renal failure a 3 2 3 1 
Hypoglycaemia a 1 0 4 1 
a: Kruskal-Wallis test 
b: Median values (range in parenthesis) [interquartile range in brackets] 
c: Geometric mean (range in parenthesis) [interquartile range in brackets] 
d: Some patients have more than one complication 
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Table 6.2.2. Results of 4 artemisinin treatment groups 
Artemether Artemisinin 
intramuscular suppositories 
Fever clearance time (h)a 48 (38-58) 42(36-48) 
Parasite clearance time (h) a 30 (26-34) 30 (24-36) 
Conciousness recovery time (h) a 47 (31-63) 24 (18-30) 
Fatality rate (%) 1l.1 17.6 
a:All values are medians (95% confidence intervals in parenthesis) except fro fatality 
b: Log rank test, except for fatality (X2) 
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Artesunate 
intramuscular 
36 (30-42) 
24 (15-33) 
30 (18-42) 
10.2 
Artesunate 
intravenous 
30 (18-42) 
24 (15-33) 
24 (4-44) 
16.6 
Pb 
0.13 
0.3 
0.18 
0.64 
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6.2.4 Discussion 
Since 1979, research m China has shown good results after the treatment of 
uncomplicated and severe and complicated malaria with artemisinin and its derivatives 
(GQ Li, et ai., 1994). Following these initial results, many other comparative studies 
(including double blind studies) have shown that both artesunate and artemether can 
lower the fatality rate in severe and complicated malaria (TT Hien, et aI., 1992a, J 
Karbwang, et ai., 1995, K Win, et aI., 1992a). However, recent large randomized studies 
have not shown significant differences in mortality and there is no consensus about the 
best drug and the best route of administration(N White, 1994a). We believe that is the 
first randomized study directly to compare artemisinin (in suppositories) with its 
derivatives, artesunate and artemether, in the treatment of severe and complicated malaria 
in a rural hospital. 
The difference in mortality rates between the 4 groups was not significant. Nevertheless, 
any conclusion about the mortality rates should be circumspect because the power to 
detect a difference between these case mortality rates was quite low (8.4-11 %) due to 
relative small number of patients. However the rates were in general, similar to those 
reported in Myanmar (14% for i.m. artemether and 8.3% for i.v. artesunate)(K Win, et at., 
1992a) and in Thailand (12.8% for i.m. artemether (J Karbwang, et at., 1995). 
The longest time to recovery of consciousness in our trial was in the artemether group 
(although the difference was not statistically significant) and this is concordant with the 
result of a recent study in which a prolonged coma period was also reported in patients 
treated with i.m artemether (median 66 hours compared with 48 hours in patients 
receiving quinine (TT Hien, et aI., 1996). The reason for this prolonged coma in patients 
treated with artemether is unknown, but an acute reversible drug effect cannot be 
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excluded (TT Hien, et at., 1996). A large study is needed to compare i.m artesunate with 
i.m art em ether. 
The results of the present study substantiate our prevIOUS report that artemisinin 
suppositories can be used to treat severe and complicated malaria with efficacy equal to 
that of i.v. artesunate (TT Hien, et aI., 1992a). Artemisinin suppositories, unlike 
artesunate or artemether given by injection, are simple to administer, easy to store, 
Artemisinin suppositories have been used successfully to treat uncomplicated falciparum 
malaria in adult (K Arnold, et aI., 1990) and children (TT Hien, et aI., 1991) and have 
also been shown to reduce the mortality of cerebral malaria (TT Hien, et aI., 1992a). For 
the best outcome, treatment of severe and complicated malaria should be started as soon 
as possible. In Vietnam, the district hospitals serve as an intermediate level of medical 
care between communes health centres and provincial or tertiary hospitals; they received 
patients transferred from commune health centres or directly from neighboring 
households. Therefore, the district hospitals are the ideal setting for early treatment of 
severe and complicated malaria. Artemisinin suppositories may, therefore, be useful at the 
peripheral level of the health care system in many tropical areas where malaria is endemic 
and resources are limited. 
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CHAPTER 7 
DISCUSSION 
7.1 Artemisinins and the treatment of acute falciparum malaria in Vietnam 
The problem of drug resistance in falciparum malaria increased throughout the 70's and 
80's in Viet Nam and contributed to the worsening malaria situation in the country during 
those decades. The need for alternative antimalarial drugs was obvious and also that any 
treatment should be effective, safe, inexpensive, well tolerated, and readily complied 
with. It was also obvious that we need to develop a research programme to address these 
issues and provide solutions. 
The cornerstone of the change in the management of malaria in Viet Nam was the 
introduction of artemisinin and other derivatives of the Chinese herb "qinghaosu" as first 
line treatment from 1995. The earlier laboratory and clinical studies in China provided the 
basis for clinical trials at the Hospital for Tropical Diseases. The artemisinin used was 
initially manufactured in China but more recently this manufacture has moved to Viet 
Nam from locally grown Artemisia annua plants. Research on Artemisia annua was 
started in early 1980s within the framework of the national malaria control programme: in 
1984 samples of this plant were collected in Lang Son Province and in 1986 the presence 
of artemisinin in Vietnam Artemisia annua with high yield (0.5-1.2% in dried leaves) was 
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confirmed. The first randomised controlled comparative studies to assess the efficacy of 
artemisinins - outside of China - conducted at our hospital in 1991, demonstrated the 
value of artemisinin suppositories in adults and children with uncomplicated falciparum 
malaria (K Arnold, et al., 1990) (TT Hien, et aI., 1991); during the 1990s we showed that 
artemisinin and its derivatives (artesunate or artemether) are the best antimalarial drugs 
available in terms of clearing malaria parasites. They may be given by the oral, parenteral 
or rectal routes (TT Hien & NJ White, 1993) (XT Cao, et al., 1997a). However, we 
realised soon after these drugs were deployed (despite the rapid reduction in parasitaemia 
they caused), that when given alone for less than 7 days, there was a high recrudescence 
rate (50%) (K Arnold, et al., 1990) (TT Hien, et aI., 1991). At that time, it was not clear 
whether the high failure rates reflected a "real" resistance (ie resistance despite using the 
maximum dose) or whether it was a failure secondary to insufficient dosage. Therefore, 
attempts were made to lower recrudescence rates in those malaria patients. There are two 
approaches to deal with high failure rate of antimalarial drugs: to increase the dose to the 
highest level at which the patient can tolerate or to combine with other drugs to exploit 
synergy. The former was the case of Thailand in 1991 when the mefloquine dose was 
increased from 15 mg/kg to 25 mg/kg (FO ter Kuile, et al., 1992) and subsequently in 
Vietnam (TT Hien, et aI., 1994) and Thailand (F Nosten, et aI., 1994). It should be 
emphasized that i) while in Thailand artesunate was used to protect mefloquine, in 
Vietnam we added mefloquine to increase the cure rate of artemisin and its derivatives. ii) 
The objective of the Vietnam national malaria programme were effective prevention of 
death due to malaria at an affordable cost and a clear need to avoid reliance on foreign 
aids for antimalarial drugs such as mefloquine. Vietnam made a crucial decision, backed 
up by a strong political commitment, to ensure availability of artemisinin and artesunate 
sourced from the local production of these drugs. Therefore, artemisinin was initially 
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provided as mono therapy (5 - day regimen) without mefloquine this choice was 
influenced by limited availability, costs and need to rely on outside asssistance). 
However because of poor compliance to this regimen the combination with mefloquine 
was introduced to increase the adherence of the patients to treatment courses with an 
effective, simple regimen: single day treatment with artemisinin + mefloquine (TT Hien, 
et ai., 1994). The efficacy of this combination, supported by results of a similar trial (C 
Luxemburger, et ai., 1994), has been one of the regimens recommended by NIMPE since 
1995. 
Manufacturers III China based on their unpublished data recommended the doses of 
artemisinin and its derivatives. Our patients were treated with artemisinin 10 - 20 mglkg 
or artesunate 1 - 2 mg/kg. The PCTs were satisfactory < 48 hours (TT Hien, et aI., 1994). 
Results from a more recent study imply that there is no reduction in PCTs with the use of 
single oral doses of artesunate higher than 2 mg/kg and that is the minimum to produce 
maximum effects in an average patient (BJ Angus, et aI., 2002). That study also 
supported the reliability of the earlier pharmacodynamic studies in China 
The efficacy of this combination had progressively declined and in 2000, the cure rate 
was reduced by 50% as presented in Chapter 5. It suggested that the single day treatment 
of artesunate (artemisinin) despite combination with mefloquine could not protect itself. 
The effects of antimalarial drugs will be determined by an array of factors: absorption, 
distribution, elimination, which also varies between individuals. In addition, one needs to 
also factor in the susceptibility profile of the causal parasite. Our in vitro testing results 
indicate that there has been no remarkable change in the susceptibility of P. falciparum 
since 1996 (Hien, unpublished data). These data suggest that in planning artemisinin 
combination therapy (ACT) regimens the artemisinins should be part of the regimen for 
longer than one day. 
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Since 1994 the combined regimen artesunate + mefloquine has been the treatment of 
choice for multidrug resistant P jalciparum in Vietnam. While the provision of 
artemisinin lartesunate was from local production, the supply of mefloquine relied on a 
financial support from AusAid - a non-refunded aid from the Australian Government _ 
which ended after 5 years. In order to move towards self-sufficiency for primary 
commodity of the malaria control programme, studies were done to assess newer 
combinations. From this Viet Nam started to assess "CV" drugs, standing for China and 
Vietnam. These were to be produced locally and were designed to replace artemisinin _ 
mefloquine. Among the prototypes, CV 4, included four drugs: dihydroartemisinin, 
trimethoprim, piperaquine, and primaquine. These combinations were tested in small non-
randomised clinical trials in China, Vietnam, and Cambodia. Modification of the doses of 
the individual components led to a new version (CV8), which was subsequently tested, 
marketed, and manufactured. CV8 was introduced to the Vietnamese National Malaria 
Control Programme in 1998. Concerns about the risklbenefit ratio of primaquine in the 
combination led to its removal and to the use of the triple combination. This preparation 
contained dihydroartemisinin (32 mg/tablet), trimethoprim (90 mg/tablet), and 
piperaquine (320 mg/tablet). Uncertainties about the contribution of the trimethoprim 
component and dose then led to an increase in the dose of dihydroartemisinin to 40 
mg/tablet, and removal of the trimethoprim. This new two-drug fixed combination 
antimalarial is quite inexpensive; in 2003 it cost approximately US$l for an adult 
treatment compared with $6 of artesunate - mefloquine and $2.4 of Coartem (artemether-
lumefantrine). Dihydroartemisinin-piperaquine has several advantages over artesunate-
mefloquine and artemether-Iumefantrine (Coartem). It is a fixed-dose co-formulation, 
which improves adherence and avoid monotherapy that could accelerate the development 
of resistance of P jalciparum to either drug these drugs; In addition, unlike artemether-
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lumefantrine, of which the absorption is very dependent on co-administration with fat , 
(NJ White, et al., 1999b) which may limit its effectiveness, the bio-availability of 
dihydroartemisinin-piperaquine may be independent with the administration of food· it is , 
better tolerated, and it is around three times less expensive. In Vietnam, this combination 
is available for about $1 for an adult treatment course. This cost is generally regarded as 
the absolute upper limit of affordability for any antimalarial treatment in most countries 
affected by malaria has become the first choice treatment for Pfalciparum malaria in 
Vietnam since 2003 and another study attempting to recruite over 4,000 patients, is 
ongoing in the same areas to assess the side effects of this new combination. In summary, 
among three available ACTs, dihydroartemisinin + piperaquine seems the most effective, 
safest, simplest administer and inexpensive combination for acute multi-drug resistant P. 
falciparum malaria in Vietnam and maybe for other malaria endemic countries. 
7.2 Artemisinins and severe falciparum malaria 
For decades, the mortality of severe and complicated falciparum malaria had been 
between 30-40% in hospitals in Vietnam (TT Hien, 1994). Many attempts had been made 
to reduce the case fatality. Thanks to the introduction of "qinghaosu" the death toll has 
been hugely reduced from almost 5000 people dying from malaria in Viet Nam in 1994 to 
50 in 2003 ( NMCP report in 2004). Unfortunately, despite conducting the largest ever 
double blind, controlled trial in malaria comparing i.m artemether and i.m quinine 
(Chapter 6) we failed to show any significant difference in mortality. Why that new and 
powerful antimalarial drug could not reduce the case fatality rates in hospitalised 
patients? These patients were severely ill, they may have been treated unsuccessfully 
elsewhere with different drugs and they may have developed complications before they or 
their families decided to go to the central hospital. At this late stage, the antimalarial 
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treatment seems to be no longer the most important measure. The failure of treatment in 
patients who die may be due to multiple pathological processes which are irreversible by 
the time these patients are seen in the tertiary hospitals. However the lowest eyer 
mortality reported in severe falciparum malaria in Vietnam in this trial indicated the 
impact of better and appropriate ancillary treatment such as renal replacement treatment 
and nursing care. Concerning the choice between artemether and artesunate, the 
pharmacokinetic study (Chapter 3) indicated that artesunate is the preferred choice for the 
treatment of severe falciparum malaria, particularly in those patients who are most 
seriously ill and in whom absorption from an i.m. lipid-soluble depot may be 
compromised. These findings have been assessed by a recent randomised clinical trial at 
our hospital and the findings of which will be available soon. 
The number of deaths from severe malaria in Vietnam, however, continues to fall from 
4646 cases in 1991 to 198 in 1996 and there were only 75,144 malaria patients with 50 
deaths in 2003 (Report from NMCP 2004). It is likely that artemisinin and its derivatives 
have contributed to the decline in malaria mortality rate, not by being more effective in 
treating the lethal form of the disease, but by reducing the number of severe cases. By 
rapidly clearing the parasitaemia in addition to a possible anti-cytoadherence effect (R 
Udomsangpetch, et al., 1996), artemisinin and derivatives may help to prevent the 
development of complications when these drugs are given early to malaria patients, 
particularly at peripheral level of health care system. Another possible advantage of 
qinghaosu which has just been demonstrated elsewhere (RN Price, et at., 1996) is a 
reduction of the transmission potential of falciparum malaria with artemisinin treatment. 
The deployment of these compounds may prevent the spread of multi-drug resistant 
disease. These factors may explain the improvement of malaria situation in China and in 
Viet Nam. 
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In the early 1990s artemisinin suppositories were shown to be as effective as parenteral 
antimalarial drugs in clinical trials for the treatment of severe malaria(XT Cao, et ai., 
1997a, V Ha, et ai., 1997, TT Hien, et ai., 1992a) The rectal bioavailability is 30% 
relative to the oral dose although there is large inter-individual variation. Because of the 
similarity in parasite clearance times between oral and rectal administration, it is assumed 
that therapeutic concentrations could be achieved with artemisinin suppositories(R 
Koopmans, et ai., 1998, JS Sidhu, et ai., 1998). Following these resuls, the WHO has 
developed artesunate suppositories (Rectocaps) and is now under large-scale evaluation 
(MI Awad, et al., 2003, KI Barnes, et ai., 2004, HA Karunajeewa, et ai., 2004)'(HA 
Karunaj eewa, et ai., 2003, S Krishna, et al., 2001). All results from those studies 
indicated that artesunate suppositories are safe, effective initial treatment for 
uncomplicated and severe falciparum malaria in Africa and in Asia. 
Today intrarectal qinghaosu (artemisinin and artesunate) is becoming an effective 
treatment for P jalciparum malaria and offers great promise as a life saving intervention 
in remote areas where facilities for parenteral drugs maybe limited and of course the 
diseases has its greatest impact. 
7.3 Neurotoxicity 
Because of concern about the possible risk of neurotoxicity of artemisinine, particularly 
artemether, detected by experimental studies at the Walter Reed Army Institute of 
Research in the USA, studies were conducted to rule out that adverse effect in man. The 
first study aiming at careful neurological evaluation of the population exposed to multiple 
treatments with the artemisinin derivatives could not detect any convincing clinical or 
neurophysiological evidence of brain stem neurotoxicity, despite thorough examination in 
subjects receiving up to twenty-one treatment episodes in a two-year period. Although as 
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a field study in a small rural community it could not meet the rigorous criteria of a drug-
safety study, the lack of evidence of neurotoxicity is reassuring. Those evidences 
consolidated the results from another study in Thailand in which 79 patients who received 
more than 2 treatments of artemether or artesunate and 79 age- and location- matched 
controls were assessed with a similar protocol (M Van Vugt, et at., 2000) 
In the second study, the results of a pathological examination of brain tissue from patients 
with severe falciparum malaria treated artemether or quinine indicated that there were no 
neuronal death in artemether recipients and other neuropathological findings between the 
two different treatments were similar. These data provide reassurance that therapeutic 
doses of these important antimalarial drugs do not damage the human nervous system. 
However surveillance programmes will be needed to identify a variety of adverse events 
caused by artemisinin and its derivatives as well as other partner drugs of artemisinin 
based combinations such as metloquine, lumefantrine or piperaquine 
7.4 Conclusion 
In summary the objectives set out in this thesis have been largely met. Through 
the production and use of artemisinin and its derivatives Vietnam has successful 
implemented a Malaria control programme that would otherwise have been impossible. 
The implementation has been underpinned by clinical and operational research. The 
research described in this thesis addresses both the treatment of severe and uncomplicated 
malaria with artemisinin and its derivatives, and artemisinin based combination treatment. 
The pharmacological properties relevant to treatment, safety and efficacy have all been 
characterised. These new drugs have been remarkably safe and effective. 
Since 1990 our studies on artemisinin and it derivatives, both oral and parenteral 
preparation, and especially in combination with metloquine (K Arnold, et al., 1990) (TT 
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Hien, et ai., 1991) (TT Hien, et ai., 1992a) (TT Hien, et ai., 1994) (XT Cao, et al., 1997b) 
have made an impact on the recommendations for the clinical management of patients 
with malaria by the National Malaria Control Programme of Vietnam. This has 
contributed directly to the success of the malaria control programme of the country and 
we also believe that our studies have also exerted considerable influence over the drug 
policy for malaria at the World Health Organisation. The results from the studies in this 
thesis are still influencing the recommendations issued by the NMCP. In 2003 
combination of dihydroartemisinin and piperaquine (CV8 and Artekin) was the first line 
antimalarial drug for falciparum malaria in Vietnam and the production of artekin will 
start in 2005. That move will allow the country to deal with the increasing failure rate of 
the original regimen (A3M), to minimise the expense for imported antimalarial drugs 
(mefloquine), and help the government's policy of being self-sufficiency in antimalarial 
drug. At an international level, these results maybe useful for the development of new 
antimalarial drugs to replace the old drugs that are rapidly loosing their effectiveness. 
They could and should contribute to "Rolling Back Malaria" throughout the malaria 
endemic world. 
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